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Parkinson’s disease (PD) is characterized by severe motor deficits, cogwheel 
rigidity, bradykinesia, and the loss of dopaminergic neurons. The aetiology of PD 
has not been clearly identified; however, oxidative stress is thought to be a common 
factor that leads to cellular dysfunction and neurodegeneration. In particular, the 
pathological events that occur in PD have been suggested to be linked to protein 
oxidation caused by oxidative stress, and excessive intracellular ROS induce 
apoptosis that is characterized by the cleavage of caspase-3, caspase-9 and poly 
 ii 
ADP-ribose polymerase (PARP). The neurotoxin 6-hydroxydopamine (6-OHDA), 
Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) destroys dopaminergic and 
noradrenergic neurons in the brain by inducing excessive ROS such as superoxide 
radicals, which leads to protein oxidation and neuronal cell death. Also, ubiquitin-
proteasome system play a key role in the etiology of PD. The proteasome selective 
degrades oxidized proteins via ubiquitin-mediated processes, and its role is 
essential for cellular protein maintenance. However, dysfunctions in the 
ubiquitination machinery or in the proteolytic activities of the proteasome induce 
the accumulation of polyubiquitinated misfolded proteins and oxidized proteins. 
Subsequently, this induces protein aggregation, further inhibits proteasome activity, 
generates additional cellular stress, and ultimately leads to neuronal cell death. 
Additionally, mitophagy play a major role in the etiology of PD. Mitophagy, a 
specialized autophagy pathway that mediates the clearance of damaged 
mitochondria by lysosomes, is important for mitochondrial quality control. 
Defective mitochondria, if left uncleared, can be a source of oxidative stress and 
compromise the health of the entire mitochondrial network. The several lines of 
evidence propose that mitochondrial dysfunction is central to the disease. PD-
associated mutations in PINK1 or parkin impair parkin recruitment, mitochondrial 
ubiquitination, and/or mitophagy. In the context of the inherently high 
mitochondrial oxidative stress in substantia nigra dopamine neurons, loss of parkin-
mediated mitophagy could explain the greater susceptibility of substantia nigra 
 iii 
neurons to neurodegeneration. Thus, promoting mitophagy and enhancing 
mitochondrial quality control could benefit dopaminergic neurons. The current 
therapeutic drugs are based on prohibiting the progress of PD through treatment of 
dopamine agonist or dopamine precursor. New therapies in development are aimed 
at protecting dopaminergic neurons. In this study, the effects of natural products on 
6-OHDA, CCCP-mediated signaling in SH-SY5Y neuroblastoma cell were 
investigated to discover new lead compounds for the treatment of PD.  
Cudrania tricuspidata (Moraceae) is a subtropical tree that is widely distributed 
in Korea, China, and Japan. The fruits of C. tricuspidata are used in jams, juices, 
and a fermented alcoholic beverage with sugar, and they are commercially 
produced as food in Korea. Also, the cortex and root bark of C. tricuspidata have 
been used as a traditional medicine for inflammation and tumors. A recent study 
demonstrated that the extracts of C. tricuspidata protect neurons against oxidative 
stress-induced cytotoxicity and inhibitory effects on nitric oxide synthase (NOS). 
The compounds isolated from C. tricuspidata are primarily xanthones and flavones 
in addition to some alkaloids, lignins, coumarins, polysaccharides, and chromones. 
The isoflavones and chromones from C. tricuspidata have been reported to exert 
protective effects against 6-OHDA-induced neurotoxicity and to have inhibitory 
effects against IgE-mediated allergic and inflammatory responses.  
In first chapter, it was investigated that 5,7-dihydroxychromone (DHC) isolated 
from the roots of C. tricuspidata for its neuronal cell protection and inhibition of 
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the generation of ROS in 6-OHDA-induced SH-SY5Y cells. Flow cytometric 
analysis revealed that DHC protected against the 6-OHDA-induced generation of 
ROS and protected against neuronal cell death. Additionally, DHC increased the 
nuclear translocation of Nrf2 and the binding of Nrf2 to ARE, which subsequently 
resulted in the up-regulation of the expression of Nrf2-dependent antioxidant genes, 
including heme oxygenase 1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1) 
and glutamate-cysteine ligase, catalytic subunit (GCLc). DHC inhibited the 
expression of cleaved caspase-3 and caspase-9 and PARP in 6-OHDA-induced SH-
SY5Y cells. The addition of Nrf2 siRNA abolished the neuroprotective effect of 
DHC against 6-OHDA-induced cell death and the expression of Nrf2-mediated 
antioxidant genes. These findings suggest that the neuroprotective effect of DHC 
against 6-OHDA-induced toxicity is partly due to the induction of Nrf2-mediated 
antioxidant gene expression via the activation of the Nrf2-ARE signaling pathway 
in SH-SY5Y cells.  
In the second chapter, the effects of ethanol extract from the fruits of C. 
tricuspidata (CTE) and it active compounds were studied. Among the nine isolates 
from a 50% ethanol extract from C. tricuspidata fruits (CTE50), orobol (OB), 6-
prenylorobol (POB), and 6,8-diprenylorobol (DPOB) showed neuroprotective 
effects in 6-OHDA-induced SH-SY5Y cell death. In addition, CTE50 and the three 
orobol derivatives (OB, POB, and DPOB) attenuated the cleavage of caspase-3, 
caspase-9, and PARP and inhibited the excessive generation of ROS. Furthermore, 
 v 
it enhanced the 6-OHDA-induced dysfunction of proteasome activity and reduced 
the accumulation of ubiquitin conjugated-proteins and the polyubiquitination of α-
synuclein and synphilin-1. The proteasome inhibitor MG132 blocked the 
neuroprotective effects and the enhanced proteasome activity produced by CTE50 
and the three orobol derivatives. These results demonstrate that CTE50 and three 
orobol derivatives protect against 6-OHDA-induced neurotoxicity by enhancing the 
ubiquitin/proteasome-dependent degradation of α-synuclein and synphilin-1, 
suggesting that they might be possible candidates for the treatment of 
neurodegenerative diseases.  
In the third chapter, the effects of active compounds from the C. tricuspidata 
extracts on deubiquitinating enzymes were studied. TH3-125-4 (TH20) isolated 
from the root barks of the C. tricuspidata protected against CCCP-induced neuronal 
cell death in Parkin K.D. SH-SY5Y cells. Also, TH20 significantly inhibited 
USP30 enzyme activity and disassembly of polyubiquitin chain in in vitro assay. 
Additionally, TH20 decreased protein expression of USP30. Based on the results, 
it was suggested that TH20 might be promising candidates for the therapy of 
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The incidence of neurodegenerative diseases is increasing with the continuous 
growth of the elderly population. Although the causes of neurodegenerative 
diseases have not been clearly elucidated, recent studies have demonstrated 
that reactive oxygen species (ROS) might be one of the important factors in 
the neurotoxicity that occurs in neurodegenerative diseases (Farooqui and 
Farooqui, 2011). Cells exposed to environment fortified with oxygen 
constantly generate oxygen free radicals. ROS includes oxygen-related free 
radicals and reactive species, and they are produced as a result of aerobic 
metabolism. Formation of ROS can occur in two ways: enzymatic and non-
enzymatic responses. Enzymatic responses generating free radicals include 
those involved in the mitochondrial respiratory chain, phagocytosis, 
prostaglandin synthesis and the cytochrome P450 system. The non-enzymatic 
process can also occur through oxidative phosphorylation (i.e. aerobic 
respiration) in the mitochondria. ROS is generated from either endogenous or 
exogenous sources. Endogenous free radicals are generated from immune cell 
activation, inflammation, mental stress, excessive exercise, ischemia, 
infection, cancer and aging. Exogenous ROS result from air and water 
 3 
pollution, cigarette smoke, alcohol, heavy or transition metals (Cd, Hg, Pb, Fe, 
As), certain drugs (cyclosporine, tacrolimus, gentamycin, bleomycin), 
industrial solvents, cooking (smoked meat, used oil, fat) and radiation. After 
penetrated into the body by different ways, these exogenous agents are 
decomposed or metabolized into free radicals (Chen et al., 2012). Increased 
ROS production causes impairment to cell organelles. Many studies have 
confirmed the benefits of antioxidants in reducing oxidative stress in neurons 
and protecting against neurodegenerative diseases (Alfieri et al., 2011). In 
response to excessive ROS, the cellular expressions and bioactivity of 
numerous antioxidant enzymes are changed via initiating the upstream factor 
NF-E2-related factor 2 (Nrf2)/antioxidant response elements (AREs) complex 
(Leutner et al., 2000).  
 The Nrf2/ARE signal has an important effect on the induction of antioxidant 
gene expression, and it has been reported that the activation of Nrf2 is an 
important signal which can neutralize oxidative stress (Sun et al., 2010). Nrf2 
activity is regulated partly by Keap1 protein, which was initially proposed to 
act by binding and tethering the transcription factor in the cytoplasm. 
Activation of Nrf2 in response to stress signals was thought to result from a 
interruption of this association, releasing Nrf2 for translocation into the 
nucleus to affect its transcriptional activity. Independently, Nrf2 has been 
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found to be a highly unstable protein, subject to proteolytic degradation 
catalyzed by the proteasome via the ubiquitin-dependent pathway. In this case, 
activation of Nrf2 was suggested to be dependent on mechanisms that increase 
its stability, leading to its accumulation in the cell. The unstable nature of the 
Nrf2 protein and its regulation through this dynamic mechanism suggest that 
Nrf2 is unlikely to be joined in a passive complex in the cytoplasm. This was 
supported by a number of studies demonstrating a more active role of Keap1 
in its repression of Nrf2 activity. Keap1 appears to promote Nrf2 
ubiquitylation in a constitutive manner through the cullin-3-dependent 
pathway. That Nrf2 is constantly degraded in non-stressed cells implies that 
Keap1 is a constitutively active protein and that it promotes Nrf2 
ubiquitylation in an unregulated manner. This is supported by the observation 
that overexpression of Keap1 leads to increased levels of ubiquitin-conjugated 
forms of Nrf2 in cells, indicating that Keap1 is expressed as a functionally 
active protein. Thus, interaction between the two proteins is more likely a 
transient encounter rather than a sustained association. Given that the steady-
state level of Nrf2 in the cell is maintained in part through its constitutive 
expression, requiring de novo gene transcription and protein synthesis, the 
pathway through which Nrf2 activity is regulated, from synthesis to 
degradation, requires examination in further detail (Nguyen et al., 2009). In 
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summary, under normal state, Nrf2 is localized in the cytoplasm and is subject 
to ubiquitination and proteasomal degradation. However, antioxidant agents 
block the elimination of Nrf2 from the cytosolic Nrf2 complex, which induces 
nuclear translocation of Nrf2 and subsequently makes the Nrf2/ARE complex 
to mediate the induction of many antioxidant enzyme genes, such as heme 
oxygenase 1 (HO-1), NAD(P)H: quinone oxidoreductase (NQO1), and 
glutamate-cysteine ligase catalytic subunit (GCLc) (Zhang et al., 2013). 
 The heme-heme oxygenase (HO) system is a controller of endothelial cell 
integrity and oxidative stress. HO-1 and HO-2, two isoforms of HO, are 
viewed as having a major role in the construction of carbon monoxide (CO) 
and bilirubin and in heme breakdown. The fact that HO-1 is strongly induced 
by oxidant stress and its substrate heme, in conjunction with the ability of HO-
1, to protect against oxidative insult suggests a countervailing system to 
oxidative stress damage. The antioxidant effects of HO-1 arise from its 
capacity to increase reduced glutathione levels and to degrade heme, as well 
as from the elaboration of biliverdin and bilirubin, which have potent 
antioxidant properties. CO, a product of HO, is not an antioxidant, but it does 
have an antiapoptotic effect. Furthermore, CO is a vasodilator that has been 
shown to enhance endothelial function and plays an important role in 
regulating basal and constrictor-induced vascular tone (Turkseven et al., 2005).  
 6 
 NQO1 has multiple protective roles that include and extend beyond its 
catalytic function. It is a widely-distributed FAD-dependent flavoprotein that 
catalyzes the reduction of quinones, quinoneimines, nitroaromatics, and azo 
dyes. NQO1 was discovered and named DT-diaphorase in the late 1950s, and 
shown to be identical to the dicoumarol-inhibited vitamin K reductase 
described. The classical direct antioxidant role of NQO1 is characteristic in its 
catalytic mechanism: the obligatory two-electron reduction of a wide array of 
quinones to their corresponding hydroquinones by using either NADPH or 
NADH as the hydride donor. In doing so, NQO1 diverts quinone electrophiles 
from participating in reactions that could lead to either sulfhydryl depletion, 
or to one-electron reductions that can produce semiquinones and various 
reactive oxygen intermediates as a result of redox cycling. In addition, the 
hydroquinone products of the NQO1 reaction can be further metabolized to 
glucuronide and sulfate conjugates, thereby facilitating their excretion. 
Remarkably, quinone reductases have been found in a wide range of 
eukaryotic organisms ranging from yeast to mammals. Although in many 
systems much remains to be learned about the complicated details of the 
function and regulation of these enzymes, it is clear that in all cases quinone 
reductases are at the forefront of the cellular defense by providing multiple 
layers of protection (Dinkova-Kostova and Talalay, 2010).  
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 Glutathione (GSH) is considered the most abundant molecule among 
endogenous antioxidants. GSH is a reduced peptide consisting of three-
residues (γ-l-glutamyl-l-cysteinyl glycine) which can donate an electron with 
the consequence that two electrons donating GSH molecules form oxidized 
GSSG. In humans, GSH is almost uniquely present in a quite high 
concentration (1–10 mM) which allows to scavenge ROS either directly or 
indirectly. It can directly react with O2- and some other ROS, but its indirect 
ROS-scavenging functions, such as revitalizing other antioxidants, are likely 
more important; e.g. it can reduce dehydroascorbic acid which is formed in 
the reconversion of α-tocopheroxyl radical to α-tocopherol, a lipophilic chain 
breaking antioxidant, which interacts with the polyunsaturated acyl groups of 
lipids, stabilizes membranes and scavenges various reactive oxygen species 
and lipid oxy-radicals. As an antioxidant it reacts with ROS, RNS and radicals 
produced in association with electron transport, xenobiotic metabolism and 
inflammatory responses. GSH is synthesized from its constituent amino acids 
forming a tripeptide thiol and this synthesis requires two ATP-dependent steps. 
The first and limiting synthesis is catalyzed by γ-glutamyl-cysteine ligase 
(GCL) and the second step mediated by GSH synthetase (GS). GCL is a 
heterodimeric enzyme composed by a heavy subunit, GCLc with catalytic 
activity and a smaller one, GCLm that has a regulatory role on the other 
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subunit. GSH homeostasis in the cell is not only regulated by its de novo 
synthesis, but also by other factors such as utilization, recycling and cellular 
export. This redox cycle is known as the GSH cycle and incorporates other 
important antioxidant, redox-related enzymes. Nearly every eukaryotic cell, 
from plants to yeast to humans, expresses a form of the GCL protein for the 
purpose of synthesizing GSH. To further highlight the critical nature of this 
enzyme, genetic knockdown of GCL results in embryonic lethality. 
Furthermore, dysregulation of GCL enzymatic function and activity is known 
to be involved in the vast majority of human diseases, such as diabetes, 
Parkinson's disease, Alzheimer’s disease, COPD, HIV/AIDS, and cancer. 
This typically involves impaired function leading to decreased GSH 
biosynthesis, reduced cellular antioxidant capacity, and the induction of 
oxidative stress (Espinosa-Diez et al., 2015). Numerous research results 
reported that Nrf2 and Nrf2 dependent antioxidant genes are potent factors for 
developing the therapy of neurodegenerative diseases due to its abilities to 
regulate the excessive oxidative stress and inflammation. A recent study 
demonstrated that the extracts of Cudrania tricuspidata protect neurons 
against oxidative stress-induced cytotoxicity (Jeong et al., 2010) and have 
inhibitory effects on nitric oxide synthase (NOS) (Kang et al., 2002). It was 
also reported that 5,7-Dihydroxychromone (DHC), from Cudrania 
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tricuspidata, has an antioxidant activity (Qiu et al., 2012). However, 
neuroprotective effects of DHC and the related mechanisms of 
neuroprotection were poorly elucidated.  
In this study, it was demonstrated that neuroprotective effects of DHC against 

















2. Materials and methods 
 
2.1. Chemicals and reagents  
Propidium iodide (PI), 6-hydroxydopamine (6-OHDA), and 2',7'-
dichlorfluorescein-diacetate (DCFH-DA) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Dulbecco’s modified Eagle’s medium 
(DMEM) and fetal bovine serum (FBS) were purchased from Gibco BRL 
(Rockville, MD, USA). Hybond-polyvinylidene difluoride (PVDF) 
membranes were purchased from Amersham Pharmacia Biotechnology. 
(Piscataway, NJ, USA). Easy-Blue® total RNA extraction solution, PRO-
PREP protein extraction solution and WEST-ZOL® ECL solution were 
purchased from iNtRON Biotech. (Kyunggi, Korea). SuPrimeScript RT 
premix®, and SYBRs HS Prime qPCR premix® were purchased from Genet 
Bio (Daejeon, Korea). Nrf2 siRNA, scrambled siRNA, Nrf2, HO-1, NQO1, 
GCLc, LaminB1, α-tubulin, β-actin, caspase-3, caspase-9, PARP, secondary 
antibody and FITC-conjugated secondary antibody were purchased from 





2.2. Preparation of 5,7-dihydroxychromone (DHC) 
Cudrania tricuspidata was stored at the Korea Forest Research Institute at 
Southern Forest Research Center (Jinju, Korea) in September 2008. A voucher 
specimen (accession number KH1-4-090814) was kept at the Department of 
Biosystems and Biotechnology at Korea University (Seoul, Korea). 5,7-
Dihydroxychromone (DHC) was isolated from the roots of Cudrania 
tricuspidata and the structure of DHC was determined by spectroscopic 
methods, and the purity was more than 98.5% (Wei and Yu, 2008). DHC was 
dissolved in DMSO and diluted with PBS to obtain the proper concentration 
of DHC. Final concentration of DMSO was less than 0.1% and it didn’t 
influence the performed assays. 
 
2.3. Cell cultures  
The human neuroblastoma cell line SH-SY5Y (ATCC No. CRL-2266) was 
purchased from the American Type Culture Collection (Manassas, VA, USA) 
and cultured in DMEM supplemented with 10 % heat-inactivated FBS and 1 % 





2.4. Measurement of cell viability  
SH-SY5Y cells were seeded at a density of 1×105 cells/200 µL/well in 96-well 
plates for 24 h, and the cells were pre-treated with DHC (0.4, 2, or 10 µM) for 
24 h followed by subsequent treatment with 6-OHDA (100 µM) for an 
additional 24 h. To evaluate the effect of Nrf2, cells were transfected with 
scrambled siRNA or Nrf2 siRNA for 48 h and its final concentration was 50 
nM. After transfected cells were treated with DHC (10 µM) and 6-OHDA (100 
µM), cell viability was determined using a MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-Diphenyltetrazolium Bromide) and measured by ELISA (Koo 
et al., 2011). 
 
2.5. Measurement of cell necrosis by propidium iodide staining 
SH-SY5Y cells were seeded at a density of 2×105 cells/2 mL/well in 6-well 
plates for 24 h, and the cells were pre-treated with DHC (0.4, 2, or 10 µM) for 
24 h followed by subsequent treatment with 6-OHDA (100 µM) for an 
additional 24 h. To evaluate the effect of Nrf2, cells were transfected with 
scrambled siRNA or Nrf2 siRNA for 48 h and its final concentration was 50 
nM. After transfected cells were treated with DHC (10 µM) and 6-OHDA (100 
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µM), cell viability was determined using a propidium iodide (PI) staining and 
measured by flow cytometry (BD FACSCalibur TM) (Koo et al., 2011). 
 
2.6. Measurement of intracellular ROS by Flow cytometry  
ROS levels in cells were measured with the 2',7'-dichlorofluorescein diacetate 
(DCFH-DA) method (Munch et al., 1998a). Briefly, the cells were washed 
with PBS, and then incubated with 4 µM of DCFH-DA for 30 min at 37 ºC in 
the dark. The cells were then washed with PBS. The fluorescence intensities 
were measured by flow cytometry (BD FACSCalibur TM San Jose, CA, USA). 
 
2.7. Nuclear and cytosolic lysate preparations  
The nuclear and cytosolic proteins were extracted with a commercial kit 
(Nuclear Extract Kit) according to the manufacturer’s procedure (Active 
Motif, Carlsbad, CA). Briefly, the cells were incubated in hypotonic buffer on 
ice for 15 min, homogenized with detergent, and centrifuged for 30 sec at 
14,000 x g in a microcentrifuge at 4 ºC. The supernatant was used as the 
cytosolic proteins. The nuclear pellets were washed with cold PBS, extracted 
completely with lysis buffer for 30 min on ice and centrifuged for 10 min at 
14,000 x g in a microcentrifuge at 4 ºC. The supernatant was used as the 
nuclear proteins. 
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2.8. Electrophoretic mobility shift assay (EMSA) 
To determine the Nrf2-ARE binding activity, an electrophoretic mobility shift 
assay (EMSA) was accomplished as previously described (Meyer et al., 1998). 
Briefly, the nuclear proteins from the SH-SY5Y cells were reacted with 32P-
end-labeled 22-mer double-stranded oligonucleotide containing the Nrf2 
sequence for 30 min at 37 ºC. The DNA-protein complexes were 
electrophoresed and gels were dried. The binding signals were visualized by 
BAS-1500 (Fuji, Tokyo, Japan). 
 
2.9. Nrf2 knockout via the transfection of small interfering RNA (siRNA)  
The transfection with scrambled siRNA or Nrf2 siRNA were progressed at 
final concentrations of 50 nM for 48 h by Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) prior to treatment with DHC (10 µM) and 6-OHDA (100 µM) 
as recommended by the manufacturer’s guidelines.  
 
2.10. Measurement of mRNA expression  
After treatments, total RNA was isolated from SH-SY5Y cells by easy-
BLUE® and cDNA was synthesized by using SuPrimeScript RT premix® 
according to the manufacturer’s procedure. The synthesized cDNA was used 
for PCR and the primer pair sequence were listed as follows:  
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HO-1 5-TGCTCGCATGAACACTCTG-3 (Sense) and  
5- TCCTCTGTCAGCAGTGCC-3 (antisense);  
NQO1 5-AGCCCAGATATTGTGGCTGA-3 (Sense) and 
5-AAGCCACAGAAATGCAGAATG-3 (antisense); 
GCLc 5-AGGCCAACATGCGAAAC-3 (Sense) and 
5-CGGATATTTCTTGTTAAGGTACTGG-3 (antisense); 
GAPDH 5-CTCTGCTCCTCCTGTTCGAC-3 (Sense) and  
5-ACGACCAAATCCGTTGACTC-3 (antisense). The cycle condition was as 
follow; 94℃ for 20s, 56℃ for 20s, 72℃ for 30s and 40 cycles. PCR were 
performed by using SYBRs HS Prime qPCR premix® in an ABI 7300 real-
time PCR (Applied Bio systems, CA, USA). Ct (threshold cycle) values were 
obtained using the Sequence Detection Software version1.2.3 (Applied Bio 
systems, CA, USA). To evaluate quantification of the changes in target gene 
expression, we used the 2-△△Ct method (Tucker and Munchus, 1998). Fold 






2.11. Measurement of protein expression  
The SH-SY5Y cells were collected, washed with PBS and lysed with a 
PRO-PREP protein extraction solution at -20 ºC for 20 min. After 
centrifugation at 13,000 x g for 30 min, the supernatant was used as the total 
protein extracts. Western blot analysis was accomplished as previously 
described method (Ham et al., 2013).  
 
2.12. Nuclear translocation of Nrf2 using fluorescence microscope  
The culture dish was coated with 0.2 % gelatin at 37 °C for 30 min and dried 
at RT on a clean bench. The SH-SY5Y cells were plated at a density of 5×104 
cells/200 µL/well in coated dishes for 24 h and incubated with DHC (0.4, 2, 
or 10 µM) for 6 h. After treatment with DHC, the cells were washed with 1x 
PBS/Tween-20 buffer (pH 7.4) (PBST) once. The cells were fixed with 4 % 
paraformaldehyde for 30 min at room temperature (RT). After washing with 
PBST, the blocking steps were performed with 1 % BSA in PBST. Next, the 
cells were incubated with the primary antibody at 4 °C overnight. The next 
day, the cells were washed with PBST 3 times and incubated with FITC-
conjugated secondary antibody for 1 h at RT. After 1 h, the cells were washed 
with PBST 3 times, and DAPI staining was performed for 5 min at RT. Lastly, 
the PBST washing and mounting steps were conducted. 
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2.13. Statistical analysis  
All experimental data are expressed as mean value ± standard deviation. 
Statistical significance between multiple groups was determined by one-way 
ANOVA (PRISM Graph Pad, San Diego, CA, USA). When ANOVA had a 
significant difference, post hoc Bonferroni’s multiple comparison tests was 


















3.1. Protective effect of DHC against 6-OHDA-induced neuronal cell 
death.  
 
The protective effects of DHC (Fig. 2) on SH-SY5Y cells were evaluated to 
determine the non-cytotoxic dose range (data not shown). The percentage of 
cell necrosis was evaluated with PI staining. As shown in Fig. 3, the 
percentage of PI-stained dead cells induced by 6-OHDA increased to 44.5 % 
compared to the vehicle-treated group (8.7 %). In contrast, 6-OHDA-induced 
cell death was dose-dependently prevented by DHC treatments at 
concentrations of 0.4, 2 and 10 µM within the non-toxic dose range. DHC (10 
µM) treatment elicited its neuroprotective effects against 6-OHDA by 
decreasing the percentage of PI-positive cells to 13.8 %, whereas treatment 
with Nrf2 siRNA and DHC (10 µM) reduced the neuroprotective effect by 
increasing the percentage of PI-positive cells to 50.1 %. Also, the 
neuroprotective effect of DHC was evaluated by MTT assay (Fig. 4). The 















Table 1. The protective effect of isolated compounds from Cudrania 
tricuspidata root barks against 6-OHDA-induced neuronal cell death.  
No. Sample 6-OHDA-induced neuronal cell death MTT EC50 (µM) 
1 JY1-13-2 12.9 
2 JY1-14-1 7.2 
3 JY1-15-1 >40 
4 JY1-19-1 >40 
5 JY1-19-2 >40 
6 JY1-29-2 >40 
7 JY1-30-1 >40 
8 JY1-36-1 9.5 
9 JY1-37-2 9.2 
10 JY1-53-2 15.5 
11 JY1-54-1 >40 
12 JY1-54-3 >40 
13 JY1-56-2 9.1 
14 JY1-59-2 >40 
15 JY1-64-2 >40 
16 JY1-69-3 >40 
17 JY1-88-2 30.2 
18 JY1-88-3 >40 
19 JY1-89-7 8 
20 JY1-89-9 >40 
21 JY1-89-11 >40 
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22 JY1-89-12 >40 
 
Table 1. Continued  
No. Sample 6-OHDA-induced neuronal cell death MTT EC50 (µM) 
23 JY1-91-7 >40 
24 JY1-97-1 >40 
25 JY1-62-1 >40 
26 JY1-64-4 >40 
27 JY1-64-5 >40 
28 JY1-64-7 >40 
29 JY1-88-13 >40 
30 JY1-89-8 >40 
31 JY1-99-1 >40 
32 JY1-99-2 >40 
33 JY1-101-1 >40 
34 JY1-101-4 >40 
35 JY1-102-4 >40 
36 JY1-104-3 >40 
37 JY1-120-3 >40 
38 JY1-146-1 >40 
39 JY1-153-2 >40 
40 JY1-154-2 >40 
41 JY1-158-2 >40 
42 JY1-162-1 >40 
43 JY1-164-4 >40 
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44 JY1-164-5 >40 
45 JY1-165-8 >40 
 
Table 1. Continued  
No. Sample 6-OHDA-induced neuronal cell death MTT EC50 (µM) 
46 JY1-166-3 >40 
47 JY1-167-6 >40 
48 JY1-168-6 >40 
49 JY1-170-5 >40 
50 JY1-170-6 >40 
51 JY1-172-2 >40 
52 JY1-173-1 >40 
53 JY1-179-6 >40 
54 JY1-179-8 >40 































Figure 3. Effects of DHC against 6-OHDA-induced cell necrosis in SH-
SY5Y cells. 
The cells were pre-treated with different concentrations of DHC (0.08 - 10 
µM) for 24 h and subsequently treated with 6-OHDA (100 µM) for another 
24 h. The cells were transfected with Nrf2 siRNA (50 nM) for 48 h before the 
treatment with DHC (10 µM). The cells were stained with PI dyes for 30 min 
and determined by FACS analysis using FL-2 channel. The values of 















Figure 4. Effects of DHC against 6-OHDA-induced cell death in SH-SY5Y 
cells. 
The cells were pre-treated with different concentrations of DHC (0.08 - 10 
µM) for 24 h and subsequently treated with 6-OHDA (100 µM) for another 
24 h. The cells were transfected with Nrf2 siRNA (50 nM) for 48 h before the 
treatment with DHC (10 µM). The cell viability was determined by MTT 




3.2. Inhibitory effect of DHC against 6-OHDA-induced intracellular ROS 
generation. 
 
Intracellular ROS were detected by DCFH-DA dye, which can be diffused to 
the cell membrane and deacetylated by esterase to the 2’,7’-
dichlorodihydrofluorescin (DCFH), which is swiftly converted into the 
dichlorofluorescein (DCF) emitting fluorescence by ROS. As shown in Fig. 5, 
the 6-OHDA-induced cells exhibited higher DCF fluorescence intensities than 
the vehicle-treated cells. The amount of ROS generation was decreased in a 
dose-dependent manner when the 6-OHDA-induced cells were treated with 
different concentrations of DHC (0.4 - 10 µM). The 6-OHDA-induced group 
generated approximately 5-fold greater amount of ROS than that of the 
vehicle-treated group. When the DHC (10 µM)-treated cells were treated with 
6-OHDA, the ROS level was approximately 2-fold greater than that of the 
vehicle-treated group. However, the inhibitory effect of DHC (10 µM) on 
intracellular ROS generation disappeared upon treatment with Nrf2 siRNA, 
and the combined treatment with Nrf2 siRNA and DHC (10 µM) produced the 





Figure 5. Effects of DHC against 6-OHDA-induced intracellular ROS 
generation in SH-SY5Y cells. 
The cells were pre-treated with different concentrations of DHC (0.4 - 10 µM) 
for 24 h and subsequently treated with 6-OHDA (100 µM) for another 24 h. 
The cells were transfected with Nrf2 siRNA (50 nM) for 48 h before the 
treatment with DHC (10 µM). The cells were stained with DCFH-DA dyes for 
30 min and determined by FACS analysis using FL-1 channel. The values of 
fluorescence intensity were obtained from histogram statistic of CellQuest 
software.  
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3.3. Effects of DHC on induction of the nuclear Nrf2 and binding affinity 
of Nrf2/ARE in SH-SY5Y cells 
 
Nrf2 in nucleus has a binding affinity to the ARE region and Nrf2/ARE 
complex induces the transcription of ARE-mediated antioxidant genes. DHC 
increased the induction of nuclear Nrf2 with a peak effect that occurred at 6 h. 
As shown in Fig. 6, the nuclear Nrf2 was dose-dependently increased by DHC 
treatment (0.08 - 10 µM) at 6 h (Fig. 7). The increase of nuclear Nrf2 by DHC 
was visualized by immunocytochemistry in Fig. 8. To elucidate the binding 
activity between Nrf2 and ARE, an electrophoretic mobility gel-shift assay 
(EMSA) was performed. As shown in Fig. 9, DHC (2 µM) drastically 
increased Nrf2-ARE binding activity and the maximum binding activity was 










Figure 6. Effects of DHC on the nuclear translocation of Nrf2 in SH-SY5Y 
cells. 
The cells were treated with DHC (2 µM) for different durations (0 - 12 h). The 
nuclear protein was extracted. Lamin B1 was used for nuclear marker and α-
tubulin was used for cytosol marker. The protein expression levels of Nrf2, 
Lamin B1, and α-tubulin were determined by western blot analysis. 











Figure 7. Effects of DHC on the nuclear translocation of Nrf2 in SH-SY5Y 
cells. 
The cells were treated with different concentrations of DHC (0.4 - 10 µM) for 
6 h. The nuclear protein was extracted. Lamin B1 was used for nuclear marker 
and α-tubulin was used for cytosol marker. The protein expression levels of 
Nrf2, Lamin B1, and α-tubulin were determined by western blot analysis. 










Figure 8. Effects of DHC on the nuclear translocation of Nrf2 in SH-SY5Y 
cells. 
The cells were treated with DHC (0.4 - 10 µM) for 6 h. Cells were fixed and 
the nuclei were visualized with DAPI staining. Nrf2 was detected with FITC-
conjugated antibodies. Cellular morphologies were visualized with a 
fluorescence microscope (×400). Representative images from three 




Figure 9. Effects of DHC on the binding activity of Nrf2-ARE. 
The cells were treated with DHC (2 µM) for different durations (0 - 12 h), and 
the nuclear extracts were incubated with [γ-32P]-labeled oligonucleotides 
harboring an ARE consensus sequence. Nrf2-ARE binding activity was 




3.4. Effects of DHC on HO-1, NQO1 and GCLc protein expression in SH-
SY5Y cells. 
 
The protein levels of HO-1, NQO1, and GCLc, which are reported as a major 
phase II antioxidant enzymes that are transcribed upon Nrf2/ARE binding, 
were measured in the SH-SY5Y cells. As shown in Fig. 10, HO-1, NQO1, and 
GCLc protein expression levels were increased in a time- and dose-dependent 
manner by DHC treatment. As shown in Fig. 10 (B), HO-1, NQO1, and GCLc 
protein expression levels at 24 h were gradually increased by DHC treatment 
(0.08 - 10 µM). Upon Nrf2 siRNA treatment, the increased protein expression 
levels of HO-1, NQO1, and GCLc induced by DHC treatment (10 µM) were 
drastically reduced to a near-baseline level (Fig. 11). These results revealed 
that Nrf2/ARE binding is a key step in the transcriptions of HO-1, NQO1, and 










Figure 10. Effects of DHC on the expressions of the HO-1, NQO1, and 
GCLc proteins in the SH-SY5Y cells. 
The cells were treated with DHC (2 µM) for different durations (0 - 24 h) (A). 
The cells were treated with different concentrations of DHC (0.08 - 10 µM) 
for 24 h (B). After treatment, the total protein was extracted and determined 
protein expression level by western blot assay. Representative data from three 




Figure 11. Effects of DHC on the expressions of the HO-1, NQO1, and 
GCLc proteins in Nrf2 siRNA treated SH-SY5Y cells. 
The cells were transfected with Nrf2 siRNA (50 nM) or scrambled siRNA (50 
nM) prior to treatment with DHC (10 µM) for 48 h. After DHC treatment, the 
total protein was extracted and evaluated HO-1, NQO1, and GCLc protein 
expression level by western blot assay. Representative data from three 








3.5. Effects of DHC on HO-1, NQO1 and GCLc mRNA expression in SH-
SY5Y cells 
 
The mRNA levels of HO-1, NQO1, and GCLc, which are reported as a major 
phase II antioxidant enzymes that are transcribed upon Nrf2/ARE binding, 
were measured in the SH-SY5Y cells. As shown in Fig. 12 - 14, HO-1, NQO1, 
and GCLc mRNA expression levels were increased in concentration-
dependent manner by DHC treatment. HO-1, NQO1, and GCLc mRNA 
expression levels at 24 h were gradually increased by DHC treatment (0.08 - 
10 µM). These results revealed that Nrf2/ARE binding is a key step in the 











Figure 12. Effects of DHC on the mRNA expressions of HO-1 in SH-SY5Y 
cells. 
The cells were transfected with Nrf2 siRNA (50 nM) or scrambled siRNA (50 
nM) for 48 h prior to treatment with DHC (0.08 - 10 µM). After DHC 
treatment for 24h, the total RNA was extracted. The mRNA expression levels 
of HO-1 was determined by qRT-PCR analysis. Data represent the mean ± SD 




Figure 13. Effects of DHC on the mRNA expressions of NQO1 in SH-
SY5Y cells. 
The cells were transfected with Nrf2 siRNA (50 nM) or scrambled siRNA (50 
nM) for 48 h prior to treatment with DHC (0.08 - 10 µM). After DHC 
treatment for 24h, the total RNA was extracted. The mRNA expression levels 
of NQO1 was determined by qRT-PCR analysis. Data represent the mean ± 




Figure 14. Effects of DHC on the mRNA expressions of GCLc in SH-
SY5Y cells. 
The cells were transfected with Nrf2 siRNA (50 nM) or scrambled siRNA (50 
nM) for 48 h prior to treatment with DHC (0.08 - 10 µM). After DHC 
treatment for 24h, the total RNA was extracted. The mRNA expression levels 
of GCLc was determined by qRT-PCR analysis. Data represent the mean ± 
SD of three independent experiments. 
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3.6. The inhibitory effects of DHC on the 6-OHDA-induced apoptotic 
signal. 
 
The inhibitory effects of DHC on the expressions of cleaved caspase-9, 
caspase-3, and PARP during the process of apoptosis were evaluated. ROS 
accumulation is known to activate caspase-9 and caspase-3, and activated 
caspase-3 cleaves PARP. As shown in Fig. 15, the cleaved caspase-9, caspase-
3, and PARP were over-expressed when the SH-SY5Y cells were induced by 
6-OHDA. However, the over-expression of these cleaved proteins was 













Figure 15. Inhibitory effects of DHC on the expressions of cleaved 
caspase-9, caspase-3 and PARP protein. 
The cells were pre-treated with different concentrations of DHC (0.08 - 10 µM) 
for 24 h and subsequently treated with 6-OHDA (100 µM) for another 24 h. 
Then, each cell lysate was subjected to western blot analysis. Representative 










Neurodegenerative diseases may occur without obvious causes or be the 
result of numerous circumstances that cause the impairment of cellular 
performance in neuron and ultimately cell death. Due to the rapid aging of the 
populations of societies across the world, the number of patients suffering 
from the neurodegenerative disease is also increasing. Although the causes of 
these diseases have not been clearly elucidated, recent studies have revealed 
that ROS is composed of their pathogenesis (Farooqui and Farooqui, 2011). 
Because of their abundant iron contents and relatively deficient antioxidant 
defense system, neuronal cells are vulnerable to excessive ROS and 
electrophile related stress. It has been suggested that ROS is highly involved 
in the neurotoxicity of neurodegenerative disease (Munch et al., 1998b). Over 
the past decade, many studies of antioxidant enzymes have resulted in 
progress in the treatment and prevention of diseases (Rahman, 2007). In this 
context, it has been suggested that the coordinated expression of phase II 
antioxidant enzymes via the induction of nuclear Nrf2 could be a promising 
strategy for protection against oxidative stress-related neurodegenerative 
diseases.   
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The effects of DHC (Fig. 2) have not been thoroughly examined, 
particularly in relation to protection against neuronal cell death. In this report, 
DHC was found to protect against neuronal cell death and the ROS generation 
in 6-OHDA-induced SH-SY5Y cells. It was reported that caspase-9 could be 
cleaved by the ROS generation (Zuo et al., 2009). Cleaved caspase-9 induces 
activation of caspase-3 by making cleaved form of caspase-3, which is the 
important caspase involved in the apoptotic process and neuronal cell death 
caused by 6-OHDA (Dodel et al., 1999; Kuida et al., 1998). PARP is cleaved 
by active form of caspase-3, and this cleaved PARP loses the ability to 
participate in DNA repair, which results in apoptosis. PARP cleavage by 
active form of caspase-3 is a reliable indicator of apoptosis (Kaufmann et al., 
1993). In our results, DHC prevented the 6-OHDA-induced cleavages of 
caspase-3, caspase-9, and PARP, which inhibited the activation of the 
apoptotic cascade in the SH-SY5Y cells. Moreover, DHC down-regulated the 
ROS level, which was increased by treatment with 6-OHDA. Based on its 
results, we suggest that this anti-apoptotic effect of DHC is associated with 
the down-regulation of ROS.  
 The effects of the Nrf2/ARE signaling pathway on the ROS generation were 
also evaluated. Our results revealed that treatment with DHC inhibited the 
generation of 6-OHDA-induced ROS, which affect the early and late stages 
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of apoptosis. The ability of DHC to inhibit ROS generation seems to be an 
important factor in neuronal cell protection. DHC also increased the induction 
of nuclear Nrf2, which has a binding affinity to ARE and activates ARE-
driven phase II antioxidant enzymes; NQO1, HO-1, and GCLc. Nrf2 is 
regarded as a key regulator of antioxidant defensive responses and a sensor of 
cellular redox status (Kang et al., 2005). Many lines of research have proven 
the importance of Nrf2-related antioxidant enzymes in neuroprotection (Park 
et al., 2010). It has been also reported that the levels of antioxidant genes are 
considerably decreased in Nrf2-K.O. mice and the expression levels of 
antioxidant enzymes were eliminated by Nrf2-siRNA in in vitro models 
(Ramos-Gomez et al., 2001). NQO1, HO-1, and GCLc are representative 
antioxidant enzymes whose expressions are increased by diverse 
environmental stimulus including ROS and thiol-reactive substances 
(Rizzardini et al., 1993; Su et al., 2013; Fraser et al., 2002). NQO1 has been 
reported to be a potentially attractive therapeutic target for protecting cells 
from oxidative damage because it makes stable form of hydroquinone by 
catalyzing quinone (Lim et al., 2008). Moreover, it has been reported that HO-
1 catalyzes heme to carbon monoxide, biliverdin and iron, which exerts potent 
antioxidant effects (Farooqui and Farooqui, 2011). CGLc participates in 
glutathione synthesis and prevents the impairment of cellular function from 
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the excessive ROS (Pompella et al., 2003). Many studies have shown that 
these antioxidant enzymes have powerful antioxidant effects, and it has been 
suggested that the regulation of antioxidant enzymes might be a key factor in 
the prevention of age-related disease (Uttara et al., 2009). Our results revealed 
that DHC treatment induced the nuclear translocation of Nrf2, which resulted 
in the increases in NQO1, HO-1, and CGLc at the level of protein expression, 
suggesting that the neuroprotective effects of DHC against 6-OHDA-induced 
cell death are involved in the inhibition of ROS generation. Based on our 
research, we expect that one of the neuroprotective effects exerted by DHC is 
the increased induction of the Nrf2/ARE signal. When the cells were 
transfected with Nrf2 siRNA, the protective effects of DHC against 6-OHDA-
induced neurotoxicity and ROS generation were inhibited. Moreover, the 
increased protein expression levels of NQO1, HO-1, and GCLc by DHC 
treatment (10 µM) were also drastically reduced to basal levels by treatment 
with Nrf2 siRNA. The results revealed that the neuroprotective effects of DHC 
are due to the activation of Nrf2/ARE signal pathways and the subsequent 







The present study demonstrated that DHC prevented 6-OHDA-induced 
neurotoxicity via the induction of Nrf2/ARE signal, which subsequently led 
to the overexpression of antioxidant enzymes, including NQO1, HO-1, and 
CGLc. As a result of these effects, DHC inhibited the generation of ROS and 
neuronal cell death in 6-OHDA-induced SH-SY5Y cells. Our study suggests 
that DHC can be a promising neuroprotective candidate in the therapy of 














Figure 16. A scheme of protective effects of DHC on 6-OHDA-induced 
neuronal cell death via activation of Nrf2/ARE signal.  
DHC protected 6-OHDA-induced neurotoxicity via the induction of 
Nrf2/ARE signal, which subsequently led to the overexpression of antioxidant 
enzymes, including NQO1, HO-1, and CGLc. As a result of these effects, 
DHC inhibited the generation of ROS and neuronal cell death in 6-OHDA-













Orobol derivatives and extracts from Cudrania 
tricuspidata fruits protect against 6-
hydroxydopamine-induced neuronal cell death by 
enhancing proteasome activity and the 
ubiquitin/proteasome-dependent degradation of α-









Cudrania tricuspidata (Moraceae) is a subtropical tree that is widely 
distributed in Korea, China, and Japan. The fruits of C. tricuspidata are used 
in jams, juices, and a fermented alcoholic beverage with sugar, and they are 
commercially produced as food in Korea. In addition, the root, stem, leaf, and 
fruits of this plant have been reported to have anti-atherosclerotic, anti-
inflammatory and antioxidant activities (Lee et al., 2012; Park, KH et al., 2006; 
Jeong et al., 2010). Recent studies have demonstrated that the fruit of C. 
tricuspidata inhibited pancreatic lipase (Jeong et al., 2014), protected 
neuronal cells against oxidative stress-induced toxicity (Jeong et al., 2010), 
and inhibited IgE-mediated allergic and inflammatory responses (Lee et al., 
2015). The compounds isolated from C. tricuspidata are primarily xanthones 
and flavones in addition to some alkaloids, lignins, coumarins, 
polysaccharides, and chromones (Hano et al., 1991; Lee et al., 1996; Seo et 
al., 2001; Fujimoto et al., 1984; Hiep et al., 2015). The isoflavones from the 
fruits of C. tricuspidata have been reported to exert protective effects against 
6-hydroxydopamine (6-OHDA)-induced neurotoxicity (Hiep et al., 2015) and 
to have inhibitory effects against IgE-mediated allergic and inflammatory 
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responses (Lee et al., 2015). Orobol (OB), 6-prenylorobol (POB) and 6,8-
diprenylorobol (DPOB) are prenylated isoflavones. It was reported that OB 
increases cisplatin sensitivity in human ovarian carcinoma (Shiotsuka and 
Isonishi, 2001) and that DPOB shows anti-estrogenic activity (Okamoto et al., 
2006) and inhibits lipofuscin fluorophore-mediated photo oxidation (Uddin et 
al., 2011).  
 Parkinson’s disease (PD) is characterized by severe motor deficits, cogwheel 
rigidity, bradykinesia, and the loss of dopaminergic neurons. The aetiology of 
PD has not been clearly identified; however, oxidative stress is thought to be 
a common factor that leads to cellular dysfunction and neurodegeneration. 
Reactive oxygen species (ROS) are mainly produced as a by-product of 
cellular metabolism and oxidative phosphorylation. Non-neutralized ROS 
produce oxidative stress in cellular organisms and lead to abnormal molecular 
activities (Bochkov et al., 2010). In particular, the pathological events that 
occur in PD have been suggested to be linked to protein oxidation caused by 
oxidative stress (Butterfield and Kanski, 2001), and excessive intracellular 
ROS induce apoptosis that is characterized by the cleavage of caspase-3, 
caspase-9 and poly ADP-ribose polymerase (PARP) (Klovekorn and Munch, 
1998). The neurotoxin 6-OHDA destroys dopaminergic and noradrenergic 
neurons in the brain by inducing excessive ROS such as superoxide radicals, 
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which leads to protein oxidation and neuronal cell death (Kanthasamy et al., 
2010). 
 The proteasome plays a key role in the selective degradation of oxidized 
proteins via ubiquitin-mediated processes, and its role is essential for cellular 
protein maintenance (Tai and Schuman, 2008; Jung and Grune, 2013). 
The ubiquitin-proteasome system (UPS) is responsible for the degradation of 
many cellular proteins, except membrane and extracellular proteins, which 
after endocytosis are degraded within the lysosomes. In addition, misfolded, 
mutant, and oxidatively damaged proteins are also degraded by the UPS. 
Proteins to be degraded are first marked by covalent attachment of a 
polyubiqutin chain to a lysine residue on the substrate. The polyubiquitinated 
protein is then degraded by a large proteolytic complex, the 26S proteasome. 
Monoubiquitinylation, on the other hand, regulates transcription, translation, 
protein trafficking, DNA repair, and numerous other cellular functions. 
Polyubiquitination of a target protein is accomplished through a series of 
enzyme-mediated reactions that are required to ensure specificity and activate 
the ubiquitinmoiety. First, activated ubiquitin is generated by ubiquitin-
activating enzyme (E1), which forms a thiol ester linkage between 
a cysteine residue and carboxy-terminalglycine in ubiquitin in an ATP-
dependent manner. The activated ubiquitin is transferred to one of the several 
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ubiquitin carrier proteins or ubiquitin conjugating enzymes (E2s) via the 
formation of another thiol linkage. Finally, ubiquitin is ligated to the lysine 
residue of the protein substrate that is specifically bound to an E3 ligase. 
Parkin, involved in familial PD, is an example of such an E3 ligase. Additional 
activated ubiquitin moieties can be attached to internal lysine residues within 
the ubiquitin to form polyubiquitin linkages, which then act as the degradation 
sign that is recognized by the 26S proteasome complex (Dahlmann, 2007). A 
minimum of four ubiquitin moieties is required for efficient targeting to the 
proteasome. Selectivity of ubiquitination and recognition of substrates are 
largely mediated by E3s. There are more E2s than E1s, and more E3s than E2s 
so at each step the number of proteins that can possibly be involved increases, 
as does the specificity of binding to the next component. It is the E3, either 
alone or in combination with its bound E2, that determines the specificity of 
substrate recognition (Betarbet et al., 2005). 
 Proteasomes are existing in the cytoplasm, perinuclear regions, and nuclei of 
all eukaryotic cells. Their relative abundance within these compartments is 
extremely variable. In the cytoplasm, proteasomes are associated 
with centrosomes, cytoskeletal networks, and the outer surface of 
the endoplasmic reticulum. In the nucleus, proteasomes are present 
throughout the nucleoplasm but not in the nucleoli. Impairment of 
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the proteolytic pathway results in accumulation of proteasomes in these 
locations, forming organized aggregates. Aggregates located in the 
pericentrosomal areas have been termed “aggresomes”. Aggresomes are 
known to damage proteasomal function and promote apoptosis (Wojcik and 
DeMartino, 2003). 
 The 26S proteasome consists of a catalytic core—the 20S proteasome. The 
20S proteasome is made up of 28 subunits assembled as two outer and two 
inner heptameric rings stacked axially to form a hollow cylindrical structure 
wherein proteolysis occurs (Doskeland and Flatmark, 2002). The two inner 
rings of the 20S proteasome are composed of seven different β-subunits each. 
The three different catalytic sites (chymotrypsin-like, trypsin-like, and 
caspase-like-peptide hydrolytic sites) of the proteasome reside on the inner 
surface of the inner rings, thereby preventing indiscriminate degradation of 
proteins (Huang and Figueiredo-Pereira, 2010). The noncatalytic outer rings, 
comprising of seven different α-subunits, serve as an anchor for the 19S 
(PA700) multisubunit ATPase containing proteasome activator or regulator. 
The 19S complex determines substrate specificity and consists of at least six 
ATPases and more than 15 additional subunits that lack the capacity to bind 
to ATP. The 19S regulatory complex serves at least three ATP-dependent 
functions: it selectively opens the channel through the 20S proteasome, 
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unfolds ubiquitinated proteins to allow entry into the catalytic core, and 
cleaves off the polyubiquitinated chain from the substrate. The degradation 
products of proteasomal catalysis are small peptides and amino acids that can 
be recycled to produce new proteins. At the same time, polyubiquitin chains, 
released from targeted proteins, are then disassembled by ubiquitin carboxy-
terminal hydrolases to produce monomeric ubiquitin molecules that can be 
reused. Recent research has suggested that oxidative stress-induced 
proteasome dysfunction might play a key role in neurodegenerative diseases 
and that rescuing the decrease in proteasome activity could be a new 
therapeutic strategy (Seo et al., 2007). Additionally, dysfunction in 
proteasome activity was observed in the substantia nigra of PD patients, 
suggesting that the impairment of the UPS is involved in the formation of 
Lewy bodies and in dopaminergic neuronal cell death in PD (McNaught and 
Jenner, 2001). Lewy bodies are characteristic hallmarks of PD and are 
composed of primarily α-synuclein and synphilin-1 along with ubiquitin and 
other fibrils. α-synuclein, a small acidic protein composed of 140 amino acids, 
is abundant in the human brain; is also found in the heart, muscles, and other 
tissues; and is a naturally unfolded protein with the ability to self-aggregate. 
The aggregation process of α-synuclein results in potential cell damage, 
leading to dopaminergic neuronal loss in Parkinson's disease (Cookson, 2005). 
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α-synuclein also associates with other protein partners in the cell, including a 
significant interaction with synphilin-1. It has been reported that synphilin-1 
is a presynaptic protein that could be a modulator of UPS, and the 
overexpression of synphilin-1 promotes the formation of inclusions under 
conditions of proteasome inhibition. Additionally, synphilin-1 inhibits the 
degradation of α-synuclein by the proteasome, thus increasing its half-life 
(Alvarez-Castelao and Castano, 2011). Therefore, it is possible that the 
inhibition Lewy body-associated protein accumulation through the protection 
against proteasome dysfunction could be a key aspect of PD treatment. 
 In our previous reports, we investigated the neuroprotective effect of 
different extracts (0 – 100% ethanol ratio) containing isoflavones from C. 
tricuspidata fruits (Hiep et al., 2015). Here, nine isolates obtained from 50% 
ethanol extract from C. tricuspidata fruits (CTE50) were evaluated for their 
neuroprotective potential against 6-OHDA-induced cell death in SH-SY5Y 
human neuroblastoma cells. The study focused on the potential effects on 
apoptosis, intracellular ROS generation, proteasome activities, 
polyubiquitination of Lewy body-associated α-synuclein and synphilin-1 




2. Materials and methods 
 
2.1. Chemicals and reagents 
6-Hydroxydopamine (6-OHDA), and 2',7'-dichlorfluorescein-diacetate 
(DCFH-DA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
MG132 was purchased from Enzo Life Sciences (Farmingdale, NY, USA). 
Dulbecco’s modified Eagle’s medium (DMEM) and foetal bovine serum (FBS) 
were purchased from HycloneTM Thermo Scientific (Wyman Street Waltham, 
MA, USA). Hybond®-Polyvinylidene difluoride (PVDF) membranes were 
purchased from Amersham Pharmacia Biotechnology Inc. (Piscataway, NJ, 
USA). PRO-PREP protein extraction solution and WEST-ZOL® ECL solution 
were purchased from iNtRON Biotech Inc. (Kyunggi, Korea). Antibodies 
against ubiquitin, α-synuclein, synphilin-1, β-actin, caspase-3, cleaved 
caspase-3, caspase-9, cleaved caspase-9, PARP, and A/G Plus-Agarose and 
secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. 
(CA, U.S.A.) 
 
2.2. Preparation of ethanol extracts from the fruits of C. tricuspidata (CTE) 
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The fruits of C. tricuspidata were collected from the Korea Forest Research 
Institute, Southern Forest Research Center (Jinju, Korea). A voucher 
specimen (accession no. KH1-5-090904) was deposited at the Department of 
Biosystems and Biotechnology, Korea University (Seoul, Korea). The dry 
fruit of C. tricuspidata (3.4 kg) was ground into powder form and sifted 
through a 120-mesh sieve. The dry powder (7 g) was refluxed three times for 
1 h each by means of a heating mantle with 250 mL of 0, 30, 50 70, or 100% 
ethanol in round 500-mL flasks. The combined extracts were filtered and 
concentrated in vacuo to yield 2.85 g, 2.71 g, 2.57 g, 2.67 g, and 2.1 g, 
respectively. 
 
2.3. Ultra performance liquid chromatography (UPLC) analysis of 
CTE50 
The CTE50 was analysed using an Acquity UPLC system (Waters, Millford, 
MA, USA) with an Acquity UPLC BEH C18 column (1.7 µm, 2.1 × 150 mm 
i.d.). The mobile phase consisted of solvent A (0.05% formic acid in water) 
and solvent B (acetonitrile), which flowed at rate of 0.3 mL/min. The starting 
eluent was 40% B at 0 min, and the proportion of B was increased linearly to 
100% from 0 to 10 min, held constant at 100% for 11.5 min, and then returned 
to the initial condition over the course of 1.5 min to re-equilibrate the column. 
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The sample injection volume was 4 µL for extract and 2 µL for compounds 
(CTE50: 3 mg/mL, OB, POB, and DPOB: 0.2 mg/mL). The column and 
sample managers were maintained at 35 and 15 °C, respectively, and the UV 
detection wavelength was monitored at 265 nm. 
 
2.4. Isolation and identification of compounds from CTE50  
Nine isoflavones, namely, orobol (1, 0.0021%), 6-prenylorobol (2, 0.0100%), 
6,8-diprenylorobol (3, 0.0015%), millewanins H and G (4 and 5, 0.0029 and 
0.0045%), alpinumisoflavone (6, 0.0762%), 4′-O-methylalpinumisoflavone 
(7, 0.0046%), erysenegalensein E (8, 0.0181%), and 6,8-diprenylgenistein (9, 
0.0055%), were isolated from the fruits of C. tricuspidata. The chemical 
structures were determined by interpretation of spectroscopic data, including 
MS and NMR spectra, as compared to the previously reported literature 
(supplementary data 1). The detailed isolation procedures are included in the 
supplementary materials and methods. The purity of each compound was 
more than 95%. 
 
2.5. Cell cultures 
The human neuroblastoma cell line SH-SY5Y (ATCC No. CRL-2266) was 
purchased from the American Type Culture Collection (Manassas, VA, USA) 
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and cultured in DMEM supplemented with 10% heat-inactivated FBS and 1% 
penicillin/streptomycin at 37 ºC in a humidified 5% CO2 atmosphere. Test 
samples were dissolved in 10% DMSO, and the cells were treated within non-
cytotoxic concentration ranges of test samples at a final concentration of 0.1% 
DMSO.  
 
2.6. Measurement of cell viability  
SH-SY5Y cells were plated at a density of 1×105 cells/200 µL/well in 96-well 
plates for 24 h, and the cells were simultaneously treated with 6-OHDA and 
test samples (0.16 – 20 µg/mL of 0 – 100% CTE; 0.2 – 25 µM of nine isolates) 
for 48 h. After treatment, cell viability was evaluated using the MTT assay as 
previously described (Koo et al., 2011). Briefly, the medium was removed, 
and the cells were incubated with fresh medium containing 0.5 mg/mL MTT 
for 4 h at 37 ºC, after which the medium was gently removed. Formazan 
crystals were dissolved in 100 µL DMSO, and absorbance was measured at 
540 nm using a microplate reader (SpectraMax M5, Molecular Devices, USA). 
 
2.7. Measurement of intracellular ROS by flow cytometry 
Intracellular ROS levels were measured by the 2',7'-dichlorofluorescein 
diacetate (DCFH-DA) method as described previously (Kim, D-W et al., 
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2015). Briefly, SH-SY5Y cells were plated at a density of 1×106 cells/1 
mL/well in 12-well plates for 24 h, simultaneously treated with 6-OHDA (75 
µM) and test samples (0.16 – 20 µg/mL of 0 – 100% CTE, 0.2 – 25 µM of 
isolates) for 48 h, and washed three times with PBS. DCFH-DA (4 µM/mL in 
PBS) was then added, and afterwards, the cells were incubated for 30 min at 
37 ºC in the dark. The cells were then washed 3 times with PBS, and the 
fluorescence intensities of a total of 10,000 events were measured by the FL-
1 channel of a flow cytometer (BD FACS CaliburTM). 
 
2.8. Measurement of proteasome activity 
Proteasome activity was determined using SH-SY5Y cells as previously 
described (Kim, B-H et al., 2015). Briefly, cells (1.0 ×105 cells/300 µL/well) 
were plated in 48-well plates for 24 h and then simultaneously treated with 6-
OHDA (75 µM) and samples (0.16 – 20 µg/mL of CTE50, 0.2 – 25 µM of 
nine isolates) for 48 h. After washing twice with PBS, cells were lysed by 
freeze-thawing 3 times (between -70 ºC and 37 ºC, 5 min each) and scraped 
into PBS buffer. Supernatants were collected by centrifugation at 15,000 rpm 
(15 min, 4 ºC), and the total protein concentration was determined by the 
Bradford method (Bradford, 1976). The proteolytic activity of the 
proteasomes was evaluated with a 20S proteasome activity kit (APT 280; 
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Millipore, USA). In brief, supernatants (40 µg) were incubated for 2 h at 37 °C 
in the provided buffer with fluorophore-linked peptide substrates. Suc-LLVY-
AMC (40 µM), Boc-LRR-AMC (40 µM), and Z-LLE-MCA (80 µM) were 
used as the substrates for chymotrypsin-, trypsin- and caspase-like protease 
activities, respectively. Reaction mixtures without cell lysates were used as 
negative controls, and aminomethylcoumarin (AMC) or 
methylcoumarylamide (MCA) fluorescence was measured at 
excitation/emission wavelengths of 380/460 and 380/440 nm, respectively, 
using a microplate reader (SpectraMax M5, Molecular Devices, USA).  
 
2.9. Measurement of mRNA expression 
After treatments, total RNA was isolated from SH-SY5Y cells by easy-
BLUE® and cDNA was synthesized by using SuPrimeScript RT premix® 
according to the manufacturer’s procedure. The synthesized cDNA was used 
for PCR and the primer pair sequence were listed as follows:  
Chymotrypsin-like proteasome subunit (PSMB-8) 
5-GTTCCAGCATGGAGTGATTG-3 (sense) and  
5- TGTTCACCCGTAAGGCACTA-3 (antisense);  
Trypsin-like proteasome subunit (PSMB-7)  
5-ATGGCTGTACCACGAAACAA-3 (sense) and 
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5-AGGGATCCTTCAGTTTCTTCAGT-3 (antisense); 
Caspase-like proteasome subunit (PSMB-6)  
5-TCGATTTGATACCTTTGATAGCC-3 (sense) and 
5-CCAGGGTCAATGGGTGAC-3 (antisense); 
GAPDH  
5-CTCTGCTCCTCCTGTTCGAC-3 (sense) and  
5-ACGACCAAATCCGTTGACTC-3 (antisense). The cycle condition was as 
follow; 94℃ for 20s, 56℃ for 20s, 72℃ for 30s and 40 cycles. PCR were 
performed by using SYBRs HS Prime qPCR premix® in an ABI 7300 real-
time PCR (Applied Bio systems, CA, USA). Ct (threshold cycle) values were 
obtained using the Sequence Detection Software version1.2.3 (Applied Bio 
systems, CA, USA). To evaluate quantification of the changes in target gene 
expression, we used the 2-△△Ct method (Tucker and Munchus, 1998). Fold 
change=2-△△Ct, △△Ct= (Ct target gene – Ct GAPDH)-(Ct control-Ct GAPDH) 
 
2.10. Measurement of protein expression 
SH-SY5Y cells were plated at a density of 2×106 cells/4 mL in 60-mm dishes 
for 24 h. The cells were then simultaneously treated with 6-OHDA (75 µM) 
and samples (0.16 – 20 µg/mL of CTE50, 0.2 – 25 µM of three orobol 
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derivatives) for 48 h, washed three times with PBS, and lysed with a PRO-
PREP protein extraction solution at -20 ºC for 20 min. After centrifugation at 
13,000 rpm for 30 min, the supernatant was used as the total protein extract. 
Western blot analysis was accomplished as previously described (Ham et al., 
2013). Briefly, protein extracts were separated by electrophoresis on a SDS-
PAGE gel and then transferred to PVDF membranes. Then, the PVDF 
membranes were incubated overnight at 4 ºC with primary antibodies 
followed by a 1-h incubation at RT with the secondary antibody. The blots 
were developed using WEST-Queen® ECL solution and analysed using 
LAS4000 (GE Healthcare, UK) 
 
2.11. Immunoprecipitation assay 
Immunoprecipitation was performed as previously described with slight 
modifications (Chen et al., 2014). Briefly, SH-SY5Y cells were plated at a 
density of 2×106 cells/4 mL in 100-mm dishes for 24 h. The cells were then 
simultaneously treated with 6-OHDA (75 µM) and samples (0.8 – 20 µg/mL 
of CTE50, 1 – 25 µM of three orobol derivatives) for 48 h and washed three 
times with PBS. SH-SY5Y cells were homogenized and lysed in cold-lysis 
buffer (50 mM Tris, 1 mM PMSF, 150 mM NaCl, 50 mM NaF, 1% Nonidet 
P-40, 0.25% sodium deoxycholate, 10 mM sodium pyrophosphate) and 
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centrifuged at 14,000 × g (10 min, 4 °C), and the supernatant was transferred 
to a new ep-tube and incubated with 2 µg of α-synuclein or synphilin-1 
antibody overnight at 4 °C. The next day, A/G plus agarose beads were added 
and incubated overnight at 4 °C followed by 3 washes in cold-lysis buffer. 
The loading samples were adjusted to total volume of 30 µL with lysis buffer, 
and the immune-complexes were eluted at 95 °C on a heating block for 5 min, 
vortexed, and spun down by centrifugation at 15,000 × g for 10 min.  
 
2.12. Statistical analysis 
All experimental data are expressed as t h e  mean ± standard deviation. 
Statistical significance between multiple groups was determined by one-way 
ANOVA (PRISM Graph Pad, San Diego, CA, USA). When the ANOVA 
showed a significant difference, Bonferroni’s multiple comparison post hoc 










3.1. Protective effects against 6-OHDA-induced neuronal cell death in 
SH-SY5Y cell 
 
Ethanol is often used to extract bioactive compounds from plant materials, and 
the bioactivity of plant extracts depends on the ratio of water to ethanol used 
in the extraction process (Ganora, 2009). We evaluated the neuroprotective 
effects within non-cytotoxic concentration ranges from different CTE extracts 
(0, 30, 50, 70, and 100% ethanol) and nine isolates. As shown in Table 2, 
CTE50 showed the most potent protective effects with an EC50 value of 3.3 
µg/mL. The constituents of CTE50 were identified using UPLC, and nine 
isolates were obtained (Figs. 17 and 18). Among the nine isolates, three orobol 
derivatives (OB, POB, and DPOB) significantly attenuated 6-OHDA-induced 
neurotoxicity with EC50 values of 6.4 µM, 4.5 µM, and 10.1 µM, respectively 
(Table. 2). As shown in Fig. 20, 6-OHDA-induced neuronal cell death was 
observed by the morphology of cells: 6-OHDA resulted in cellular 
morphological changes including cell shrinkage and rounding. However, 
treatment with CTE50 (20 µg/mL) or the three orobol derivatives (25 µM) 
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ameliorated the 6-OHDA-induced morphological changes to almost normal 
levels. As shown in Fig. 19, the 6-OHDA-induced group showed a significant 
decrease in cell viability compared to the vehicle-treated group. However, 
CTE50 (0.16 – 20 µg/mL) or the three orobol derivatives (0.2 – 25 µM) 
protected 6-OHDA-induced neuronal cell death in a concentration-dependent 
manner. Additionally, it was examined that the comparison of neuroprotective 
effect of CTE50 and three orobol derivatives against 6-OHDA-induced 
neurotoxicity by pre-, co-, and post treatment. Among three groups, co-













Table 2. Inhibitory effects of ethanol extracts and isolates from the fruits 
of C. tricuspidata against 6-OHDA-induced cell death and ROS 






Figure 17. UPLC chromatograms and structures of isolates from CTE50. 
UPLC chromatogram of CTE50 and isolates from CTE50. Nine compounds 
were isolated from CTE50. Among nine isolates, orobol, 6-prenylorobol, and 
6,8-diprenylorobol were selected for further study. The selected three orobol 










Figure 18. Chemical structures of the isolates from CTE50.  
The isolated compounds are orobol (1), 6-prenylorobol (2), 6,8-
diprenylorobol (3), millewanin H (4), millewanin G (5), alpinumisoflavone 






Figure 19. Inhibitory effects of CTE50 and three orobol derivatives (OB, 
POB, and DPOB) against 6-OHDA-induced neurotoxicity. 
Cells were cultured in 96-well plate for 24 h, and CTE50 or orobol derivatives 
were simultaneously treated with 6-OHDA (75 µM) for 48 h. Cell viability 
were measured by MTT reduction assay (A – D). Data represent the mean ± 
SD of three independent experiments. (***p<0.001 versus control group, 




Figure 20. Neuroprotective effects of CTE50 and the three orobol 
derivatives (OB, POB, and DPOB) against 6-OHDA-induced 
neurotoxicity in SH-SY5Y cells. 
Cells were cultured in 96-well plate for 24h, and CTE50 or three orobol 
derivatives were simultaneously treated with 6-OHDA (75 µM) for 48 h. The 
morphological change of cell was observed by inverted phase-contrast 





3.2. Inhibition of 6-OHDA-induced intracellular ROS generation 
 
Excessive intracellular ROS induce cellular stress and neuronal cell death, and 
it has been reported that ROS play important roles in the pathogenesis of 
neurodegenerative diseases. As shown in Table 2, CTE50 showed the most 
potent inhibition of 6-OHDA-induced ROS generation with an IC50 value of 
6.7 µg/mL. Among the nine compounds derived from CTE50, the three orobol 
derivatives showed a significant inhibitory effect against 6-OHDA-induced 
intracellular ROS generation with IC50 values of 7.2 µM (OB), 5.9 µM (POB), 
and 17.3 µM (DPOB). As shown in Fig. 21 and 22, 6-OHDA-treated cells 
showed strong DCF fluorescence intensities compared to vehicle-treated cells. 
The amount of intracellular ROS was decreased in a concentration-dependent 
manner when cells were treated with CTE50 (0.8 – 20 µg/mL) or the three 









Figure 21. Inhibitory effects of CTE50 and three orobol derivatives (OB, 
POB, and DPOB) against 6-OHDA-induced ROS generation. 
Cells were cultured in 12-well plate for 24h, and CTE50 or three orobol 
derivatives were simultaneously treated with 6-OHDA (75 µM) for 48 h (A – 
D). The cells were stained with DCFH-DA dyes for 30 min and determined 
by FACS analysis using FL-1 channel. The values of fluorescence intensity 





Figure 22. Inhibitory effects of CTE50 and three orobol derivatives (OB, 
POB, and DPOB) against 6-OHDA-induced ROS generation. 
Cells were cultured in 96-well plate for 24h, and CTE50 or three orobol 
derivatives were simultaneously treated with 6-OHDA (75 µM) for 48 h (E – 
H). The cells were stained with DCFH-DA dyes for 30 min and fluorescence 
intensity was measured by multi-plate reader. Data represent the mean ± SD 
of three independent experiments. (***p<0.001 versus control group, 
##p<0.01 and ###p<0.001 versus 6-OHDA-induced group) 
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3.3. Neuroprotective effects against 6-OHDA-induced apoptosis 
 
It has been reported that 6-OHDA induces ROS-dependent apoptosis, which 
is characterized by the cleavage of caspase-9, caspase-3 and PARP. Excessive 
ROS accumulation results in the activation of the caspases (caspase-9 and 
caspase-3), and activated caspase-3 cleaves the DNA repair protein PARP; 
cleaved, activated PARP is final apoptotic marker. To investigate the 
inhibitory effects of CTE50 and three orobol derivatives on the levels of 
cleaved caspase-9, caspase-3, and PARP protein, we performed a western blot 
assay. As shown in Fig. 23, the cleavage levels of caspase-9, caspase-3, and 
PARP were increased when the SH-SY5Y cells were exposed to 6-OHDA. 
However, CTE50 (0.16 – 20 µg/mL) or the three orobol derivatives (0.2 – 
25µM) inhibited the cleavage of caspase-9, caspase-3, and PARP protein in a 








Figure 23. Inhibitory effects of CTE50 and three orobol derivatives 
against 6-OHDA-induced apoptotic markers. 
Cells were simultaneously treated with 6-OHDA (75 µM) and (A) CTE50 or 
(B – D) three orobol derivatives for 48 h. The levels of cleaved caspase-9, 
caspase-3 and PARP were assessed by western blot; β-actin was used as a 
housekeeping protein. Representative data from three independent 




3.4. Protective effects against 6-OHDA-induced dysfunction of 
proteasome activity 
 
Proteasome function is essential for cellular physiology and protein 
degradation. To evaluate the effects of CTE50 and the nine isolates against 
the dysfunction of proteasome activity induced by 6-OHDA in SH-SY5Y cells, 
we measured the activities of chymotrypsin-, trypsin- and caspase-like 
proteases. As shown in Table 3 and Fig. 24, 6-OHDA significantly inhibited 
all three different types of proteasome activities; however, CTE50 most 
potently attenuated the 6-OHDA-induced dysfunction of proteasome activities 
from extracts (0 – 100%) with an EC50 value of 1.2 µg/mL (chymotrypsin-
like), 1.5 µg/mL (trypsin-like), and 6.7 µg/mL (caspase-like). The three orobol 
derivatives at the concentration of 25 µM prominently protected against 6-
OHDA-induced dysfunction of the proteasome and almost restored the 







Table 3. The protective effects of ethanol extracts and isolates from the 
fruits of C. tricuspidata against 6-OHDA-induced proteasome dysfunction 







Figure 24. Protective effects of CTE50 and three orobol derivatives (OB, 
POB, and DPOB) against 6-OHDA-induced dysfunction of proteasome 
activities in SH-SY5Y cells. 
Cells were cultured in 48-well plate for 24h, and (A) CTE50 or (B – D) three 
orobol derivatives were treated with 6-OHDA (75 µM) for 48 h. 
Chymotrypsin-, trypsin-, and caspase-like proteasome activities were 
measured by multiplate reader with fluorophore-linked peptide substrates. The 
relative fluorescence intensity was indicated. Data represent the mean ± SD 
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of three independent experiments. (***p<0.001 versus control group, 




















3.5. Effects of CTE50 and three orobol derivatives on proteasome subunit 
mRNA expression 
 
Proteasome function is essential for cellular physiology and protein 
degradation. Proteasome is composed of subunit and each subunit correlates 
chymotrypsin-like, trypsin-like, caspase-like proteasome activities. To 
evaluate the effects of CTE50 and three orobol derivatives on proteasome 
subunit mRNA expression, we measured the mRNA expression of 
chymotrypsin-, trypsin- and caspase-like proteases. As shown in Fig. 25, 
CTE50 significantly increase all three different types of proteasome subunit 
mRNA expressions; Also, three orobol derivatives increased three types of 
proteasome subunit mRNA expression at a concentration dependent manner. 
However, the increased mRNA expression of each proteasome subunits was 









Figure 25. Effects of CTE50 and three orobol derivatives (OB, POB, and 
DPOB) on mRNA expression of proteasome subunits in SH-SY5Y cells. 
Cells were cultured in 12-well plate for 24h, and (A) CTE50 or (B – D) three 
orobol derivatives were treated for 24 h. The mRNA expression of 
Chymotrypsin-, trypsin-, and caspase-like proteasome subunit were measured 







3.6. Inhibition of 6-OHDA-induced ubiquitin-conjugated proteins 
 
Proteasome dysfunction causes a reduction in the degradation of misfolded 
proteins, consequently resulting in the accumulation of polyubiquitinated 
proteins. To investigate the inhibitory effects of CTE50 and the three orobol 
derivatives against 6-OHDA-induced ubiquitin conjugated-protein formation, 
we performed western blot analysis. As shown in Fig. 26, 6-OHDA increased 
the levels of high molecular ubiquitin-conjugated proteins. When cells were 
treated with different concentrations of CTE50 (0.16 – 20 µg/mL) (Fig. 26A) 
or the three orobol derivatives (0.2 – 25 µM) (Fig. 26B – 26D), the levels of 
ubiquitin-conjugated proteins were decreased to normal in a concentration-
dependent manner. CTE50 (20 µg/mL) and the three orobol derivatives (25 









Figure 26. Inhibitory effects of CTE50 and three orobol derivatives 
against 6-OHDA-induced ubiquitin-conjugated proteins. 
Cells were simultaneously treated with 6-OHDA (75 µM) and (A) CTE50 or 
(B – D) three orobol derivatives for 48 h. The levels of ubiquitin-conjugated 
proteins were determined by western blot; β-actin was used as a housekeeping 




3.7. Inhibition of 6-OHDA-induced poly-ubiquitination of α-synuclein, 
and synphilin-1 
 
Physiologically, polyubiquitinated proteins are normally rapidly degraded by 
the proteasome. However, dysfunction in proteasome activity increases the 
polyubiquitination of α-synuclein and synphilin-1, inducing neurotoxicity. As 
shown in Fig. 27, 6-OHDA increased the polyubiquitination of α-synuclein. 
When the cells were treated with different concentrations of CTE50 (0.8 – 20 
µg/mL) or the three orobol derivatives (1 – 25 µM), the polyubiquitination of 
α-synuclein was restored to almost normal levels in a concentration-dependent 
manner (Fig. 27A – 27D). Additionally, as shown in Fig. 28, 6-OHDA 
increased the polyubiquitination of synphilin-1; however, CTE50 (0.8 – 20 
µg/mL) and the three orobol derivatives (1 – 25 µM) reduced the 
polyubiquitinated synphilin-1 to almost normal levels in a concentration-








Figure 27. Inhibitory effects of CTE50 and three orobol derivatives 
against 6-OHDA-induced polyubiquitination of α-synuclein. 
Cells were simultaneously treated with 6-OHDA (75 µM) and (A) CTE50 or 
(B – D) three orobol derivatives for 48 h. The polyubiquitination of α-
synuclein was determined by immunoprecipitation and western blot analysis. 





Figure 28. Inhibitory effects of CTE50 and three orobol derivatives 
against 6-OHDA-induced polyubiquitination of synphilin-1. 
Cells were simultaneously treated with 6-OHDA (75 µM) and (E) CTE50 or 
(F – H) three orobol derivatives for 48 h. The polyubiquitination of synphilin-
1 was determined by immunoprecipitation and western blot analysis. 





3.8. A proteasome inhibitor (MG-132) diminished the protective effects of 
CTE50 and the three orobol derivatives against 6-OHDA-induced 
neuronal cell death and proteasome dysfunction 
 
It has been reported that proteasome inhibition induces dopaminergic neuronal 
cell degeneration and apoptosis (Park et al., 2011). In contrast, proteasome 
activation enhances survival in a neuronal model of neurodegenerative disease 
(Seo et al., 2007). To investigate whether the neuroprotective effects of 
CTE50 and the three orobol derivatives are due to the amelioration of 
proteasomal dysfunction, MG132, a proteasome inhibitor, was co-applied 
with the samples. As shown in Fig. 29, CTE50 (20 µg/mL) and three orobol 
derivatives (25 µM) protected against 6-OHDA-induced neuronal cell death; 
however, co-treatment with MG132 (1 µM, non-cytotoxic concentration) 
significantly blocked the protective effects of CTE50 and the three orobol 
derivatives against 6-OHDA-induced cell death. Additionally, MG132 (1 µM) 
blocked the recovery effects of CTE50 and the three orobol derivatives against 





Figure 29. Inhibitory effects of MG132 on the protective effects of CTE50 
and three orobol derivatives against 6-OHDA-induced neuronal cell 
death. 
The protective effects of CTE50 and three orobol derivatives 6-OHDA-
induced neuronal cell death were blocked by MG132. Cell viability was 
measured by the MTT reduction assay. (Data represent the mean ± SD of three 
independent experiments. (***p<0.001 versus control group, #p<0.05, 





Figure 30. Inhibitory effects of MG132 on the protective effects of CTE50 
and three orobol derivatives against 6-OHDA-induced proteasome 
dysfunction. 
The protective effects of CTE50 and three orobol derivatives against 6-
OHDA-induced proteasome dysfunction were blocked by MG132. Three 
types of proteasome activity were measured using a multi-plate reader with 
fluorophore-linked peptide substrates. Data represent the mean ± SD of three 
independent experiments. (***p<0.001 versus control group, #p<0.05, 




Figure 31. Comparison of neuroprotective effect of CTE50 and three 
orobol derivatives (OB, POB, and DPOB) against 6-OHDA-induced 
neurotoxicity by pre-, co-, and post treatment. 
In pre-treatment group, cells were cultured in 96-well plate for 24 h, and 
CTE50 or orobol derivatives pre-treated for 48h. After 48h, medium was 
changed and cells were treated with 6-OHDA (75 µM) for 48 h. In co-
treatment group, cells were cultured, and CTE50 or orobol derivatives were 
simultaneously treated with 6-OHDA for 48 h. In post-treatment group, cells 
were cultured, and treated with 6-OHDA for 48 h. After 48h, medium was 
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changed and cells were treated CTE50 or orobol derivatives for 48 h. Cell 
viability were measured by MTT reduction assay. Data represent the mean ± 
SD of three independent experiments. (***p<0.001 versus control group, 














Figure 32. The effects of N-acetylcystein (NAC) against 6-OHDA-induced 
neurotoxicity and ROS generation. 
Cells were cultured in 96-well plate for 24 h, and NAC was simultaneously 
treated with 6-OHDA (75 µM) for 48 h. Cell viability were measured by MTT 
reduction assay (A). Cells were cultured in 12-well plate for 24h, and NAC 
were simultaneously treated with 6-OHDA (75 µM) for 48 h. The relative 
fluorescence intensities of total 10,000 events by FACs analysis with DCFH-
DA dye were quantified (B). Data represent the mean ± SD of three 
independent experiments. (***p<0.001 versus control group, ###p<0.001 







Figure 33. The effect of MG132 on neurotoxicity and ROS generation.  
Cells were cultured in 96-well plate for 24 h, and MG132 was for 48 h. Cell 
viability were measured by MTT reduction assay (A). Cells were cultured in 
12-well plate for 24h, and MG132 were for 48 h. The relative fluorescence 
intensities of total 10,000 events by FACS analysis with DCFH-DA dye were 
quantified (B). Data represent the mean ± SD of three independent 











As the world’s population is rapidly ageing, the number of patients suffering 
from PD is increasing significantly. Although the cause of PD has not been 
definitively verified, recent research findings have suggested that oxidative 
stress and the impairment of the proteasome are major events in its 
pathogenesis (Ciechanover and Kwon, 2015). Oxidative stress has been 
implicated in ageing and neurodegenerative diseases such as PD. Oxidative 
stress induces the oxidation and aggregation of proteins in the brain 
(Butterfield and Kanski, 2001). In addition, excessive oxidative stress 
advances cellular apoptosis through the accumulation of oxidized proteins 
(Klovekorn and Munch, 1998). Many studies have reported that protein 
homeostasis is essential for cellular physiology and that the proteasome is 
responsible for selectively degrading targets including short-lived, damaged 
or misfolded protein, which comprise approximately 80% of all intracellular 
proteins. Hence, considerable interest has been paid to the importance of the 
role of the proteasome. The ubiquitination process is activated by ubiquitin-
activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin-
transferring enzymes (E3). Through a sequential enzymatic reaction, proteins 
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are polyubiquitinated by E3 ligase. The polyubiquitin chain is recognized by 
the regulatory domain of the proteasome, in which the target protein is 
degraded by the catalytic core domain (Amm et al., 2014). Under normal 
conditions, polyubiquitinated proteins are rapidly degraded and do not 
accumulate. The accumulation of polyubiquitinated proteins is observed when 
excessive intracellular ROS, cellular stress, and diverse stress impair 
proteasome function (Elkon et al., 2004), and the accumulation of 
polyubiquitinated proteins induces neurotoxicity and neurodegeneration. 
Thus, the restoration of proteasome activity through the down-regulation of 
intracellular ROS is one of the primary mechanisms regulating ubiquitin-
conjugated proteins, Lewy body-associated α-synuclein, and synphilin-1 
proteins and the protection against neuronal cell death.  
 In the present study, 6-OHDA-induced ROS generation decreased in a 
concentration-dependent manner when cells were treated with different 
concentrations of CTE50 or the three orobol derivatives, and these compounds 
significantly elicited their neuroprotective effects against 6-OHDA-induced 
cell death and inhibited 6-OHDA-induced changes in cell morphology 
including shrinkage and rounding. In addition, we evaluated the inhibitory 
effects of CTE50 and the three orobol derivatives on the levels of cleaved 
caspase-9, caspase-3 and PARP, which are apoptosis signal factors; 6-OHDA 
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treatment increased the levels of cleaved caspase-9, caspase-3 and PARP 
protein; however, these increases were inhibited by co-treatment with CTE50 
and the three orobol derivatives. A previous study demonstrated that the 
inhibitory effect of (-)-epigallocatechin-3-gallate (EGCG) on ROS generation 
led to a suppression of apoptosis (Ning et al., 2016). In our results, the 
inhibitory effects of CTE50 and three orobol derivatives on ROS generation 
are also concomitant with the protection against neuronal cell death and the 
activation of apoptosis signalling markers. Based on the neuroprotective 
effects of three orobol derivatives, we evaluated structure-bioactivity 
relationship (SAR). The compounds with two hydroxy groups at C-3′ and C-
4′ in B-ring of flavonoid (1 – 5) exhibited neuroprotective effects, whereas the 
others with one hydroxy group at C-4’ (6 – 9) did not. This suggested that the 
hydroxy group in the B-ring of flavonoid influences neuroprotective effects. 
The neuroprotective effect of prenyl-groups is not clear from 9 isolates to 
evaluate SAR. Therefore, further study will be necessary to evaluate SAR with 
prenylated flavonoids on neuroprotective activity. 
 A recent study emphasized the role of the proteasome in neurodegenerative 
disease and showed that proteasome inhibition induced neurotoxicity via the 
accumulation of polyubiquitinated proteins and protein aggregation (Canu et 
al., 2000). As neuronal cells are vulnerable to the accumulation of 
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polyubiquitinated proteins, several neurodegenerative diseases are related to 
the neurotoxicity resulting from protein accumulation. It has been shown that 
proteasome activity can gradually decrease with ageing and environmental 
stress, among other reasons, which results in a reduced ability to degrade 
misfolded proteins, contributing to the development of pathological protein 
aggregates (Ciechanover and Kwon, 2015). In cellular models, proteasome 
inhibition induced apoptosis and neuronal cell degeneration (Park et al., 2011; 
Sun et al., 2006), whereas proteasome activation enhanced neuronal cell 
survival (Seo et al., 2007). Thus, the protection against proteasome 
dysfunction could be a possible therapeutic strategy for neuroprotection. To 
investigate the mechanism underlying the protective effects of CTE50 and the 
three orobol derivatives against 6-OHDA-induced neuronal cell death, 
chymotrypsin-, trypsin-, and caspase-like proteasome activities were 
measured in SH-SY5Y cells. Our results showed that 6-OHDA significantly 
inhibited all three types of proteasome activities due to excessive ROS 
generation, and these results correlate with previously reported studies (Elkon 
et al., 2004). CTE50 and the three orobol derivatives at concentration of 20 
µg/mL and 25 µM, respectively, attenuated 6-OHDA-induced dysfunction of 
the proteasome and nearly restored proteasome activities to normal levels. 
Additionally, we measured the levels of ubiquitin-conjugated proteins and 
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found an increase following 6-OHDA treatment. However, CTE50 (20 µg/mL) 
and the three orobol derivatives (25 µM) attenuated the 6-OHDA-induced 
increase in ubiquitin-conjugated protein levels to almost normal. These results 
suggested that 6-OHDA-induced proteasome dysfunction triggers the 
accumulation of ubiquitin-conjugated proteins, leading to neuronal cell death; 
however, CTE50 and the three orobol derivatives prevented the dysfunction 
of ubiquitin proteasome system (UPS) and protected against neuronal cell 
death. The impairment of UPS is involved in the formation of Lewy bodies, 
which is a characteristic hallmark of PD. Lewy bodies are composed of 
abnormal filamentous aggregates containing α-synuclein, and synphilin-1 has 
been found to colocalize with α-synuclein in Lewy bodies. It has been 
demonstrated that the overexpression of α-synuclein in Drosophila and C. 
elegans induced neuronal cell loss (Kontopoulos et al., 2006; Pesah et al., 
2005). It has also been reported that α-synuclein filaments and oligomers 
themselves inhibited proteasome activities (Lindersson et al., 2004). 
Synphilin-1 has been reported to enhance the aggregation and neurotoxicity 
of α-synuclein (Buttner et al., 2010) and to promote inclusion formation under 
conditions of proteasome inhibition. Additionally, it has been reported that 
synphilin-1 inhibits the degradation of α-synuclein by the proteasome and thus 
increases the half-life of α-synuclein (Alvarez-Castelao and Castano, 2011). 
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Therefore, it has been suggested that the regulation of α-synuclein and 
synphilin-1 through UPS is important for neuroprotection (Sidhu et al., 2004). 
It was also previously reported that a relationship exists between proteasome 
dysfunction and neuronal cell death. Proteasome inhibition triggers a dramatic 
activation of the pro-apoptotic caspase-3,-9, PARP and DNA fragment (Sun 
et al., 2006; Yuan et al., 2008). The proteasome inhibitor MG132 induces 
dopaminergic neuronal cell degeneration and apoptosis (Park et al., 2011), and 
bortezomib, a proteasome inhibitor, induces caspase-dependent apoptosis. In 
contrast, a proteasome activator enhances the survival of neuronal cells (Seo 
et al., 2007), and betulinic acid and demethylsuberosin, reported to be 
proteasome activators, showed neuroprotective effects (Eksioglu-Demiralp et 
al., 2010; Kim, B-H et al., 2015). In our results, 6-OHDA-induced proteasome 
dysfunction resulted in the polyubiquitination of α-synuclein and synphilin-1 
protein. However, CTE50 and the three orobol derivatives reduced the levels 
of 6-OHDA-induced polyubiquitination of α-synuclein and synphilin-1 
protein in addition to ameliorating the dysfunction of proteasome activities. 
Furthermore, treatment with MG132, a proteasome inhibitor, significantly 
reduced the protective effects of CTE50 and the three orobol derivatives 
against 6-OHDA-induced neuronal cell death and proteasome dysfunction, 
suggesting that their neuronal cell protective effects are partly due to the 
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protection against proteasome dysfunction. In spite of the evidence for 
neuroprotection by orobol derivatives, there has been little research reported 
on the blood-brain barrier (BBB) permeability of orobol derivatives. However, 
some studies have demonstrated that isoflavones and several metabolites have 
been proven to transverse the BBB (Chandrasekharan and Aglin, 2013; 
Youdim et al., 2003). Therefore, BBB permeability of orobol and its 
derivatives should be studied to elucidate its potential for permeation across 
















In conclusion, this study demonstrated that CTE50 and three orobol 
derivatives protected against neuronal cell death and ROS generation, and 
attenuated proteasome dysfunction, the accumulation of ubiquitin-conjugated 
proteins, and the levels of polyubiquitinated α-synuclein and synphilin-1, the 
constituents of Lewy bodies. However, the neuroprotective effects of CTE50 
and three orobol derivatives and the attenuation of proteasome dysfunction 
were significantly inhibited by MG132, suggesting their neuroprotective 
effects are partly due to the protection of the ubiquitin/proteasome-dependent 
degradation of α-synuclein and synphilin-1. Based on the results, it was 
suggested that CTE50 and the three orobol derivatives might be promising 









Figure 34. A scheme of protective effects of CTE50 and three orobol 
derivatives on 6-OHDA-induced neuronal cell death via enhancing 
proteasome activity and the ubiquitin/proteasome-dependent 
degradation of α-synuclein and synphilin-1. 
CTE50 and three orobol derivatives protected against neuronal cell death, 
ROS generation, and accumulation of ubiquitin-conjugated proteins, 













Protective effects of TH3-125-4 (TH20) from the root 
barks of Cudrania tricuspidata on CCCP-induced 
neuronal cell death via the inhibition of USP30 












Mitophagy, a specialized autophagy pathway that mediates the clearance of 
damaged mitochondria by lysosomes, is important for mitochondrial quality 
control. Defective mitochondria, if left uncleared, can be a source of oxidative 
stress and compromise the health of the entire mitochondrial network. 
Parkinson’s disease is characterized prominently, but not solely, by loss of 
dopaminergic neurons in the substantia nigra. Although the pathogenic 
mechanisms of Parkinson’s disease are unclear, several lines of evidence 
propose that mitochondrial dysfunction is central to the disease. Most 
compellingly, familial Parkinson’s disease can be caused by mutations in the 
ubiquitin ligase parkin and protein kinase PINK1 (Valente et al., 2004), both 
of which maintain healthy mitochondria via regulating mitochondrial 
dynamics and quality control (Narendra and Youle, 2011). Genetic studies 
established that PINK1 acts upstream of parkin (Park, J et al., 2006a). PINK1 
recruits parkin from the cytoplasm to the surface of damaged mitochondria, 
leading to parkin-mediated ubiquitination of mitochondrial outer membrane 
proteins and deletion of damaged mitochondria by mitophagy (Narendra et al., 
2010; Chan et al., 2011). Parkinson’s disease-associated mutations in PINK1 
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or parkin impair parkin recruitment, mitochondrial ubiquitination, and/or 
mitophagy (Matsuda et al., 2010; Vives-Bauza et al., 2010). In the context of 
the inherently high mitochondrial oxidative stress in substantia nigra 
dopamine neurons, loss of parkin-mediated mitophagy could explain the 
greater susceptibility of substantia nigra neurons to neurodegeneration. Thus, 
promoting mitophagy and enhancing mitochondrial quality control could 
benefit dopaminergic neurons. Recent studies reported that deubiquitinating 
enzyme antagonizes the role of parkin e3 ligase. In culture of dopaminergic 
cells overexpressing parkin, Ubiquitin-specific protease (USP) 15, 30 blocks 
ubiquitination of mitochondrial proteins by parkin and inhibits lysosomal 
delivery of mitochondria and mitophagy (Nakamura and Hirose, 2008) . USP 
30 can counteract parkin-mediated ubiquitination and degradation of 
mitochondrial Rho GTPase 1 (MIRO1) and translocase of outer mitochondrial 
membrane 20 (TOM20), two mitochondrial proteins, after mitochondrial 
damage. Also, USP30 can inhibit parkin-mediated ubiquitination of mitofusin 
1, 2 (Mfn1,2), mitochondria fusion proteins. In cells transfected with green-
fluorescent-protein-parkin (GFP-parkin) and expressing pathogenic parkin 
mutations, the mitophagy process is deficient. In this model, a knockdown of 
USP30 protein restores mitophagy, allowing cells to overcome parkin 
deficiency. Finally, using PINK1 or parkin mutant Drosophilia, the authors 
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demonstrated that USP30 suppression maintained mitochondrial health, 
improved climbing capability, and prevented dopamine depletion (Park, J et 
al., 2006b). Finally, in flies treated by paraquat, a mitochondrial toxin 
inducing parkinsonism, knockdown of USP30 rescued climbing ability, 
improved flies’ survival, and prevented dopamine depletion (Tanner et al., 
2011). All of these experiments show that USP30 plays a major role in 
dopaminergic cell dysfunction by altering mitophagy and that inhibiting this 
protein could represent a promising strategy for PD treatment. In this study, 
we evaluated the inhibitory effects of the isolated compounds from C. 
tricuspidata on USP15, 30. Also, the study investigated the potential effects 
on neuroprotection, parkin mediated mitophagy, mitochondrial membrane 
potential against CCCP-induced SH-SY5Y cells and parkin knock down SH-









2. Material and methods  
 
2.1. Chemicals and reagents  
Carbonyl cyanide 3-chlorophenylhydrazone (CCCP), JC-1, MG132, CCK-8, 
mitotracker, and PR-619 were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Dulbecco’s modified Eagle’s medium (DMEM) and fetal bovine serum 
(FBS) were purchased from Gibco BRL (Rockville, MD, USA). Hybond-
polyvinylidene difluoride (PVDF) membranes were purchased from 
Amersham Pharmacia Biotechnology Inc. (Piscataway, NJ, USA). PRO-
PREP protein extraction solution and WEST-Queen® ECL solution were 
purchased from iNtRON Biotech Inc. (Kyunggi, Korea). USP15, USP30, tetra 
ubiquitin peptides were purchased from Bio-Vision, Inc. (Milpitas, CA, USA) 
Parkin siRNA, scrambled siRNA, Mfn1, Mfn2, ubiquitin, USP15, USP30, 
OPA1, VDAC, alpha-tubulin, parkin, LC3-II first antibody, secondary 
antibody and FITC-conjugated secondary antibody were purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA)  
 
2.2. Preparation of TH3-125-4 (TH20) 
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Cudrania tricuspidata was stored at the Korea Forest Research Institute at 
Southern Forest Research Center (Jinju, Korea) in September 2008. A voucher 
specimen (accession number KH1-4-090814) was kept at the Department of 
Biosystems and Biotechnology at Korea University (Seoul, Korea). TH3-125-
4 (TH20) was isolated from the roots of Cudrania tricuspidata and the 
structure of TH3-125-4 (TH20) was determined by spectroscopic methods, 
and the purity was more than 98% (Wei and Yu, 2008). TH3-125-4 (TH20) 
was dissolved in DMSO and diluted with PBS to obtain the proper 
concentration. Final concentration of DMSO was less than 0.1% and it didn’t 
influence the performed assays. 
 
2.3. Cell cultures  
The human neuroblastoma cell line SH-SY5Y (ATCC No. CRL-2266) was 
purchased from the American Type Culture Collection (Manassas, VA, USA) 
and cultured in DMEM supplemented with 10 % heat-inactivated FBS and 1 % 
penicillin/streptomycin at 37 ºC in a humidified 5 % CO2 atmosphere.  
 
2.4. Measurement of cell viability  
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SH-SY5Y cells were seeded at a density of 1×105 cells/200 µL/well in 96-well 
plates for 24 h, and the cells were pre-treated with isolated compounds from 
C. tricuspidata for 24 h followed by subsequent treatment with CCCP (10 µM) 
for an additional 24 h. To evaluate the effect of parkin, cells were transfected 
with scrambled siRNA or parkin siRNA for 48 h and its final concentration 
was 100 nM. After transfected cells were treated with isolated compounds and 
CCCP (10 µM), cell viability was determined using a CCK-8 and measured 
by ELISA (Koo et al., 2011). 
 
2.5. Measurement of mitochondrial membrane potential by JC-1 staining 
SH-SY5Y cells were seeded at a density of 2×105 cells/2 mL/well in 6-well 
plates for 24 h, and the cells were pre-treated with isolated compounds for 24 
h followed by subsequent treatment with CCCP (10 µM) for an additional 8 h. 
Mitochondrial membrane potential was determined using a JC-1 dyes. Briefly, 
the cells were washed with PBS, and then incubated with 10 µg/mL of JC-1 
for 30 min at 37 ºC in the dark. The cells were then washed with PBS. The 




2.6. Measurement of intracellular ROS by Flow cytometry  
ROS levels in cells were measured with the 2',7'-dichlorofluorescein diacetate 
(DCFH-DA) method (Munch et al., 1998a). Briefly, the cells were washed 
with PBS, and then incubated with 4 µM of DCFH-DA for 30 min at 37 ºC in 
the dark. The cells were then washed with PBS. The fluorescence intensities 
were measured by flow cytometry (BD FACSCalibur TM). 
 
2.7. Mitochondrial and cytosolic fraction preparations  
The mitochondrial and cytosolic proteins were extracted with a commercial 
kit (Mitochondria/Cytosol Fractionation Kit) according to the manufacturer’s 
procedure (Bio-Vision, Milpitas, CA,). Briefly, the cells were incubated in 
cytosolic fraction buffer on ice for 15 min and homogenize cells in an ice-cold 
dounce tissue grinder. After homogenize, centrifuged for 10 min at 700 x g in 
a microcentrifuge at 4 ºC. Transfer the supernatant to a fresh 1.5-ml tube, and 
centrifuge at 10,000 x g in a microcentrifuge for 30 min at 4 ºC. Collect 
supernatant as a cytosolic fraction and mitochondrial pellet were washed with 
cold PBS, extracted completely with mitochondrial fraction buffer.  
 
2.8. Parkin knock down via the transfection of small interfering RNA 
(siRNA)  
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The transfection with scrambled siRNA or parkin siRNA were progressed at 
final concentrations of 100 nM for 48 h by Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) prior to treatment with isolated compounds and CCCP (10 µM) 
as recommended by the manufacturer’s guidelines.  
 
2.9. Measurement of protein expression  
The cells were collected, washed with PBS and lysed with a PRO-PREP 
protein extraction solution at -20 ºC for 20 min. After centrifugation at 13,000 
x g for 30 min, the supernatant was used as the total protein extracts. Western 
blot analysis was accomplished as previously described method (Ham et al., 
2013).  
 
2.10. Immunoprecipitation assay 
Immunoprecipitation was performed as previously described with slight 
modifications (Chen et al., 2014). After treatment, cells were washed three 
times with PBS and homogenized and lysed in cold-lysis buffer (50 mM Tris, 
1 mM PMSF, 150 mM NaCl, 50 mM NaF, 1% Nonidet P-40, 0.25% sodium 
deoxycholate, 10 mM sodium pyrophosphate) and centrifuged at 14,000 × g 
(10 min, 4 °C), and the supernatant was transferred to a new ep-tube and 
incubated with 2 µg of Mfn1 or Mfn2 antibody overnight at 4 °C. The next 
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day, A/G plus agarose beads were added and incubated overnight at 4 °C 
followed by 3 washes in cold-lysis buffer. The loading samples were adjusted 
to total volume of 30 µL with lysis buffer, and the immune-complexes were 
eluted at 95 °C on a heating block for 5 min, vortexed, and spun down by 
centrifugation at 15,000 × g for 10 min.  
 
2.11. Measurement of mitophagy by fluorescence microscope  
The culture dish was coated with 0.2 % gelatin at 37 °C for 30 min and dried 
at RT on a clean bench. The SH-SY5Y cells were plated at a density of 5×104 
cells/200 µL/well in coated dishes for 24 h and CCCP for 8 h. After treatment, 
the cells were washed with 1x PBS/Tween-20 buffer (pH 7.4) (PBST) once. 
The cells were fixed with 4 % paraformaldehyde for 30 min at room 
temperature (RT). After washing with PBST, the blocking steps were 
performed with 1 % BSA in PBST. Next, the cells were incubated with the 
primary antibody at 4 °C overnight. The next day, the cells were washed with 
PBST 3 times and incubated with FITC-conjugated secondary antibody for 1 
h at RT. After 1 h, the cells were washed with PBST 3 times, and DAPI 
staining was performed for 5 min at RT. Lastly, the PBST washing and 
mounting steps were conducted. 
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2.12. Measurement of deubiquitinating enzyme activity 
DUB assay buffer is composed of 20 mM HEPES at pH7.2, 100 mM NaCl, 
0.05 % Tween 20, 0.1 mg/mL BSA, 1 mM DTT. Purified DUBs at optimal 
concentrations (USP 15, 50 nmol/L; USP30, 50 nmol/L) were incubated in 
DUB buffer containing isolated compounds (indicated concentration), vehicle 
alone (DMSO), or PR-619, (positive control for DUB inhibition) in a 100 µL 
reaction volume for 30 to 60 minutes at 37 °C. The reaction was initiated by 
the addition of 500 nmol/L Ub-AMC, and the release of AMC fluorescence 
was recorded at excitation/emission of 380/480 using a fluorometer. 
  
2.13. Measurement of ubiquitin chain disassembly 
In vitro disassembly of purified polyubiquitin chains (K48/K63 linked) was 
performed as described earlier (Dayal et al., 2009). USP30 (50 ng) prepared 
in DUB buffer was incubated with K48- or K63-linked chains (1 µg) and 
isolated compound for 15 min at 37 °C. The extent of chain disassembly was 
assessed by Western blotting. 
 
2.14. Statistical analysis  
All experimental data are expressed as mean value ± standard deviation. 
Statistical significance between multiple groups was determined by one-way 
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ANOVA (PRISM Graph Pad, San Diego, CA, USA). When ANOVA had a 
significant difference, post hoc Bonferroni’s multiple comparison tests was 





















3.1. Inhibitory effect of TH3-125-4 (TH20) on deubiquitinating enzymes, 
USP15, USP30.  
 
The isolated compounds from C. tricuspidata were evaluated to determine its 
inhibitory effects on deubiquitinating enzyme (DUB) activity. As shown in 
Table. 4, twelve isolated compounds inhibited USP15, USP30 activity. 
Among twelve isolated compounds, TH3-125-4 (TH20) showed potent 
inhibitory effects on USP30 with an IC50 values of 38.1 µM. TH20 inhibited 
USP30 enzyme activity concentration-dependently manner (Fig. 36). 
However, TH20 did not show inhibitory effect on USP15, total DUB enzyme 
activity. PR-619, a non-selective DUB inhibitor, significantly inhibited 
USP15, USP30, and total DUB enzyme activities, respectively (Fig. 37). The 




















Table 4. Inhibitory effect of isolated compounds from C.tricuspidata on 












































































155.2 >160 >160 
… … … … … 
129 JY1-134-5 >160 >160 >160 
130 PR619 4 6.7 8.5 
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Figure 36. Inhibitory effects of TH3-125-4 (TH20) on USP15 and USP30 
enzyme activities. 
TH20 was incubated with 1 x DUB assay buffer for 30 min. DUB enzyme 
activities were measured by multiplate reader with fluorophore-linked Ub-
AMC peptide substrates. The relative fluorescence intensity was indicated. 








Figure 37. Inhibitory effects of PR-619 on USP15 and USP30 enzyme 
activities. 
PR-619 was incubated with 1 x DUB assay buffer for 30 min. DUB enzyme 
activities were measured by multiplate reader with fluorophore-linked Ub-
AMC peptide substrates. The relative fluorescence intensity was indicated. 






3.2. Effect of TH3-125-4 (TH20) on ubiquitin chain disassembly 
 
The polyubiquitin chains (K48/K63 linked) are formed by e3 ligase like a 
parkin. The polyubiquitin chains are resolved by DUB. The incubation 
polyubiquitin chain with USP30 significantly induced disassembly of tetra 
ubiquitin. However, incubation with TH3-125-4 (TH20) inhibited 
disassembly of tetra ubiquitin at a concentration-dependent manner. The 80 
µM of TH20 completely blocked the degradation of tetra ubiquitin. The results 














Figure 38. Inhibitory effects of TH3-125-4 (TH20) on USP30 enzyme 
mediated tetra ubiquitin disassembly. 
TH20 was incubated with 1 x DUB assay buffer for 30 min. USP30 enzyme 
activities were measured by western blot assay with tetra ubiquitin peptide 







3.3. The protective effects of TH3-125-4 (TH20) against CCCP-induced 
neuronal cell death in parkin knock down SH-SY5Y cells.  
 
The previous study revealed that parkin knock down cells were increased the 
vulnerability against CCCP neurotoxin. In the results, parkin siRNA 
transfected SH-SY5Y cells were more vulnerable to CCCP induce than 
scramble siRNA transfected SH-SY5Y cells. Also, USP15 or USP30 siRNA-
transfected SH-SY5Y cells significantly protected the CCCP-induced cell 
death (Fig.39 and 40). Pre-treatment of TH20 protected CCCP-induced parkin 
knock down cell death at a concentration dependent manner. However, TH20 












Figure 39. The protective effects of USP15 siRNA against CCCP-induced 
neuronal cell death in parkin knock down SH-SY5Y cells.  
The cells were double-transfected with different concentrations of USP15 
siRNA (10 - 50 nM) and Parkin siRNA or scramble siRNA (100 nM) for 48 
h. After 24h, cells were subsequently treated with CCCP (10 µM) for another 





Figure 40. The protective effects of TH3-125-4 (TH20) against CCCP-
induced neuronal cell death in parkin knock down SH-SY5Y cells.  
The cells were double-transfected with different concentrations of USP30 
siRNA (10 - 50 nM) and Parkin siRNA or scramble siRNA (100 nM) for 48 
h. After 24h, cells were subsequently treated with CCCP (10 µM) for another 





Figure 41. The protective effects of TH3-125-4 (TH20) against CCCP-
induced neuronal cell death in parkin knock down SH-SY5Y cells.  
The cells were pre-treated with different concentrations of TH20 (1 - 10 µM) 
for 24 h and subsequently treated with CCCP (10 µM) for another 24 h. The 
cells were transfected with Parkin siRNA or scramble siRNA (100 nM) for 
48 h before the treatment with TH20. The cell viability was determined by 






3.4. Inhibitory effect of TH3-125-4 (TH20) on USP30 protein expression 
in SH-SY5Y cells. 
 
We evaluated USP15, USP30 protein expression in SH-SY5Y cells. Among 
twelve isolated compounds, TH20 inhibited USP30 protein expression (Fig. 
42). However, TH20 did not affect the protein expression of USP15. The 
protein expression of USP30 were gradually decreased by TH20 treatment at 
a concentration dependent manner. PR-619, a non-selective DUB inhibitor, 
did not affect the protein expression of USP15, USP30 (Fig. 43). The 













Figure 42. Inhibitory effect of TH3-125-4 (TH20) on USP30 protein 
expression in SH-SY5Y cells. 
The cells were treated with TH20 (10 µM) for different durations (0 - 24 h). 
After treatment, the total protein was extracted and determined protein 
expression level by western blot assay. Representative data from three 









Figure 43. The protective effects of TH3-125-4 (TH20) against CCCP-
induced neuronal cell death in parkin knock down SH-SY5Y cells.  
The cells were treated with PR-619 (2.5 µM) for different durations (0 - 24 h). 
After treatment, the total protein was extracted and determined protein 
expression level by western blot assay. Representative data from three 









3.5. Effect of TH3-125-4 (TH20) on CCCP-induced disruption of 
mitochondrial membrane potential. 
 
CCCP induces the rapid collapse of mitochondrial membrane potential 
(MMP) in SH-SY5Y cells. In our results, CCCP-induced collapse of MMP 
was peaked at 8 h. To evaluate the effect of TH20 on MMP, SH-SY5Y cell 
were pre-treated by TH20 for 24h. After then, MMP was disrupted by CCCP 
for 8h. TH20 did not protected CCCP-induced disruption of MMP (Fig. 44). 
The 10 µM of TH20 treatment slightly protected CCCP-induced collapse of 













Figure 44. Effect of TH3-125-4 (TH20) on CCCP-induced disruption of 
mitochondrial membrane potential. 
The cells were pre-treated with different concentrations of TH20 (1 - 10 µM) 
for 24 h and subsequently treated with CCCP (10 µM) for another 8 h. The 
cells were stained with JC-1 dyes for 30 min and determined by FACS 
analysis using FL-1 and FL-2 channel. The values of fluorescence intensity 







Parkinson’s disease is the most common neurodegenerative movement 
disorder. Although most cases are sporadic, several genes have been recently 
linked to familial PD, and loss-of-function mutations in Park2, the gene 
coding for the ubiquitin ligase Parkin, represent the most common recessive 
cause (Kitada et al., 1998). Parkin-null Drosophila melanogaster exhibit a 
severe phenotype, with the loss of dopaminergic neurons, disrupted 
spermatogenesis, and swollen and disordered mitochondria appearing before 
degeneration of their indirect flight muscles (Greene et al., 2003). The role of 
parkin in mitochondria phenotype was demonstrated. Parkin is selectively 
recruited to dysfunctional mitochondria in mammalian cells, and that after 
recruitment, Parkin mediates the engulfment of mitochondria by 
autophagosomes and their subsequent degradation. The results suggest that 
loss of Parkin activity may allow the accumulation of dysfunctional 
mitochondria, leading to neuron loss in PD, and that Parkin normally functions 
to survey mitochondrial activity and maintain mitochondrial fidelity by 
activating the autophagy of damaged organelles (Narendra et al., 2008). A 
recent proteomic study in human cells showed that Parkin ubiquitinates over 
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100 sites in more than 30 different MOM proteins, including Mfn1,2, in 
response to mitochondrial depolarization (Sarraf et al., 2013). In a recent 
research, deubiquitinating enzymes were reported that it can be an antagonist 
of parkin e3 ligase and inhibit parkin-mediated mitophagy. Among diverse 
DUBs, USP15 and USP30 were emerged as a major factor in opposing parkin 
e3 ligase activity. USP15, -30 deubiquitinates parkin-mediated mitochondrial 
fusion, fission proteins (Bingol et al., 2014; Cornelissen et al., 2014). Hence, 
the inhibition of USP15,-30 could be a therapeutic implication for familial PD. 
 In the current study, we identified a small natural compound, TH3-125-4 
(TH20) derived from C. tricuspidata, which potently inhibits USP30 enzyme 
activity. However, TH20 did not significantly affect USP15 and total DUB 
enzyme activity. The inhibition of USP30 enzyme activity has a major role in 
PINK1-Parkin mediated mitophagy. It was reported that UPS30 physically 
interacts with Mfn1, 2 and decreases ubiquitination of Mfn1and Mfn2, 
whereas mutation of the active cysteine (C77) in the catalytic domain to serine 
abolishes its deubiquitinase activity, and thus the USP30-C77S mutant is 
unable to affect the ubiquitination of Mfns. Furthermore, it was demonstrated 
that inhibition of USP30 could lead to enhanced ubiquitination of Mfn1 or 
Mfn2, which promotes mitochondrial fusion (Yue et al., 2014). Hence, 
inhibitory effect of TH20 on USP30 enzyme activity could enhance PINK1-
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Parkin mediated mitophagy. When the cells were transfected with Parkin 
siRNA, CCCP-induced neuronal cell death was increased comparing scramble 
siRNA treated SH-SY5Y. While TH20 treatment protected CCCP-induced 
neuronal cell death in Parkin K.D. SH-SY5Y cells, TH20 did not show 
protective effect against CCCP-induced neuronal cell death in scramble K.D. 
SH-SY5Y cells. Also, TH20 did not protect CCCP-induced disruption of 
MMP. The neuroprotective effect of TH20 in Parkin K.D. SH-SY5Y cells was 
predicted to be due to the DUB inhibitory effect, and the experiment for the 
DUB inhibitory effect was carried out. TH20 inhibited the enzymatic activity 
of USP30, while the inhibitory effect on USP15 and total DUB activity was 
weak. In addition, TH20 decreased the protein expression of USP30 in SH-
SY5Y cells. Based on our results, we suggest that the protective effect of 
TH20 on CCCP-induced neuronal cell death in Parkin K.D. SH-SY5Y cells is 
mainly inhibition of USP30 enzyme activity. Further studies are needed to 
validate the hypothesis of the study, such as the effects of TH20 on Mfn1,2, 
OPA1, VDAC, LC3-beta, and p62 which are one of Parkin-mediated 
mitophagy factors. We are under investigating the effect of TH20 on Parkin-






In conclusion, this study demonstrated that TH20 protected against CCCP-
induced neuronal cell death in Parkin K.D. SH-SY5Y cells. Also, TH20 
significantly inhibited USP30 enzyme activity and disassembly of 
polyubiquitin chain in in vitro assay. Our results showed that the protein 
expression of USP30 was decreased by treatment with TH20. Based on our 
results, we suggest that TH20 might be promising candidates for the therapy 
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꾸지뽕나무로부터 분리한 유효성분물질의 파킨슨병 
세포모델에서의 신경보호효과: Ubiquitin-proteasome system 및  
Nrf2-ARE 관련 기전에 관한 효과연구 
 
김 동 우 
약학과 천연물과학 전공 
서울대학교 약학대학 대학원 
 
파킨슨 병은  운동 장애, 기억 상실, 운동 부조 및 도파민 신경의 
손실등의 특징을 보이는 퇴행성 뇌질환이다. 파킨슨 병의 원인은 
명확하게 특정되지 않았지만 산화적 스트레스, 유비퀴틴 – 
프로테아좀 기능저하, mitophagy 기능이상은 세포 기능 장애 및 
과도한 독성단백질의 축적 및 미토콘드리아 장애를 초래하며 주요 
병인으로 간주되고있다. 신경독성으로 알려진 6-OHDA, CCCP 는 
라디칼과 같은 과도한 활성산소종을 유도하거나 미토콘드리아의 
기능이상을 유도함으로써 도파민 뉴런을 파괴하고 단백질 산화 및 
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신경 세포 사멸을 일으킨다. 산화적스트레스는 다양한 
분자병리학적 기전을 통해 세포사멸을 유발하며, 유비퀴틴 – 
프로테아좀 기능저하는 독성 단백질의 과다축적을 유도하고 
이로인해 신경 세포사를 초래한다. Mitophagy 의 기능이상은  
제거해야할 미토콘드리아의 과축적을 유발하여 신경 세포사를 
초래한다. 현재 개발중인 새로운 치료법은 도파민 뉴런을 보호하는 
것을 목적으로 하고 있다. 본 연구에서 파킨슨 병의 치료제제로써 
가능성 있는 선도 화합물을 발견하기 위해 SH-SY5Y 신경아종 
세포에서 6-OHDA, CCCP 로 유도한 뇌세포 사멸 보호효과 및 관련 
기전에 대하여 연구하였다. 
 첫번째로, 꾸지뽕나무 뿌리로부터 분리한 5,7-Dihydroxychromone 
(DHC)의 Nrf2/ARE 기전 활성화를 통한 6-OHDA 로 유도한 
뇌세포사멸 보호효과를 연구하고자 하였다. 6-OHDA 로 유도한 SH-
SY5Y 뇌세포 사멸은 DHC 처리에 의해 농도의존적으로 감소하는 
결과를 보였으며, 세포내 활성산소종 역시 DHC 처리에 의해 
감소하는 결과를 확인하였다. 이에 DHC 의 뇌세포사멸 보호효과의 
기전을 확인하고자, DHC 의 Nrf2 nuclear translocation 에 대해 
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연구하였고, DHC 처리에 의해 Nrf2 의 핵안으로 이동이 증가함을 
확인하였다. 이어진 연구에 의해 핵안으로 이동한 Nrf2 가 ARE 와 
binding 하는 것을 확인할 수 있었으며, 이로인해 phase 2 antioxidant 
enzyme 의 발현량이 증가하는 결과를 확인하였다. 이어진 실험에서 
Nrf2  knock down 시킨 세포주에서 DHC 의 뇌세포사멸 보호효과는 
현저히 감소되는 결과를 확인하였다. 즉, DHC 의  6-OHDA 로 
유도한 뇌세포사멸의 보호효과가 Nrf2/ARE 기전을 통한 phase 2 
antioxidant enzyme 의 활성화를 통한것임을 증명할 수 있었다. 
최종적으로 Nrf2/ARE 기전의 활성화를 통한 퇴행성뇌질환 예방 및 
치료제 선도물질로써 가능성을 제시할 수 있다.  
 두번째로, 꾸지뽕나무 열매로부터 분리한 Orobol 유도체 및 
에탄올 추출물을 이용하여 6-OHDA 로 유도한 뇌세포 사멸 및 
ubiquitin-proteasome system 에 대한 효과를 연구 하였다. 꾸지뽕나무 
열매 50% 에탄올 추출물 및 orobol, 6-prenylorobol, 6,8-
diprenylorobol 이 6-OHDA 로 유도한 SH-SY5Y 뇌세포사멸 
보호효과가 가장 우수하였다. 또한, 50% 에탄올 추출물 및 orobol 
유도체는 6-OHDA 로 유도한 proteasome dysfunction 을 효과적으로 
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보호하는 결과를 보였다. Proteasome  보호효과를 통해 파킨슨 
질환의 주요 독성 단백질 중 하나인 a-synuclein, synphilin-1 의 
제거를 효과적으로 유도하였다. 하지만 proteasome inhibitor 인 
MG132 를 처리함에 따라 50% 에탄올 추출물 및 orobol 유도체의 
세포사멸 보호효과 및 proteasome 보호효과가 현저히 저하되는 
결과를 보였다. 즉, 꾸지뽕나무 열매 50% 에탄올 추출물 및 orobol 
유도체는 ubiquituin-proteasome system 의 정상화를 통해 a-synuclein, 
synphilin-1 의 제거를 유도하고, apoptosis, 활성산소종 생성을 
억제하며 뇌세포를 효과적으로 보호함을 증명할 수 있었다. 
최종적으로 proteasome 보호효과를 통한 퇴행성 뇌질환 예방 및 
치료제의 선도물질로써의 가능성을 제시할 수 있다. 
 마지막으로, 꾸지뽕나무로부터 분리한 유효물질이 deubiquitinating 
효소에 미치는 영향을 연구 하였다. 꾸지뽕나무 뿌리로부터 분리 
된 TH3-125-4 (TH20)는 Parkin K.D. SH-SY5Y 세포주에서 CCCP 로 
유도한 신경 세포 사멸을 보호하였다. TH20 은 deubiquitinating 
효소로 알려진 USP30 의 활성을 효과적으로 억제하였으며, USP30 의 
polyubiquitin 분해활성 역시 억제하는 효과를 보였다. 또한, TH20 은 
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USP30 의 단백질 발현을 감소시켰다. 연구 결과에 따르면 TH20 은 
Parkin 매개 mitophagy 를 정상적으로 회복하여 유전형 파킨슨 병의 
치료제 선도물질로써의 가능성을 보였다.  
 
 
주요어: 꾸지뽕나무, 산화적 스트레스, 6-OHDA, 뇌세포사멸 보호, 
5,7-Dihydroxychromone, Nrf2/ARE pathway, orobol 유도체, 프로테아좀 



































































































저 시-비 리- 경 지 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적 된 허락조건
 명확하게 나타내어야 합니다.  
l 저 터  허가를 면 러한 조건들  적 되지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 목적  할 수 없습니다. 
경 지. 하는  저 물  개 , 형 또는 가공할 수 없습니다. 
A Thesis for the Degree of Doctor of Philosophy in Pharmacology 
 
 
Neuroprotection of active principles from the Cudrania 
tricuspidata in in vitro models of Parkinson’s disease: Effect 




꾸지뽕나무로부터 분리한 유효성분물질의 파킨슨병 
세포모델에서의 신경보호효과: Ubiquitin-proteasome 







Natural Products Science Major, College of Pharmacy 





Neuroprotection of active principles from the Cudrania 
tricuspidata in in vitro models of Parkinson’s disease: Effect on the 




Natural Products Science Major  
College of Pharmacy 
Doctor Course in the Graduate School 
Seoul National University 
  
Parkinson’s disease (PD) is characterized by severe motor deficits, cogwheel 
rigidity, bradykinesia, and the loss of dopaminergic neurons. The aetiology of PD 
has not been clearly identified; however, oxidative stress is thought to be a common 
factor that leads to cellular dysfunction and neurodegeneration. In particular, the 
pathological events that occur in PD have been suggested to be linked to protein 
oxidation caused by oxidative stress, and excessive intracellular ROS induce 
apoptosis that is characterized by the cleavage of caspase-3, caspase-9 and poly 
 ii 
ADP-ribose polymerase (PARP). The neurotoxin 6-hydroxydopamine (6-OHDA), 
Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) destroys dopaminergic and 
noradrenergic neurons in the brain by inducing excessive ROS such as superoxide 
radicals, which leads to protein oxidation and neuronal cell death. Also, ubiquitin-
proteasome system play a key role in the etiology of PD. The proteasome selective 
degrades oxidized proteins via ubiquitin-mediated processes, and its role is 
essential for cellular protein maintenance. However, dysfunctions in the 
ubiquitination machinery or in the proteolytic activities of the proteasome induce 
the accumulation of polyubiquitinated misfolded proteins and oxidized proteins. 
Subsequently, this induces protein aggregation, further inhibits proteasome activity, 
generates additional cellular stress, and ultimately leads to neuronal cell death. 
Additionally, mitophagy play a major role in the etiology of PD. Mitophagy, a 
specialized autophagy pathway that mediates the clearance of damaged 
mitochondria by lysosomes, is important for mitochondrial quality control. 
Defective mitochondria, if left uncleared, can be a source of oxidative stress and 
compromise the health of the entire mitochondrial network. The several lines of 
evidence propose that mitochondrial dysfunction is central to the disease. PD-
associated mutations in PINK1 or parkin impair parkin recruitment, mitochondrial 
ubiquitination, and/or mitophagy. In the context of the inherently high 
mitochondrial oxidative stress in substantia nigra dopamine neurons, loss of parkin-
mediated mitophagy could explain the greater susceptibility of substantia nigra 
 iii 
neurons to neurodegeneration. Thus, promoting mitophagy and enhancing 
mitochondrial quality control could benefit dopaminergic neurons. The current 
therapeutic drugs are based on prohibiting the progress of PD through treatment of 
dopamine agonist or dopamine precursor. New therapies in development are aimed 
at protecting dopaminergic neurons. In this study, the effects of natural products on 
6-OHDA, CCCP-mediated signaling in SH-SY5Y neuroblastoma cell were 
investigated to discover new lead compounds for the treatment of PD.  
Cudrania tricuspidata (Moraceae) is a subtropical tree that is widely distributed 
in Korea, China, and Japan. The fruits of C. tricuspidata are used in jams, juices, 
and a fermented alcoholic beverage with sugar, and they are commercially 
produced as food in Korea. Also, the cortex and root bark of C. tricuspidata have 
been used as a traditional medicine for inflammation and tumors. A recent study 
demonstrated that the extracts of C. tricuspidata protect neurons against oxidative 
stress-induced cytotoxicity and inhibitory effects on nitric oxide synthase (NOS). 
The compounds isolated from C. tricuspidata are primarily xanthones and flavones 
in addition to some alkaloids, lignins, coumarins, polysaccharides, and chromones. 
The isoflavones and chromones from C. tricuspidata have been reported to exert 
protective effects against 6-OHDA-induced neurotoxicity and to have inhibitory 
effects against IgE-mediated allergic and inflammatory responses.  
In first chapter, it was investigated that 5,7-dihydroxychromone (DHC) isolated 
from the roots of C. tricuspidata for its neuronal cell protection and inhibition of 
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the generation of ROS in 6-OHDA-induced SH-SY5Y cells. Flow cytometric 
analysis revealed that DHC protected against the 6-OHDA-induced generation of 
ROS and protected against neuronal cell death. Additionally, DHC increased the 
nuclear translocation of Nrf2 and the binding of Nrf2 to ARE, which subsequently 
resulted in the up-regulation of the expression of Nrf2-dependent antioxidant genes, 
including heme oxygenase 1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1) 
and glutamate-cysteine ligase, catalytic subunit (GCLc). DHC inhibited the 
expression of cleaved caspase-3 and caspase-9 and PARP in 6-OHDA-induced SH-
SY5Y cells. The addition of Nrf2 siRNA abolished the neuroprotective effect of 
DHC against 6-OHDA-induced cell death and the expression of Nrf2-mediated 
antioxidant genes. These findings suggest that the neuroprotective effect of DHC 
against 6-OHDA-induced toxicity is partly due to the induction of Nrf2-mediated 
antioxidant gene expression via the activation of the Nrf2-ARE signaling pathway 
in SH-SY5Y cells.  
In the second chapter, the effects of ethanol extract from the fruits of C. 
tricuspidata (CTE) and it active compounds were studied. Among the nine isolates 
from a 50% ethanol extract from C. tricuspidata fruits (CTE50), orobol (OB), 6-
prenylorobol (POB), and 6,8-diprenylorobol (DPOB) showed neuroprotective 
effects in 6-OHDA-induced SH-SY5Y cell death. In addition, CTE50 and the three 
orobol derivatives (OB, POB, and DPOB) attenuated the cleavage of caspase-3, 
caspase-9, and PARP and inhibited the excessive generation of ROS. Furthermore, 
 v 
it enhanced the 6-OHDA-induced dysfunction of proteasome activity and reduced 
the accumulation of ubiquitin conjugated-proteins and the polyubiquitination of α-
synuclein and synphilin-1. The proteasome inhibitor MG132 blocked the 
neuroprotective effects and the enhanced proteasome activity produced by CTE50 
and the three orobol derivatives. These results demonstrate that CTE50 and three 
orobol derivatives protect against 6-OHDA-induced neurotoxicity by enhancing the 
ubiquitin/proteasome-dependent degradation of α-synuclein and synphilin-1, 
suggesting that they might be possible candidates for the treatment of 
neurodegenerative diseases.  
In the third chapter, the effects of active compounds from the C. tricuspidata 
extracts on deubiquitinating enzymes were studied. TH3-125-4 (TH20) isolated 
from the root barks of the C. tricuspidata protected against CCCP-induced neuronal 
cell death in Parkin K.D. SH-SY5Y cells. Also, TH20 significantly inhibited 
USP30 enzyme activity and disassembly of polyubiquitin chain in in vitro assay. 
Additionally, TH20 decreased protein expression of USP30. Based on the results, 
it was suggested that TH20 might be promising candidates for the therapy of 
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The incidence of neurodegenerative diseases is increasing with the continuous 
growth of the elderly population. Although the causes of neurodegenerative 
diseases have not been clearly elucidated, recent studies have demonstrated 
that reactive oxygen species (ROS) might be one of the important factors in 
the neurotoxicity that occurs in neurodegenerative diseases (Farooqui and 
Farooqui, 2011). Cells exposed to environment fortified with oxygen 
constantly generate oxygen free radicals. ROS includes oxygen-related free 
radicals and reactive species, and they are produced as a result of aerobic 
metabolism. Formation of ROS can occur in two ways: enzymatic and non-
enzymatic responses. Enzymatic responses generating free radicals include 
those involved in the mitochondrial respiratory chain, phagocytosis, 
prostaglandin synthesis and the cytochrome P450 system. The non-enzymatic 
process can also occur through oxidative phosphorylation (i.e. aerobic 
respiration) in the mitochondria. ROS is generated from either endogenous or 
exogenous sources. Endogenous free radicals are generated from immune cell 
activation, inflammation, mental stress, excessive exercise, ischemia, 
infection, cancer and aging. Exogenous ROS result from air and water 
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pollution, cigarette smoke, alcohol, heavy or transition metals (Cd, Hg, Pb, Fe, 
As), certain drugs (cyclosporine, tacrolimus, gentamycin, bleomycin), 
industrial solvents, cooking (smoked meat, used oil, fat) and radiation. After 
penetrated into the body by different ways, these exogenous agents are 
decomposed or metabolized into free radicals (Chen et al., 2012). Increased 
ROS production causes impairment to cell organelles. Many studies have 
confirmed the benefits of antioxidants in reducing oxidative stress in neurons 
and protecting against neurodegenerative diseases (Alfieri et al., 2011). In 
response to excessive ROS, the cellular expressions and bioactivity of 
numerous antioxidant enzymes are changed via initiating the upstream factor 
NF-E2-related factor 2 (Nrf2)/antioxidant response elements (AREs) complex 
(Leutner et al., 2000).  
 The Nrf2/ARE signal has an important effect on the induction of antioxidant 
gene expression, and it has been reported that the activation of Nrf2 is an 
important signal which can neutralize oxidative stress (Sun et al., 2010). Nrf2 
activity is regulated partly by Keap1 protein, which was initially proposed to 
act by binding and tethering the transcription factor in the cytoplasm. 
Activation of Nrf2 in response to stress signals was thought to result from a 
interruption of this association, releasing Nrf2 for translocation into the 
nucleus to affect its transcriptional activity. Independently, Nrf2 has been 
 4 
found to be a highly unstable protein, subject to proteolytic degradation 
catalyzed by the proteasome via the ubiquitin-dependent pathway. In this case, 
activation of Nrf2 was suggested to be dependent on mechanisms that increase 
its stability, leading to its accumulation in the cell. The unstable nature of the 
Nrf2 protein and its regulation through this dynamic mechanism suggest that 
Nrf2 is unlikely to be joined in a passive complex in the cytoplasm. This was 
supported by a number of studies demonstrating a more active role of Keap1 
in its repression of Nrf2 activity. Keap1 appears to promote Nrf2 
ubiquitylation in a constitutive manner through the cullin-3-dependent 
pathway. That Nrf2 is constantly degraded in non-stressed cells implies that 
Keap1 is a constitutively active protein and that it promotes Nrf2 
ubiquitylation in an unregulated manner. This is supported by the observation 
that overexpression of Keap1 leads to increased levels of ubiquitin-conjugated 
forms of Nrf2 in cells, indicating that Keap1 is expressed as a functionally 
active protein. Thus, interaction between the two proteins is more likely a 
transient encounter rather than a sustained association. Given that the steady-
state level of Nrf2 in the cell is maintained in part through its constitutive 
expression, requiring de novo gene transcription and protein synthesis, the 
pathway through which Nrf2 activity is regulated, from synthesis to 
degradation, requires examination in further detail (Nguyen et al., 2009). In 
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summary, under normal state, Nrf2 is localized in the cytoplasm and is subject 
to ubiquitination and proteasomal degradation. However, antioxidant agents 
block the elimination of Nrf2 from the cytosolic Nrf2 complex, which induces 
nuclear translocation of Nrf2 and subsequently makes the Nrf2/ARE complex 
to mediate the induction of many antioxidant enzyme genes, such as heme 
oxygenase 1 (HO-1), NAD(P)H: quinone oxidoreductase (NQO1), and 
glutamate-cysteine ligase catalytic subunit (GCLc) (Zhang et al., 2013). 
 The heme-heme oxygenase (HO) system is a controller of endothelial cell 
integrity and oxidative stress. HO-1 and HO-2, two isoforms of HO, are 
viewed as having a major role in the construction of carbon monoxide (CO) 
and bilirubin and in heme breakdown. The fact that HO-1 is strongly induced 
by oxidant stress and its substrate heme, in conjunction with the ability of HO-
1, to protect against oxidative insult suggests a countervailing system to 
oxidative stress damage. The antioxidant effects of HO-1 arise from its 
capacity to increase reduced glutathione levels and to degrade heme, as well 
as from the elaboration of biliverdin and bilirubin, which have potent 
antioxidant properties. CO, a product of HO, is not an antioxidant, but it does 
have an antiapoptotic effect. Furthermore, CO is a vasodilator that has been 
shown to enhance endothelial function and plays an important role in 
regulating basal and constrictor-induced vascular tone (Turkseven et al., 2005).  
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 NQO1 has multiple protective roles that include and extend beyond its 
catalytic function. It is a widely-distributed FAD-dependent flavoprotein that 
catalyzes the reduction of quinones, quinoneimines, nitroaromatics, and azo 
dyes. NQO1 was discovered and named DT-diaphorase in the late 1950s, and 
shown to be identical to the dicoumarol-inhibited vitamin K reductase 
described. The classical direct antioxidant role of NQO1 is characteristic in its 
catalytic mechanism: the obligatory two-electron reduction of a wide array of 
quinones to their corresponding hydroquinones by using either NADPH or 
NADH as the hydride donor. In doing so, NQO1 diverts quinone electrophiles 
from participating in reactions that could lead to either sulfhydryl depletion, 
or to one-electron reductions that can produce semiquinones and various 
reactive oxygen intermediates as a result of redox cycling. In addition, the 
hydroquinone products of the NQO1 reaction can be further metabolized to 
glucuronide and sulfate conjugates, thereby facilitating their excretion. 
Remarkably, quinone reductases have been found in a wide range of 
eukaryotic organisms ranging from yeast to mammals. Although in many 
systems much remains to be learned about the complicated details of the 
function and regulation of these enzymes, it is clear that in all cases quinone 
reductases are at the forefront of the cellular defense by providing multiple 
layers of protection (Dinkova-Kostova and Talalay, 2010).  
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 Glutathione (GSH) is considered the most abundant molecule among 
endogenous antioxidants. GSH is a reduced peptide consisting of three-
residues (γ-l-glutamyl-l-cysteinyl glycine) which can donate an electron with 
the consequence that two electrons donating GSH molecules form oxidized 
GSSG. In humans, GSH is almost uniquely present in a quite high 
concentration (1–10 mM) which allows to scavenge ROS either directly or 
indirectly. It can directly react with O2- and some other ROS, but its indirect 
ROS-scavenging functions, such as revitalizing other antioxidants, are likely 
more important; e.g. it can reduce dehydroascorbic acid which is formed in 
the reconversion of α-tocopheroxyl radical to α-tocopherol, a lipophilic chain 
breaking antioxidant, which interacts with the polyunsaturated acyl groups of 
lipids, stabilizes membranes and scavenges various reactive oxygen species 
and lipid oxy-radicals. As an antioxidant it reacts with ROS, RNS and radicals 
produced in association with electron transport, xenobiotic metabolism and 
inflammatory responses. GSH is synthesized from its constituent amino acids 
forming a tripeptide thiol and this synthesis requires two ATP-dependent steps. 
The first and limiting synthesis is catalyzed by γ-glutamyl-cysteine ligase 
(GCL) and the second step mediated by GSH synthetase (GS). GCL is a 
heterodimeric enzyme composed by a heavy subunit, GCLc with catalytic 
activity and a smaller one, GCLm that has a regulatory role on the other 
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subunit. GSH homeostasis in the cell is not only regulated by its de novo 
synthesis, but also by other factors such as utilization, recycling and cellular 
export. This redox cycle is known as the GSH cycle and incorporates other 
important antioxidant, redox-related enzymes. Nearly every eukaryotic cell, 
from plants to yeast to humans, expresses a form of the GCL protein for the 
purpose of synthesizing GSH. To further highlight the critical nature of this 
enzyme, genetic knockdown of GCL results in embryonic lethality. 
Furthermore, dysregulation of GCL enzymatic function and activity is known 
to be involved in the vast majority of human diseases, such as diabetes, 
Parkinson's disease, Alzheimer’s disease, COPD, HIV/AIDS, and cancer. 
This typically involves impaired function leading to decreased GSH 
biosynthesis, reduced cellular antioxidant capacity, and the induction of 
oxidative stress (Espinosa-Diez et al., 2015). Numerous research results 
reported that Nrf2 and Nrf2 dependent antioxidant genes are potent factors for 
developing the therapy of neurodegenerative diseases due to its abilities to 
regulate the excessive oxidative stress and inflammation. A recent study 
demonstrated that the extracts of Cudrania tricuspidata protect neurons 
against oxidative stress-induced cytotoxicity (Jeong et al., 2010) and have 
inhibitory effects on nitric oxide synthase (NOS) (Kang et al., 2002). It was 
also reported that 5,7-Dihydroxychromone (DHC), from Cudrania 
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tricuspidata, has an antioxidant activity (Qiu et al., 2012). However, 
neuroprotective effects of DHC and the related mechanisms of 
neuroprotection were poorly elucidated.  
In this study, it was demonstrated that neuroprotective effects of DHC against 

















2. Materials and methods 
 
2.1. Chemicals and reagents  
Propidium iodide (PI), 6-hydroxydopamine (6-OHDA), and 2',7'-
dichlorfluorescein-diacetate (DCFH-DA) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Dulbecco’s modified Eagle’s medium 
(DMEM) and fetal bovine serum (FBS) were purchased from Gibco BRL 
(Rockville, MD, USA). Hybond-polyvinylidene difluoride (PVDF) 
membranes were purchased from Amersham Pharmacia Biotechnology. 
(Piscataway, NJ, USA). Easy-Blue® total RNA extraction solution, PRO-
PREP protein extraction solution and WEST-ZOL® ECL solution were 
purchased from iNtRON Biotech. (Kyunggi, Korea). SuPrimeScript RT 
premix®, and SYBRs HS Prime qPCR premix® were purchased from Genet 
Bio (Daejeon, Korea). Nrf2 siRNA, scrambled siRNA, Nrf2, HO-1, NQO1, 
GCLc, LaminB1, α-tubulin, β-actin, caspase-3, caspase-9, PARP, secondary 
antibody and FITC-conjugated secondary antibody were purchased from 





2.2. Preparation of 5,7-dihydroxychromone (DHC) 
Cudrania tricuspidata was stored at the Korea Forest Research Institute at 
Southern Forest Research Center (Jinju, Korea) in September 2008. A voucher 
specimen (accession number KH1-4-090814) was kept at the Department of 
Biosystems and Biotechnology at Korea University (Seoul, Korea). 5,7-
Dihydroxychromone (DHC) was isolated from the roots of Cudrania 
tricuspidata and the structure of DHC was determined by spectroscopic 
methods, and the purity was more than 98.5% (Wei and Yu, 2008). DHC was 
dissolved in DMSO and diluted with PBS to obtain the proper concentration 
of DHC. Final concentration of DMSO was less than 0.1% and it didn’t 
influence the performed assays. 
 
2.3. Cell cultures  
The human neuroblastoma cell line SH-SY5Y (ATCC No. CRL-2266) was 
purchased from the American Type Culture Collection (Manassas, VA, USA) 
and cultured in DMEM supplemented with 10 % heat-inactivated FBS and 1 % 





2.4. Measurement of cell viability  
SH-SY5Y cells were seeded at a density of 1×105 cells/200 µL/well in 96-well 
plates for 24 h, and the cells were pre-treated with DHC (0.4, 2, or 10 µM) for 
24 h followed by subsequent treatment with 6-OHDA (100 µM) for an 
additional 24 h. To evaluate the effect of Nrf2, cells were transfected with 
scrambled siRNA or Nrf2 siRNA for 48 h and its final concentration was 50 
nM. After transfected cells were treated with DHC (10 µM) and 6-OHDA (100 
µM), cell viability was determined using a MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-Diphenyltetrazolium Bromide) and measured by ELISA (Koo 
et al., 2011). 
 
2.5. Measurement of cell necrosis by propidium iodide staining 
SH-SY5Y cells were seeded at a density of 2×105 cells/2 mL/well in 6-well 
plates for 24 h, and the cells were pre-treated with DHC (0.4, 2, or 10 µM) for 
24 h followed by subsequent treatment with 6-OHDA (100 µM) for an 
additional 24 h. To evaluate the effect of Nrf2, cells were transfected with 
scrambled siRNA or Nrf2 siRNA for 48 h and its final concentration was 50 
nM. After transfected cells were treated with DHC (10 µM) and 6-OHDA (100 
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µM), cell viability was determined using a propidium iodide (PI) staining and 
measured by flow cytometry (BD FACSCalibur TM) (Koo et al., 2011). 
 
2.6. Measurement of intracellular ROS by Flow cytometry  
ROS levels in cells were measured with the 2',7'-dichlorofluorescein diacetate 
(DCFH-DA) method (Munch et al., 1998a). Briefly, the cells were washed 
with PBS, and then incubated with 4 µM of DCFH-DA for 30 min at 37 ºC in 
the dark. The cells were then washed with PBS. The fluorescence intensities 
were measured by flow cytometry (BD FACSCalibur TM San Jose, CA, USA). 
 
2.7. Nuclear and cytosolic lysate preparations  
The nuclear and cytosolic proteins were extracted with a commercial kit 
(Nuclear Extract Kit) according to the manufacturer’s procedure (Active 
Motif, Carlsbad, CA). Briefly, the cells were incubated in hypotonic buffer on 
ice for 15 min, homogenized with detergent, and centrifuged for 30 sec at 
14,000 x g in a microcentrifuge at 4 ºC. The supernatant was used as the 
cytosolic proteins. The nuclear pellets were washed with cold PBS, extracted 
completely with lysis buffer for 30 min on ice and centrifuged for 10 min at 
14,000 x g in a microcentrifuge at 4 ºC. The supernatant was used as the 
nuclear proteins. 
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2.8. Electrophoretic mobility shift assay (EMSA) 
To determine the Nrf2-ARE binding activity, an electrophoretic mobility shift 
assay (EMSA) was accomplished as previously described (Meyer et al., 1998). 
Briefly, the nuclear proteins from the SH-SY5Y cells were reacted with 32P-
end-labeled 22-mer double-stranded oligonucleotide containing the Nrf2 
sequence for 30 min at 37 ºC. The DNA-protein complexes were 
electrophoresed and gels were dried. The binding signals were visualized by 
BAS-1500 (Fuji, Tokyo, Japan). 
 
2.9. Nrf2 knockout via the transfection of small interfering RNA (siRNA)  
The transfection with scrambled siRNA or Nrf2 siRNA were progressed at 
final concentrations of 50 nM for 48 h by Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) prior to treatment with DHC (10 µM) and 6-OHDA (100 µM) 
as recommended by the manufacturer’s guidelines.  
 
2.10. Measurement of mRNA expression  
After treatments, total RNA was isolated from SH-SY5Y cells by easy-
BLUE® and cDNA was synthesized by using SuPrimeScript RT premix® 
according to the manufacturer’s procedure. The synthesized cDNA was used 
for PCR and the primer pair sequence were listed as follows:  
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HO-1 5-TGCTCGCATGAACACTCTG-3 (Sense) and  
5- TCCTCTGTCAGCAGTGCC-3 (antisense);  
NQO1 5-AGCCCAGATATTGTGGCTGA-3 (Sense) and 
5-AAGCCACAGAAATGCAGAATG-3 (antisense); 
GCLc 5-AGGCCAACATGCGAAAC-3 (Sense) and 
5-CGGATATTTCTTGTTAAGGTACTGG-3 (antisense); 
GAPDH 5-CTCTGCTCCTCCTGTTCGAC-3 (Sense) and  
5-ACGACCAAATCCGTTGACTC-3 (antisense). The cycle condition was as 
follow; 94℃ for 20s, 56℃ for 20s, 72℃ for 30s and 40 cycles. PCR were 
performed by using SYBRs HS Prime qPCR premix® in an ABI 7300 real-
time PCR (Applied Bio systems, CA, USA). Ct (threshold cycle) values were 
obtained using the Sequence Detection Software version1.2.3 (Applied Bio 
systems, CA, USA). To evaluate quantification of the changes in target gene 
expression, we used the 2-△△Ct method (Tucker and Munchus, 1998). Fold 






2.11. Measurement of protein expression  
The SH-SY5Y cells were collected, washed with PBS and lysed with a 
PRO-PREP protein extraction solution at -20 ºC for 20 min. After 
centrifugation at 13,000 x g for 30 min, the supernatant was used as the total 
protein extracts. Western blot analysis was accomplished as previously 
described method (Ham et al., 2013).  
 
2.12. Nuclear translocation of Nrf2 using fluorescence microscope  
The culture dish was coated with 0.2 % gelatin at 37 °C for 30 min and dried 
at RT on a clean bench. The SH-SY5Y cells were plated at a density of 5×104 
cells/200 µL/well in coated dishes for 24 h and incubated with DHC (0.4, 2, 
or 10 µM) for 6 h. After treatment with DHC, the cells were washed with 1x 
PBS/Tween-20 buffer (pH 7.4) (PBST) once. The cells were fixed with 4 % 
paraformaldehyde for 30 min at room temperature (RT). After washing with 
PBST, the blocking steps were performed with 1 % BSA in PBST. Next, the 
cells were incubated with the primary antibody at 4 °C overnight. The next 
day, the cells were washed with PBST 3 times and incubated with FITC-
conjugated secondary antibody for 1 h at RT. After 1 h, the cells were washed 
with PBST 3 times, and DAPI staining was performed for 5 min at RT. Lastly, 
the PBST washing and mounting steps were conducted. 
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2.13. Statistical analysis  
All experimental data are expressed as mean value ± standard deviation. 
Statistical significance between multiple groups was determined by one-way 
ANOVA (PRISM Graph Pad, San Diego, CA, USA). When ANOVA had a 
significant difference, post hoc Bonferroni’s multiple comparison tests was 


















3.1. Protective effect of DHC against 6-OHDA-induced neuronal cell 
death.  
 
The protective effects of DHC (Fig. 2) on SH-SY5Y cells were evaluated to 
determine the non-cytotoxic dose range (data not shown). The percentage of 
cell necrosis was evaluated with PI staining. As shown in Fig. 3, the 
percentage of PI-stained dead cells induced by 6-OHDA increased to 44.5 % 
compared to the vehicle-treated group (8.7 %). In contrast, 6-OHDA-induced 
cell death was dose-dependently prevented by DHC treatments at 
concentrations of 0.4, 2 and 10 µM within the non-toxic dose range. DHC (10 
µM) treatment elicited its neuroprotective effects against 6-OHDA by 
decreasing the percentage of PI-positive cells to 13.8 %, whereas treatment 
with Nrf2 siRNA and DHC (10 µM) reduced the neuroprotective effect by 
increasing the percentage of PI-positive cells to 50.1 %. Also, the 
neuroprotective effect of DHC was evaluated by MTT assay (Fig. 4). The 















Table 1. The protective effect of isolated compounds from Cudrania 
tricuspidata root barks against 6-OHDA-induced neuronal cell death.  
No. Sample 6-OHDA-induced neuronal cell death MTT EC50 (µM) 
1 JY1-13-2 12.9 
2 JY1-14-1 7.2 
3 JY1-15-1 >40 
4 JY1-19-1 >40 
5 JY1-19-2 >40 
6 JY1-29-2 >40 
7 JY1-30-1 >40 
8 JY1-36-1 9.5 
9 JY1-37-2 9.2 
10 JY1-53-2 15.5 
11 JY1-54-1 >40 
12 JY1-54-3 >40 
13 JY1-56-2 9.1 
14 JY1-59-2 >40 
15 JY1-64-2 >40 
16 JY1-69-3 >40 
17 JY1-88-2 30.2 
18 JY1-88-3 >40 
19 JY1-89-7 8 
20 JY1-89-9 >40 
21 JY1-89-11 >40 
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22 JY1-89-12 >40 
 
Table 1. Continued  
No. Sample 6-OHDA-induced neuronal cell death MTT EC50 (µM) 
23 JY1-91-7 >40 
24 JY1-97-1 >40 
25 JY1-62-1 >40 
26 JY1-64-4 >40 
27 JY1-64-5 >40 
28 JY1-64-7 >40 
29 JY1-88-13 >40 
30 JY1-89-8 >40 
31 JY1-99-1 >40 
32 JY1-99-2 >40 
33 JY1-101-1 >40 
34 JY1-101-4 >40 
35 JY1-102-4 >40 
36 JY1-104-3 >40 
37 JY1-120-3 >40 
38 JY1-146-1 >40 
39 JY1-153-2 >40 
40 JY1-154-2 >40 
41 JY1-158-2 >40 
42 JY1-162-1 >40 
43 JY1-164-4 >40 
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44 JY1-164-5 >40 
45 JY1-165-8 >40 
 
Table 1. Continued  
No. Sample 6-OHDA-induced neuronal cell death MTT EC50 (µM) 
46 JY1-166-3 >40 
47 JY1-167-6 >40 
48 JY1-168-6 >40 
49 JY1-170-5 >40 
50 JY1-170-6 >40 
51 JY1-172-2 >40 
52 JY1-173-1 >40 
53 JY1-179-6 >40 
54 JY1-179-8 >40 































Figure 3. Effects of DHC against 6-OHDA-induced cell necrosis in SH-
SY5Y cells. 
The cells were pre-treated with different concentrations of DHC (0.08 - 10 
µM) for 24 h and subsequently treated with 6-OHDA (100 µM) for another 
24 h. The cells were transfected with Nrf2 siRNA (50 nM) for 48 h before the 
treatment with DHC (10 µM). The cells were stained with PI dyes for 30 min 
and determined by FACS analysis using FL-2 channel. The values of 















Figure 4. Effects of DHC against 6-OHDA-induced cell death in SH-SY5Y 
cells. 
The cells were pre-treated with different concentrations of DHC (0.08 - 10 
µM) for 24 h and subsequently treated with 6-OHDA (100 µM) for another 
24 h. The cells were transfected with Nrf2 siRNA (50 nM) for 48 h before the 
treatment with DHC (10 µM). The cell viability was determined by MTT 




3.2. Inhibitory effect of DHC against 6-OHDA-induced intracellular ROS 
generation. 
 
Intracellular ROS were detected by DCFH-DA dye, which can be diffused to 
the cell membrane and deacetylated by esterase to the 2’,7’-
dichlorodihydrofluorescin (DCFH), which is swiftly converted into the 
dichlorofluorescein (DCF) emitting fluorescence by ROS. As shown in Fig. 5, 
the 6-OHDA-induced cells exhibited higher DCF fluorescence intensities than 
the vehicle-treated cells. The amount of ROS generation was decreased in a 
dose-dependent manner when the 6-OHDA-induced cells were treated with 
different concentrations of DHC (0.4 - 10 µM). The 6-OHDA-induced group 
generated approximately 5-fold greater amount of ROS than that of the 
vehicle-treated group. When the DHC (10 µM)-treated cells were treated with 
6-OHDA, the ROS level was approximately 2-fold greater than that of the 
vehicle-treated group. However, the inhibitory effect of DHC (10 µM) on 
intracellular ROS generation disappeared upon treatment with Nrf2 siRNA, 
and the combined treatment with Nrf2 siRNA and DHC (10 µM) produced the 





Figure 5. Effects of DHC against 6-OHDA-induced intracellular ROS 
generation in SH-SY5Y cells. 
The cells were pre-treated with different concentrations of DHC (0.4 - 10 µM) 
for 24 h and subsequently treated with 6-OHDA (100 µM) for another 24 h. 
The cells were transfected with Nrf2 siRNA (50 nM) for 48 h before the 
treatment with DHC (10 µM). The cells were stained with DCFH-DA dyes for 
30 min and determined by FACS analysis using FL-1 channel. The values of 
fluorescence intensity were obtained from histogram statistic of CellQuest 
software.  
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3.3. Effects of DHC on induction of the nuclear Nrf2 and binding affinity 
of Nrf2/ARE in SH-SY5Y cells 
 
Nrf2 in nucleus has a binding affinity to the ARE region and Nrf2/ARE 
complex induces the transcription of ARE-mediated antioxidant genes. DHC 
increased the induction of nuclear Nrf2 with a peak effect that occurred at 6 h. 
As shown in Fig. 6, the nuclear Nrf2 was dose-dependently increased by DHC 
treatment (0.08 - 10 µM) at 6 h (Fig. 7). The increase of nuclear Nrf2 by DHC 
was visualized by immunocytochemistry in Fig. 8. To elucidate the binding 
activity between Nrf2 and ARE, an electrophoretic mobility gel-shift assay 
(EMSA) was performed. As shown in Fig. 9, DHC (2 µM) drastically 
increased Nrf2-ARE binding activity and the maximum binding activity was 










Figure 6. Effects of DHC on the nuclear translocation of Nrf2 in SH-SY5Y 
cells. 
The cells were treated with DHC (2 µM) for different durations (0 - 12 h). The 
nuclear protein was extracted. Lamin B1 was used for nuclear marker and α-
tubulin was used for cytosol marker. The protein expression levels of Nrf2, 
Lamin B1, and α-tubulin were determined by western blot analysis. 











Figure 7. Effects of DHC on the nuclear translocation of Nrf2 in SH-SY5Y 
cells. 
The cells were treated with different concentrations of DHC (0.4 - 10 µM) for 
6 h. The nuclear protein was extracted. Lamin B1 was used for nuclear marker 
and α-tubulin was used for cytosol marker. The protein expression levels of 
Nrf2, Lamin B1, and α-tubulin were determined by western blot analysis. 










Figure 8. Effects of DHC on the nuclear translocation of Nrf2 in SH-SY5Y 
cells. 
The cells were treated with DHC (0.4 - 10 µM) for 6 h. Cells were fixed and 
the nuclei were visualized with DAPI staining. Nrf2 was detected with FITC-
conjugated antibodies. Cellular morphologies were visualized with a 
fluorescence microscope (×400). Representative images from three 




Figure 9. Effects of DHC on the binding activity of Nrf2-ARE. 
The cells were treated with DHC (2 µM) for different durations (0 - 12 h), and 
the nuclear extracts were incubated with [γ-32P]-labeled oligonucleotides 
harboring an ARE consensus sequence. Nrf2-ARE binding activity was 




3.4. Effects of DHC on HO-1, NQO1 and GCLc protein expression in SH-
SY5Y cells. 
 
The protein levels of HO-1, NQO1, and GCLc, which are reported as a major 
phase II antioxidant enzymes that are transcribed upon Nrf2/ARE binding, 
were measured in the SH-SY5Y cells. As shown in Fig. 10, HO-1, NQO1, and 
GCLc protein expression levels were increased in a time- and dose-dependent 
manner by DHC treatment. As shown in Fig. 10 (B), HO-1, NQO1, and GCLc 
protein expression levels at 24 h were gradually increased by DHC treatment 
(0.08 - 10 µM). Upon Nrf2 siRNA treatment, the increased protein expression 
levels of HO-1, NQO1, and GCLc induced by DHC treatment (10 µM) were 
drastically reduced to a near-baseline level (Fig. 11). These results revealed 
that Nrf2/ARE binding is a key step in the transcriptions of HO-1, NQO1, and 










Figure 10. Effects of DHC on the expressions of the HO-1, NQO1, and 
GCLc proteins in the SH-SY5Y cells. 
The cells were treated with DHC (2 µM) for different durations (0 - 24 h) (A). 
The cells were treated with different concentrations of DHC (0.08 - 10 µM) 
for 24 h (B). After treatment, the total protein was extracted and determined 
protein expression level by western blot assay. Representative data from three 




Figure 11. Effects of DHC on the expressions of the HO-1, NQO1, and 
GCLc proteins in Nrf2 siRNA treated SH-SY5Y cells. 
The cells were transfected with Nrf2 siRNA (50 nM) or scrambled siRNA (50 
nM) prior to treatment with DHC (10 µM) for 48 h. After DHC treatment, the 
total protein was extracted and evaluated HO-1, NQO1, and GCLc protein 
expression level by western blot assay. Representative data from three 








3.5. Effects of DHC on HO-1, NQO1 and GCLc mRNA expression in SH-
SY5Y cells 
 
The mRNA levels of HO-1, NQO1, and GCLc, which are reported as a major 
phase II antioxidant enzymes that are transcribed upon Nrf2/ARE binding, 
were measured in the SH-SY5Y cells. As shown in Fig. 12 - 14, HO-1, NQO1, 
and GCLc mRNA expression levels were increased in concentration-
dependent manner by DHC treatment. HO-1, NQO1, and GCLc mRNA 
expression levels at 24 h were gradually increased by DHC treatment (0.08 - 
10 µM). These results revealed that Nrf2/ARE binding is a key step in the 











Figure 12. Effects of DHC on the mRNA expressions of HO-1 in SH-SY5Y 
cells. 
The cells were transfected with Nrf2 siRNA (50 nM) or scrambled siRNA (50 
nM) for 48 h prior to treatment with DHC (0.08 - 10 µM). After DHC 
treatment for 24h, the total RNA was extracted. The mRNA expression levels 
of HO-1 was determined by qRT-PCR analysis. Data represent the mean ± SD 




Figure 13. Effects of DHC on the mRNA expressions of NQO1 in SH-
SY5Y cells. 
The cells were transfected with Nrf2 siRNA (50 nM) or scrambled siRNA (50 
nM) for 48 h prior to treatment with DHC (0.08 - 10 µM). After DHC 
treatment for 24h, the total RNA was extracted. The mRNA expression levels 
of NQO1 was determined by qRT-PCR analysis. Data represent the mean ± 




Figure 14. Effects of DHC on the mRNA expressions of GCLc in SH-
SY5Y cells. 
The cells were transfected with Nrf2 siRNA (50 nM) or scrambled siRNA (50 
nM) for 48 h prior to treatment with DHC (0.08 - 10 µM). After DHC 
treatment for 24h, the total RNA was extracted. The mRNA expression levels 
of GCLc was determined by qRT-PCR analysis. Data represent the mean ± 
SD of three independent experiments. 
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3.6. The inhibitory effects of DHC on the 6-OHDA-induced apoptotic 
signal. 
 
The inhibitory effects of DHC on the expressions of cleaved caspase-9, 
caspase-3, and PARP during the process of apoptosis were evaluated. ROS 
accumulation is known to activate caspase-9 and caspase-3, and activated 
caspase-3 cleaves PARP. As shown in Fig. 15, the cleaved caspase-9, caspase-
3, and PARP were over-expressed when the SH-SY5Y cells were induced by 
6-OHDA. However, the over-expression of these cleaved proteins was 













Figure 15. Inhibitory effects of DHC on the expressions of cleaved 
caspase-9, caspase-3 and PARP protein. 
The cells were pre-treated with different concentrations of DHC (0.08 - 10 µM) 
for 24 h and subsequently treated with 6-OHDA (100 µM) for another 24 h. 
Then, each cell lysate was subjected to western blot analysis. Representative 










Neurodegenerative diseases may occur without obvious causes or be the 
result of numerous circumstances that cause the impairment of cellular 
performance in neuron and ultimately cell death. Due to the rapid aging of the 
populations of societies across the world, the number of patients suffering 
from the neurodegenerative disease is also increasing. Although the causes of 
these diseases have not been clearly elucidated, recent studies have revealed 
that ROS is composed of their pathogenesis (Farooqui and Farooqui, 2011). 
Because of their abundant iron contents and relatively deficient antioxidant 
defense system, neuronal cells are vulnerable to excessive ROS and 
electrophile related stress. It has been suggested that ROS is highly involved 
in the neurotoxicity of neurodegenerative disease (Munch et al., 1998b). Over 
the past decade, many studies of antioxidant enzymes have resulted in 
progress in the treatment and prevention of diseases (Rahman, 2007). In this 
context, it has been suggested that the coordinated expression of phase II 
antioxidant enzymes via the induction of nuclear Nrf2 could be a promising 
strategy for protection against oxidative stress-related neurodegenerative 
diseases.   
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The effects of DHC (Fig. 2) have not been thoroughly examined, 
particularly in relation to protection against neuronal cell death. In this report, 
DHC was found to protect against neuronal cell death and the ROS generation 
in 6-OHDA-induced SH-SY5Y cells. It was reported that caspase-9 could be 
cleaved by the ROS generation (Zuo et al., 2009). Cleaved caspase-9 induces 
activation of caspase-3 by making cleaved form of caspase-3, which is the 
important caspase involved in the apoptotic process and neuronal cell death 
caused by 6-OHDA (Dodel et al., 1999; Kuida et al., 1998). PARP is cleaved 
by active form of caspase-3, and this cleaved PARP loses the ability to 
participate in DNA repair, which results in apoptosis. PARP cleavage by 
active form of caspase-3 is a reliable indicator of apoptosis (Kaufmann et al., 
1993). In our results, DHC prevented the 6-OHDA-induced cleavages of 
caspase-3, caspase-9, and PARP, which inhibited the activation of the 
apoptotic cascade in the SH-SY5Y cells. Moreover, DHC down-regulated the 
ROS level, which was increased by treatment with 6-OHDA. Based on its 
results, we suggest that this anti-apoptotic effect of DHC is associated with 
the down-regulation of ROS.  
 The effects of the Nrf2/ARE signaling pathway on the ROS generation were 
also evaluated. Our results revealed that treatment with DHC inhibited the 
generation of 6-OHDA-induced ROS, which affect the early and late stages 
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of apoptosis. The ability of DHC to inhibit ROS generation seems to be an 
important factor in neuronal cell protection. DHC also increased the induction 
of nuclear Nrf2, which has a binding affinity to ARE and activates ARE-
driven phase II antioxidant enzymes; NQO1, HO-1, and GCLc. Nrf2 is 
regarded as a key regulator of antioxidant defensive responses and a sensor of 
cellular redox status (Kang et al., 2005). Many lines of research have proven 
the importance of Nrf2-related antioxidant enzymes in neuroprotection (Park 
et al., 2010). It has been also reported that the levels of antioxidant genes are 
considerably decreased in Nrf2-K.O. mice and the expression levels of 
antioxidant enzymes were eliminated by Nrf2-siRNA in in vitro models 
(Ramos-Gomez et al., 2001). NQO1, HO-1, and GCLc are representative 
antioxidant enzymes whose expressions are increased by diverse 
environmental stimulus including ROS and thiol-reactive substances 
(Rizzardini et al., 1993; Su et al., 2013; Fraser et al., 2002). NQO1 has been 
reported to be a potentially attractive therapeutic target for protecting cells 
from oxidative damage because it makes stable form of hydroquinone by 
catalyzing quinone (Lim et al., 2008). Moreover, it has been reported that HO-
1 catalyzes heme to carbon monoxide, biliverdin and iron, which exerts potent 
antioxidant effects (Farooqui and Farooqui, 2011). CGLc participates in 
glutathione synthesis and prevents the impairment of cellular function from 
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the excessive ROS (Pompella et al., 2003). Many studies have shown that 
these antioxidant enzymes have powerful antioxidant effects, and it has been 
suggested that the regulation of antioxidant enzymes might be a key factor in 
the prevention of age-related disease (Uttara et al., 2009). Our results revealed 
that DHC treatment induced the nuclear translocation of Nrf2, which resulted 
in the increases in NQO1, HO-1, and CGLc at the level of protein expression, 
suggesting that the neuroprotective effects of DHC against 6-OHDA-induced 
cell death are involved in the inhibition of ROS generation. Based on our 
research, we expect that one of the neuroprotective effects exerted by DHC is 
the increased induction of the Nrf2/ARE signal. When the cells were 
transfected with Nrf2 siRNA, the protective effects of DHC against 6-OHDA-
induced neurotoxicity and ROS generation were inhibited. Moreover, the 
increased protein expression levels of NQO1, HO-1, and GCLc by DHC 
treatment (10 µM) were also drastically reduced to basal levels by treatment 
with Nrf2 siRNA. The results revealed that the neuroprotective effects of DHC 
are due to the activation of Nrf2/ARE signal pathways and the subsequent 







The present study demonstrated that DHC prevented 6-OHDA-induced 
neurotoxicity via the induction of Nrf2/ARE signal, which subsequently led 
to the overexpression of antioxidant enzymes, including NQO1, HO-1, and 
CGLc. As a result of these effects, DHC inhibited the generation of ROS and 
neuronal cell death in 6-OHDA-induced SH-SY5Y cells. Our study suggests 
that DHC can be a promising neuroprotective candidate in the therapy of 














Figure 16. A scheme of protective effects of DHC on 6-OHDA-induced 
neuronal cell death via activation of Nrf2/ARE signal.  
DHC protected 6-OHDA-induced neurotoxicity via the induction of 
Nrf2/ARE signal, which subsequently led to the overexpression of antioxidant 
enzymes, including NQO1, HO-1, and CGLc. As a result of these effects, 
DHC inhibited the generation of ROS and neuronal cell death in 6-OHDA-













Orobol derivatives and extracts from Cudrania 
tricuspidata fruits protect against 6-
hydroxydopamine-induced neuronal cell death by 
enhancing proteasome activity and the 
ubiquitin/proteasome-dependent degradation of α-









Cudrania tricuspidata (Moraceae) is a subtropical tree that is widely 
distributed in Korea, China, and Japan. The fruits of C. tricuspidata are used 
in jams, juices, and a fermented alcoholic beverage with sugar, and they are 
commercially produced as food in Korea. In addition, the root, stem, leaf, and 
fruits of this plant have been reported to have anti-atherosclerotic, anti-
inflammatory and antioxidant activities (Lee et al., 2012; Park, KH et al., 2006; 
Jeong et al., 2010). Recent studies have demonstrated that the fruit of C. 
tricuspidata inhibited pancreatic lipase (Jeong et al., 2014), protected 
neuronal cells against oxidative stress-induced toxicity (Jeong et al., 2010), 
and inhibited IgE-mediated allergic and inflammatory responses (Lee et al., 
2015). The compounds isolated from C. tricuspidata are primarily xanthones 
and flavones in addition to some alkaloids, lignins, coumarins, 
polysaccharides, and chromones (Hano et al., 1991; Lee et al., 1996; Seo et 
al., 2001; Fujimoto et al., 1984; Hiep et al., 2015). The isoflavones from the 
fruits of C. tricuspidata have been reported to exert protective effects against 
6-hydroxydopamine (6-OHDA)-induced neurotoxicity (Hiep et al., 2015) and 
to have inhibitory effects against IgE-mediated allergic and inflammatory 
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responses (Lee et al., 2015). Orobol (OB), 6-prenylorobol (POB) and 6,8-
diprenylorobol (DPOB) are prenylated isoflavones. It was reported that OB 
increases cisplatin sensitivity in human ovarian carcinoma (Shiotsuka and 
Isonishi, 2001) and that DPOB shows anti-estrogenic activity (Okamoto et al., 
2006) and inhibits lipofuscin fluorophore-mediated photo oxidation (Uddin et 
al., 2011).  
 Parkinson’s disease (PD) is characterized by severe motor deficits, cogwheel 
rigidity, bradykinesia, and the loss of dopaminergic neurons. The aetiology of 
PD has not been clearly identified; however, oxidative stress is thought to be 
a common factor that leads to cellular dysfunction and neurodegeneration. 
Reactive oxygen species (ROS) are mainly produced as a by-product of 
cellular metabolism and oxidative phosphorylation. Non-neutralized ROS 
produce oxidative stress in cellular organisms and lead to abnormal molecular 
activities (Bochkov et al., 2010). In particular, the pathological events that 
occur in PD have been suggested to be linked to protein oxidation caused by 
oxidative stress (Butterfield and Kanski, 2001), and excessive intracellular 
ROS induce apoptosis that is characterized by the cleavage of caspase-3, 
caspase-9 and poly ADP-ribose polymerase (PARP) (Klovekorn and Munch, 
1998). The neurotoxin 6-OHDA destroys dopaminergic and noradrenergic 
neurons in the brain by inducing excessive ROS such as superoxide radicals, 
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which leads to protein oxidation and neuronal cell death (Kanthasamy et al., 
2010). 
 The proteasome plays a key role in the selective degradation of oxidized 
proteins via ubiquitin-mediated processes, and its role is essential for cellular 
protein maintenance (Tai and Schuman, 2008; Jung and Grune, 2013). 
The ubiquitin-proteasome system (UPS) is responsible for the degradation of 
many cellular proteins, except membrane and extracellular proteins, which 
after endocytosis are degraded within the lysosomes. In addition, misfolded, 
mutant, and oxidatively damaged proteins are also degraded by the UPS. 
Proteins to be degraded are first marked by covalent attachment of a 
polyubiqutin chain to a lysine residue on the substrate. The polyubiquitinated 
protein is then degraded by a large proteolytic complex, the 26S proteasome. 
Monoubiquitinylation, on the other hand, regulates transcription, translation, 
protein trafficking, DNA repair, and numerous other cellular functions. 
Polyubiquitination of a target protein is accomplished through a series of 
enzyme-mediated reactions that are required to ensure specificity and activate 
the ubiquitinmoiety. First, activated ubiquitin is generated by ubiquitin-
activating enzyme (E1), which forms a thiol ester linkage between 
a cysteine residue and carboxy-terminalglycine in ubiquitin in an ATP-
dependent manner. The activated ubiquitin is transferred to one of the several 
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ubiquitin carrier proteins or ubiquitin conjugating enzymes (E2s) via the 
formation of another thiol linkage. Finally, ubiquitin is ligated to the lysine 
residue of the protein substrate that is specifically bound to an E3 ligase. 
Parkin, involved in familial PD, is an example of such an E3 ligase. Additional 
activated ubiquitin moieties can be attached to internal lysine residues within 
the ubiquitin to form polyubiquitin linkages, which then act as the degradation 
sign that is recognized by the 26S proteasome complex (Dahlmann, 2007). A 
minimum of four ubiquitin moieties is required for efficient targeting to the 
proteasome. Selectivity of ubiquitination and recognition of substrates are 
largely mediated by E3s. There are more E2s than E1s, and more E3s than E2s 
so at each step the number of proteins that can possibly be involved increases, 
as does the specificity of binding to the next component. It is the E3, either 
alone or in combination with its bound E2, that determines the specificity of 
substrate recognition (Betarbet et al., 2005). 
 Proteasomes are existing in the cytoplasm, perinuclear regions, and nuclei of 
all eukaryotic cells. Their relative abundance within these compartments is 
extremely variable. In the cytoplasm, proteasomes are associated 
with centrosomes, cytoskeletal networks, and the outer surface of 
the endoplasmic reticulum. In the nucleus, proteasomes are present 
throughout the nucleoplasm but not in the nucleoli. Impairment of 
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the proteolytic pathway results in accumulation of proteasomes in these 
locations, forming organized aggregates. Aggregates located in the 
pericentrosomal areas have been termed “aggresomes”. Aggresomes are 
known to damage proteasomal function and promote apoptosis (Wojcik and 
DeMartino, 2003). 
 The 26S proteasome consists of a catalytic core—the 20S proteasome. The 
20S proteasome is made up of 28 subunits assembled as two outer and two 
inner heptameric rings stacked axially to form a hollow cylindrical structure 
wherein proteolysis occurs (Doskeland and Flatmark, 2002). The two inner 
rings of the 20S proteasome are composed of seven different β-subunits each. 
The three different catalytic sites (chymotrypsin-like, trypsin-like, and 
caspase-like-peptide hydrolytic sites) of the proteasome reside on the inner 
surface of the inner rings, thereby preventing indiscriminate degradation of 
proteins (Huang and Figueiredo-Pereira, 2010). The noncatalytic outer rings, 
comprising of seven different α-subunits, serve as an anchor for the 19S 
(PA700) multisubunit ATPase containing proteasome activator or regulator. 
The 19S complex determines substrate specificity and consists of at least six 
ATPases and more than 15 additional subunits that lack the capacity to bind 
to ATP. The 19S regulatory complex serves at least three ATP-dependent 
functions: it selectively opens the channel through the 20S proteasome, 
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unfolds ubiquitinated proteins to allow entry into the catalytic core, and 
cleaves off the polyubiquitinated chain from the substrate. The degradation 
products of proteasomal catalysis are small peptides and amino acids that can 
be recycled to produce new proteins. At the same time, polyubiquitin chains, 
released from targeted proteins, are then disassembled by ubiquitin carboxy-
terminal hydrolases to produce monomeric ubiquitin molecules that can be 
reused. Recent research has suggested that oxidative stress-induced 
proteasome dysfunction might play a key role in neurodegenerative diseases 
and that rescuing the decrease in proteasome activity could be a new 
therapeutic strategy (Seo et al., 2007). Additionally, dysfunction in 
proteasome activity was observed in the substantia nigra of PD patients, 
suggesting that the impairment of the UPS is involved in the formation of 
Lewy bodies and in dopaminergic neuronal cell death in PD (McNaught and 
Jenner, 2001). Lewy bodies are characteristic hallmarks of PD and are 
composed of primarily α-synuclein and synphilin-1 along with ubiquitin and 
other fibrils. α-synuclein, a small acidic protein composed of 140 amino acids, 
is abundant in the human brain; is also found in the heart, muscles, and other 
tissues; and is a naturally unfolded protein with the ability to self-aggregate. 
The aggregation process of α-synuclein results in potential cell damage, 
leading to dopaminergic neuronal loss in Parkinson's disease (Cookson, 2005). 
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α-synuclein also associates with other protein partners in the cell, including a 
significant interaction with synphilin-1. It has been reported that synphilin-1 
is a presynaptic protein that could be a modulator of UPS, and the 
overexpression of synphilin-1 promotes the formation of inclusions under 
conditions of proteasome inhibition. Additionally, synphilin-1 inhibits the 
degradation of α-synuclein by the proteasome, thus increasing its half-life 
(Alvarez-Castelao and Castano, 2011). Therefore, it is possible that the 
inhibition Lewy body-associated protein accumulation through the protection 
against proteasome dysfunction could be a key aspect of PD treatment. 
 In our previous reports, we investigated the neuroprotective effect of 
different extracts (0 – 100% ethanol ratio) containing isoflavones from C. 
tricuspidata fruits (Hiep et al., 2015). Here, nine isolates obtained from 50% 
ethanol extract from C. tricuspidata fruits (CTE50) were evaluated for their 
neuroprotective potential against 6-OHDA-induced cell death in SH-SY5Y 
human neuroblastoma cells. The study focused on the potential effects on 
apoptosis, intracellular ROS generation, proteasome activities, 
polyubiquitination of Lewy body-associated α-synuclein and synphilin-1 




2. Materials and methods 
 
2.1. Chemicals and reagents 
6-Hydroxydopamine (6-OHDA), and 2',7'-dichlorfluorescein-diacetate 
(DCFH-DA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
MG132 was purchased from Enzo Life Sciences (Farmingdale, NY, USA). 
Dulbecco’s modified Eagle’s medium (DMEM) and foetal bovine serum (FBS) 
were purchased from HycloneTM Thermo Scientific (Wyman Street Waltham, 
MA, USA). Hybond®-Polyvinylidene difluoride (PVDF) membranes were 
purchased from Amersham Pharmacia Biotechnology Inc. (Piscataway, NJ, 
USA). PRO-PREP protein extraction solution and WEST-ZOL® ECL solution 
were purchased from iNtRON Biotech Inc. (Kyunggi, Korea). Antibodies 
against ubiquitin, α-synuclein, synphilin-1, β-actin, caspase-3, cleaved 
caspase-3, caspase-9, cleaved caspase-9, PARP, and A/G Plus-Agarose and 
secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. 
(CA, U.S.A.) 
 
2.2. Preparation of ethanol extracts from the fruits of C. tricuspidata (CTE) 
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The fruits of C. tricuspidata were collected from the Korea Forest Research 
Institute, Southern Forest Research Center (Jinju, Korea). A voucher 
specimen (accession no. KH1-5-090904) was deposited at the Department of 
Biosystems and Biotechnology, Korea University (Seoul, Korea). The dry 
fruit of C. tricuspidata (3.4 kg) was ground into powder form and sifted 
through a 120-mesh sieve. The dry powder (7 g) was refluxed three times for 
1 h each by means of a heating mantle with 250 mL of 0, 30, 50 70, or 100% 
ethanol in round 500-mL flasks. The combined extracts were filtered and 
concentrated in vacuo to yield 2.85 g, 2.71 g, 2.57 g, 2.67 g, and 2.1 g, 
respectively. 
 
2.3. Ultra performance liquid chromatography (UPLC) analysis of 
CTE50 
The CTE50 was analysed using an Acquity UPLC system (Waters, Millford, 
MA, USA) with an Acquity UPLC BEH C18 column (1.7 µm, 2.1 × 150 mm 
i.d.). The mobile phase consisted of solvent A (0.05% formic acid in water) 
and solvent B (acetonitrile), which flowed at rate of 0.3 mL/min. The starting 
eluent was 40% B at 0 min, and the proportion of B was increased linearly to 
100% from 0 to 10 min, held constant at 100% for 11.5 min, and then returned 
to the initial condition over the course of 1.5 min to re-equilibrate the column. 
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The sample injection volume was 4 µL for extract and 2 µL for compounds 
(CTE50: 3 mg/mL, OB, POB, and DPOB: 0.2 mg/mL). The column and 
sample managers were maintained at 35 and 15 °C, respectively, and the UV 
detection wavelength was monitored at 265 nm. 
 
2.4. Isolation and identification of compounds from CTE50  
Nine isoflavones, namely, orobol (1, 0.0021%), 6-prenylorobol (2, 0.0100%), 
6,8-diprenylorobol (3, 0.0015%), millewanins H and G (4 and 5, 0.0029 and 
0.0045%), alpinumisoflavone (6, 0.0762%), 4′-O-methylalpinumisoflavone 
(7, 0.0046%), erysenegalensein E (8, 0.0181%), and 6,8-diprenylgenistein (9, 
0.0055%), were isolated from the fruits of C. tricuspidata. The chemical 
structures were determined by interpretation of spectroscopic data, including 
MS and NMR spectra, as compared to the previously reported literature 
(supplementary data 1). The detailed isolation procedures are included in the 
supplementary materials and methods. The purity of each compound was 
more than 95%. 
 
2.5. Cell cultures 
The human neuroblastoma cell line SH-SY5Y (ATCC No. CRL-2266) was 
purchased from the American Type Culture Collection (Manassas, VA, USA) 
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and cultured in DMEM supplemented with 10% heat-inactivated FBS and 1% 
penicillin/streptomycin at 37 ºC in a humidified 5% CO2 atmosphere. Test 
samples were dissolved in 10% DMSO, and the cells were treated within non-
cytotoxic concentration ranges of test samples at a final concentration of 0.1% 
DMSO.  
 
2.6. Measurement of cell viability  
SH-SY5Y cells were plated at a density of 1×105 cells/200 µL/well in 96-well 
plates for 24 h, and the cells were simultaneously treated with 6-OHDA and 
test samples (0.16 – 20 µg/mL of 0 – 100% CTE; 0.2 – 25 µM of nine isolates) 
for 48 h. After treatment, cell viability was evaluated using the MTT assay as 
previously described (Koo et al., 2011). Briefly, the medium was removed, 
and the cells were incubated with fresh medium containing 0.5 mg/mL MTT 
for 4 h at 37 ºC, after which the medium was gently removed. Formazan 
crystals were dissolved in 100 µL DMSO, and absorbance was measured at 
540 nm using a microplate reader (SpectraMax M5, Molecular Devices, USA). 
 
2.7. Measurement of intracellular ROS by flow cytometry 
Intracellular ROS levels were measured by the 2',7'-dichlorofluorescein 
diacetate (DCFH-DA) method as described previously (Kim, D-W et al., 
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2015). Briefly, SH-SY5Y cells were plated at a density of 1×106 cells/1 
mL/well in 12-well plates for 24 h, simultaneously treated with 6-OHDA (75 
µM) and test samples (0.16 – 20 µg/mL of 0 – 100% CTE, 0.2 – 25 µM of 
isolates) for 48 h, and washed three times with PBS. DCFH-DA (4 µM/mL in 
PBS) was then added, and afterwards, the cells were incubated for 30 min at 
37 ºC in the dark. The cells were then washed 3 times with PBS, and the 
fluorescence intensities of a total of 10,000 events were measured by the FL-
1 channel of a flow cytometer (BD FACS CaliburTM). 
 
2.8. Measurement of proteasome activity 
Proteasome activity was determined using SH-SY5Y cells as previously 
described (Kim, B-H et al., 2015). Briefly, cells (1.0 ×105 cells/300 µL/well) 
were plated in 48-well plates for 24 h and then simultaneously treated with 6-
OHDA (75 µM) and samples (0.16 – 20 µg/mL of CTE50, 0.2 – 25 µM of 
nine isolates) for 48 h. After washing twice with PBS, cells were lysed by 
freeze-thawing 3 times (between -70 ºC and 37 ºC, 5 min each) and scraped 
into PBS buffer. Supernatants were collected by centrifugation at 15,000 rpm 
(15 min, 4 ºC), and the total protein concentration was determined by the 
Bradford method (Bradford, 1976). The proteolytic activity of the 
proteasomes was evaluated with a 20S proteasome activity kit (APT 280; 
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Millipore, USA). In brief, supernatants (40 µg) were incubated for 2 h at 37 °C 
in the provided buffer with fluorophore-linked peptide substrates. Suc-LLVY-
AMC (40 µM), Boc-LRR-AMC (40 µM), and Z-LLE-MCA (80 µM) were 
used as the substrates for chymotrypsin-, trypsin- and caspase-like protease 
activities, respectively. Reaction mixtures without cell lysates were used as 
negative controls, and aminomethylcoumarin (AMC) or 
methylcoumarylamide (MCA) fluorescence was measured at 
excitation/emission wavelengths of 380/460 and 380/440 nm, respectively, 
using a microplate reader (SpectraMax M5, Molecular Devices, USA).  
 
2.9. Measurement of mRNA expression 
After treatments, total RNA was isolated from SH-SY5Y cells by easy-
BLUE® and cDNA was synthesized by using SuPrimeScript RT premix® 
according to the manufacturer’s procedure. The synthesized cDNA was used 
for PCR and the primer pair sequence were listed as follows:  
Chymotrypsin-like proteasome subunit (PSMB-8) 
5-GTTCCAGCATGGAGTGATTG-3 (sense) and  
5- TGTTCACCCGTAAGGCACTA-3 (antisense);  
Trypsin-like proteasome subunit (PSMB-7)  
5-ATGGCTGTACCACGAAACAA-3 (sense) and 
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5-AGGGATCCTTCAGTTTCTTCAGT-3 (antisense); 
Caspase-like proteasome subunit (PSMB-6)  
5-TCGATTTGATACCTTTGATAGCC-3 (sense) and 
5-CCAGGGTCAATGGGTGAC-3 (antisense); 
GAPDH  
5-CTCTGCTCCTCCTGTTCGAC-3 (sense) and  
5-ACGACCAAATCCGTTGACTC-3 (antisense). The cycle condition was as 
follow; 94℃ for 20s, 56℃ for 20s, 72℃ for 30s and 40 cycles. PCR were 
performed by using SYBRs HS Prime qPCR premix® in an ABI 7300 real-
time PCR (Applied Bio systems, CA, USA). Ct (threshold cycle) values were 
obtained using the Sequence Detection Software version1.2.3 (Applied Bio 
systems, CA, USA). To evaluate quantification of the changes in target gene 
expression, we used the 2-△△Ct method (Tucker and Munchus, 1998). Fold 
change=2-△△Ct, △△Ct= (Ct target gene – Ct GAPDH)-(Ct control-Ct GAPDH) 
 
2.10. Measurement of protein expression 
SH-SY5Y cells were plated at a density of 2×106 cells/4 mL in 60-mm dishes 
for 24 h. The cells were then simultaneously treated with 6-OHDA (75 µM) 
and samples (0.16 – 20 µg/mL of CTE50, 0.2 – 25 µM of three orobol 
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derivatives) for 48 h, washed three times with PBS, and lysed with a PRO-
PREP protein extraction solution at -20 ºC for 20 min. After centrifugation at 
13,000 rpm for 30 min, the supernatant was used as the total protein extract. 
Western blot analysis was accomplished as previously described (Ham et al., 
2013). Briefly, protein extracts were separated by electrophoresis on a SDS-
PAGE gel and then transferred to PVDF membranes. Then, the PVDF 
membranes were incubated overnight at 4 ºC with primary antibodies 
followed by a 1-h incubation at RT with the secondary antibody. The blots 
were developed using WEST-Queen® ECL solution and analysed using 
LAS4000 (GE Healthcare, UK) 
 
2.11. Immunoprecipitation assay 
Immunoprecipitation was performed as previously described with slight 
modifications (Chen et al., 2014). Briefly, SH-SY5Y cells were plated at a 
density of 2×106 cells/4 mL in 100-mm dishes for 24 h. The cells were then 
simultaneously treated with 6-OHDA (75 µM) and samples (0.8 – 20 µg/mL 
of CTE50, 1 – 25 µM of three orobol derivatives) for 48 h and washed three 
times with PBS. SH-SY5Y cells were homogenized and lysed in cold-lysis 
buffer (50 mM Tris, 1 mM PMSF, 150 mM NaCl, 50 mM NaF, 1% Nonidet 
P-40, 0.25% sodium deoxycholate, 10 mM sodium pyrophosphate) and 
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centrifuged at 14,000 × g (10 min, 4 °C), and the supernatant was transferred 
to a new ep-tube and incubated with 2 µg of α-synuclein or synphilin-1 
antibody overnight at 4 °C. The next day, A/G plus agarose beads were added 
and incubated overnight at 4 °C followed by 3 washes in cold-lysis buffer. 
The loading samples were adjusted to total volume of 30 µL with lysis buffer, 
and the immune-complexes were eluted at 95 °C on a heating block for 5 min, 
vortexed, and spun down by centrifugation at 15,000 × g for 10 min.  
 
2.12. Statistical analysis 
All experimental data are expressed as t h e  mean ± standard deviation. 
Statistical significance between multiple groups was determined by one-way 
ANOVA (PRISM Graph Pad, San Diego, CA, USA). When the ANOVA 
showed a significant difference, Bonferroni’s multiple comparison post hoc 










3.1. Protective effects against 6-OHDA-induced neuronal cell death in 
SH-SY5Y cell 
 
Ethanol is often used to extract bioactive compounds from plant materials, and 
the bioactivity of plant extracts depends on the ratio of water to ethanol used 
in the extraction process (Ganora, 2009). We evaluated the neuroprotective 
effects within non-cytotoxic concentration ranges from different CTE extracts 
(0, 30, 50, 70, and 100% ethanol) and nine isolates. As shown in Table 2, 
CTE50 showed the most potent protective effects with an EC50 value of 3.3 
µg/mL. The constituents of CTE50 were identified using UPLC, and nine 
isolates were obtained (Figs. 17 and 18). Among the nine isolates, three orobol 
derivatives (OB, POB, and DPOB) significantly attenuated 6-OHDA-induced 
neurotoxicity with EC50 values of 6.4 µM, 4.5 µM, and 10.1 µM, respectively 
(Table. 2). As shown in Fig. 20, 6-OHDA-induced neuronal cell death was 
observed by the morphology of cells: 6-OHDA resulted in cellular 
morphological changes including cell shrinkage and rounding. However, 
treatment with CTE50 (20 µg/mL) or the three orobol derivatives (25 µM) 
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ameliorated the 6-OHDA-induced morphological changes to almost normal 
levels. As shown in Fig. 19, the 6-OHDA-induced group showed a significant 
decrease in cell viability compared to the vehicle-treated group. However, 
CTE50 (0.16 – 20 µg/mL) or the three orobol derivatives (0.2 – 25 µM) 
protected 6-OHDA-induced neuronal cell death in a concentration-dependent 
manner. Additionally, it was examined that the comparison of neuroprotective 
effect of CTE50 and three orobol derivatives against 6-OHDA-induced 
neurotoxicity by pre-, co-, and post treatment. Among three groups, co-













Table 2. Inhibitory effects of ethanol extracts and isolates from the fruits 
of C. tricuspidata against 6-OHDA-induced cell death and ROS 






Figure 17. UPLC chromatograms and structures of isolates from CTE50. 
UPLC chromatogram of CTE50 and isolates from CTE50. Nine compounds 
were isolated from CTE50. Among nine isolates, orobol, 6-prenylorobol, and 
6,8-diprenylorobol were selected for further study. The selected three orobol 










Figure 18. Chemical structures of the isolates from CTE50.  
The isolated compounds are orobol (1), 6-prenylorobol (2), 6,8-
diprenylorobol (3), millewanin H (4), millewanin G (5), alpinumisoflavone 






Figure 19. Inhibitory effects of CTE50 and three orobol derivatives (OB, 
POB, and DPOB) against 6-OHDA-induced neurotoxicity. 
Cells were cultured in 96-well plate for 24 h, and CTE50 or orobol derivatives 
were simultaneously treated with 6-OHDA (75 µM) for 48 h. Cell viability 
were measured by MTT reduction assay (A – D). Data represent the mean ± 
SD of three independent experiments. (***p<0.001 versus control group, 




Figure 20. Neuroprotective effects of CTE50 and the three orobol 
derivatives (OB, POB, and DPOB) against 6-OHDA-induced 
neurotoxicity in SH-SY5Y cells. 
Cells were cultured in 96-well plate for 24h, and CTE50 or three orobol 
derivatives were simultaneously treated with 6-OHDA (75 µM) for 48 h. The 
morphological change of cell was observed by inverted phase-contrast 





3.2. Inhibition of 6-OHDA-induced intracellular ROS generation 
 
Excessive intracellular ROS induce cellular stress and neuronal cell death, and 
it has been reported that ROS play important roles in the pathogenesis of 
neurodegenerative diseases. As shown in Table 2, CTE50 showed the most 
potent inhibition of 6-OHDA-induced ROS generation with an IC50 value of 
6.7 µg/mL. Among the nine compounds derived from CTE50, the three orobol 
derivatives showed a significant inhibitory effect against 6-OHDA-induced 
intracellular ROS generation with IC50 values of 7.2 µM (OB), 5.9 µM (POB), 
and 17.3 µM (DPOB). As shown in Fig. 21 and 22, 6-OHDA-treated cells 
showed strong DCF fluorescence intensities compared to vehicle-treated cells. 
The amount of intracellular ROS was decreased in a concentration-dependent 
manner when cells were treated with CTE50 (0.8 – 20 µg/mL) or the three 









Figure 21. Inhibitory effects of CTE50 and three orobol derivatives (OB, 
POB, and DPOB) against 6-OHDA-induced ROS generation. 
Cells were cultured in 12-well plate for 24h, and CTE50 or three orobol 
derivatives were simultaneously treated with 6-OHDA (75 µM) for 48 h (A – 
D). The cells were stained with DCFH-DA dyes for 30 min and determined 
by FACS analysis using FL-1 channel. The values of fluorescence intensity 





Figure 22. Inhibitory effects of CTE50 and three orobol derivatives (OB, 
POB, and DPOB) against 6-OHDA-induced ROS generation. 
Cells were cultured in 96-well plate for 24h, and CTE50 or three orobol 
derivatives were simultaneously treated with 6-OHDA (75 µM) for 48 h (E – 
H). The cells were stained with DCFH-DA dyes for 30 min and fluorescence 
intensity was measured by multi-plate reader. Data represent the mean ± SD 
of three independent experiments. (***p<0.001 versus control group, 
##p<0.01 and ###p<0.001 versus 6-OHDA-induced group) 
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3.3. Neuroprotective effects against 6-OHDA-induced apoptosis 
 
It has been reported that 6-OHDA induces ROS-dependent apoptosis, which 
is characterized by the cleavage of caspase-9, caspase-3 and PARP. Excessive 
ROS accumulation results in the activation of the caspases (caspase-9 and 
caspase-3), and activated caspase-3 cleaves the DNA repair protein PARP; 
cleaved, activated PARP is final apoptotic marker. To investigate the 
inhibitory effects of CTE50 and three orobol derivatives on the levels of 
cleaved caspase-9, caspase-3, and PARP protein, we performed a western blot 
assay. As shown in Fig. 23, the cleavage levels of caspase-9, caspase-3, and 
PARP were increased when the SH-SY5Y cells were exposed to 6-OHDA. 
However, CTE50 (0.16 – 20 µg/mL) or the three orobol derivatives (0.2 – 
25µM) inhibited the cleavage of caspase-9, caspase-3, and PARP protein in a 








Figure 23. Inhibitory effects of CTE50 and three orobol derivatives 
against 6-OHDA-induced apoptotic markers. 
Cells were simultaneously treated with 6-OHDA (75 µM) and (A) CTE50 or 
(B – D) three orobol derivatives for 48 h. The levels of cleaved caspase-9, 
caspase-3 and PARP were assessed by western blot; β-actin was used as a 
housekeeping protein. Representative data from three independent 




3.4. Protective effects against 6-OHDA-induced dysfunction of 
proteasome activity 
 
Proteasome function is essential for cellular physiology and protein 
degradation. To evaluate the effects of CTE50 and the nine isolates against 
the dysfunction of proteasome activity induced by 6-OHDA in SH-SY5Y cells, 
we measured the activities of chymotrypsin-, trypsin- and caspase-like 
proteases. As shown in Table 3 and Fig. 24, 6-OHDA significantly inhibited 
all three different types of proteasome activities; however, CTE50 most 
potently attenuated the 6-OHDA-induced dysfunction of proteasome activities 
from extracts (0 – 100%) with an EC50 value of 1.2 µg/mL (chymotrypsin-
like), 1.5 µg/mL (trypsin-like), and 6.7 µg/mL (caspase-like). The three orobol 
derivatives at the concentration of 25 µM prominently protected against 6-
OHDA-induced dysfunction of the proteasome and almost restored the 







Table 3. The protective effects of ethanol extracts and isolates from the 
fruits of C. tricuspidata against 6-OHDA-induced proteasome dysfunction 







Figure 24. Protective effects of CTE50 and three orobol derivatives (OB, 
POB, and DPOB) against 6-OHDA-induced dysfunction of proteasome 
activities in SH-SY5Y cells. 
Cells were cultured in 48-well plate for 24h, and (A) CTE50 or (B – D) three 
orobol derivatives were treated with 6-OHDA (75 µM) for 48 h. 
Chymotrypsin-, trypsin-, and caspase-like proteasome activities were 
measured by multiplate reader with fluorophore-linked peptide substrates. The 
relative fluorescence intensity was indicated. Data represent the mean ± SD 
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of three independent experiments. (***p<0.001 versus control group, 




















3.5. Effects of CTE50 and three orobol derivatives on proteasome subunit 
mRNA expression 
 
Proteasome function is essential for cellular physiology and protein 
degradation. Proteasome is composed of subunit and each subunit correlates 
chymotrypsin-like, trypsin-like, caspase-like proteasome activities. To 
evaluate the effects of CTE50 and three orobol derivatives on proteasome 
subunit mRNA expression, we measured the mRNA expression of 
chymotrypsin-, trypsin- and caspase-like proteases. As shown in Fig. 25, 
CTE50 significantly increase all three different types of proteasome subunit 
mRNA expressions; Also, three orobol derivatives increased three types of 
proteasome subunit mRNA expression at a concentration dependent manner. 
However, the increased mRNA expression of each proteasome subunits was 









Figure 25. Effects of CTE50 and three orobol derivatives (OB, POB, and 
DPOB) on mRNA expression of proteasome subunits in SH-SY5Y cells. 
Cells were cultured in 12-well plate for 24h, and (A) CTE50 or (B – D) three 
orobol derivatives were treated for 24 h. The mRNA expression of 
Chymotrypsin-, trypsin-, and caspase-like proteasome subunit were measured 







3.6. Inhibition of 6-OHDA-induced ubiquitin-conjugated proteins 
 
Proteasome dysfunction causes a reduction in the degradation of misfolded 
proteins, consequently resulting in the accumulation of polyubiquitinated 
proteins. To investigate the inhibitory effects of CTE50 and the three orobol 
derivatives against 6-OHDA-induced ubiquitin conjugated-protein formation, 
we performed western blot analysis. As shown in Fig. 26, 6-OHDA increased 
the levels of high molecular ubiquitin-conjugated proteins. When cells were 
treated with different concentrations of CTE50 (0.16 – 20 µg/mL) (Fig. 26A) 
or the three orobol derivatives (0.2 – 25 µM) (Fig. 26B – 26D), the levels of 
ubiquitin-conjugated proteins were decreased to normal in a concentration-
dependent manner. CTE50 (20 µg/mL) and the three orobol derivatives (25 









Figure 26. Inhibitory effects of CTE50 and three orobol derivatives 
against 6-OHDA-induced ubiquitin-conjugated proteins. 
Cells were simultaneously treated with 6-OHDA (75 µM) and (A) CTE50 or 
(B – D) three orobol derivatives for 48 h. The levels of ubiquitin-conjugated 
proteins were determined by western blot; β-actin was used as a housekeeping 




3.7. Inhibition of 6-OHDA-induced poly-ubiquitination of α-synuclein, 
and synphilin-1 
 
Physiologically, polyubiquitinated proteins are normally rapidly degraded by 
the proteasome. However, dysfunction in proteasome activity increases the 
polyubiquitination of α-synuclein and synphilin-1, inducing neurotoxicity. As 
shown in Fig. 27, 6-OHDA increased the polyubiquitination of α-synuclein. 
When the cells were treated with different concentrations of CTE50 (0.8 – 20 
µg/mL) or the three orobol derivatives (1 – 25 µM), the polyubiquitination of 
α-synuclein was restored to almost normal levels in a concentration-dependent 
manner (Fig. 27A – 27D). Additionally, as shown in Fig. 28, 6-OHDA 
increased the polyubiquitination of synphilin-1; however, CTE50 (0.8 – 20 
µg/mL) and the three orobol derivatives (1 – 25 µM) reduced the 
polyubiquitinated synphilin-1 to almost normal levels in a concentration-








Figure 27. Inhibitory effects of CTE50 and three orobol derivatives 
against 6-OHDA-induced polyubiquitination of α-synuclein. 
Cells were simultaneously treated with 6-OHDA (75 µM) and (A) CTE50 or 
(B – D) three orobol derivatives for 48 h. The polyubiquitination of α-
synuclein was determined by immunoprecipitation and western blot analysis. 





Figure 28. Inhibitory effects of CTE50 and three orobol derivatives 
against 6-OHDA-induced polyubiquitination of synphilin-1. 
Cells were simultaneously treated with 6-OHDA (75 µM) and (E) CTE50 or 
(F – H) three orobol derivatives for 48 h. The polyubiquitination of synphilin-
1 was determined by immunoprecipitation and western blot analysis. 





3.8. A proteasome inhibitor (MG-132) diminished the protective effects of 
CTE50 and the three orobol derivatives against 6-OHDA-induced 
neuronal cell death and proteasome dysfunction 
 
It has been reported that proteasome inhibition induces dopaminergic neuronal 
cell degeneration and apoptosis (Park et al., 2011). In contrast, proteasome 
activation enhances survival in a neuronal model of neurodegenerative disease 
(Seo et al., 2007). To investigate whether the neuroprotective effects of 
CTE50 and the three orobol derivatives are due to the amelioration of 
proteasomal dysfunction, MG132, a proteasome inhibitor, was co-applied 
with the samples. As shown in Fig. 29, CTE50 (20 µg/mL) and three orobol 
derivatives (25 µM) protected against 6-OHDA-induced neuronal cell death; 
however, co-treatment with MG132 (1 µM, non-cytotoxic concentration) 
significantly blocked the protective effects of CTE50 and the three orobol 
derivatives against 6-OHDA-induced cell death. Additionally, MG132 (1 µM) 
blocked the recovery effects of CTE50 and the three orobol derivatives against 





Figure 29. Inhibitory effects of MG132 on the protective effects of CTE50 
and three orobol derivatives against 6-OHDA-induced neuronal cell 
death. 
The protective effects of CTE50 and three orobol derivatives 6-OHDA-
induced neuronal cell death were blocked by MG132. Cell viability was 
measured by the MTT reduction assay. (Data represent the mean ± SD of three 
independent experiments. (***p<0.001 versus control group, #p<0.05, 





Figure 30. Inhibitory effects of MG132 on the protective effects of CTE50 
and three orobol derivatives against 6-OHDA-induced proteasome 
dysfunction. 
The protective effects of CTE50 and three orobol derivatives against 6-
OHDA-induced proteasome dysfunction were blocked by MG132. Three 
types of proteasome activity were measured using a multi-plate reader with 
fluorophore-linked peptide substrates. Data represent the mean ± SD of three 
independent experiments. (***p<0.001 versus control group, #p<0.05, 




Figure 31. Comparison of neuroprotective effect of CTE50 and three 
orobol derivatives (OB, POB, and DPOB) against 6-OHDA-induced 
neurotoxicity by pre-, co-, and post treatment. 
In pre-treatment group, cells were cultured in 96-well plate for 24 h, and 
CTE50 or orobol derivatives pre-treated for 48h. After 48h, medium was 
changed and cells were treated with 6-OHDA (75 µM) for 48 h. In co-
treatment group, cells were cultured, and CTE50 or orobol derivatives were 
simultaneously treated with 6-OHDA for 48 h. In post-treatment group, cells 
were cultured, and treated with 6-OHDA for 48 h. After 48h, medium was 
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changed and cells were treated CTE50 or orobol derivatives for 48 h. Cell 
viability were measured by MTT reduction assay. Data represent the mean ± 
SD of three independent experiments. (***p<0.001 versus control group, 














Figure 32. The effects of N-acetylcystein (NAC) against 6-OHDA-induced 
neurotoxicity and ROS generation. 
Cells were cultured in 96-well plate for 24 h, and NAC was simultaneously 
treated with 6-OHDA (75 µM) for 48 h. Cell viability were measured by MTT 
reduction assay (A). Cells were cultured in 12-well plate for 24h, and NAC 
were simultaneously treated with 6-OHDA (75 µM) for 48 h. The relative 
fluorescence intensities of total 10,000 events by FACs analysis with DCFH-
DA dye were quantified (B). Data represent the mean ± SD of three 
independent experiments. (***p<0.001 versus control group, ###p<0.001 







Figure 33. The effect of MG132 on neurotoxicity and ROS generation.  
Cells were cultured in 96-well plate for 24 h, and MG132 was for 48 h. Cell 
viability were measured by MTT reduction assay (A). Cells were cultured in 
12-well plate for 24h, and MG132 were for 48 h. The relative fluorescence 
intensities of total 10,000 events by FACS analysis with DCFH-DA dye were 
quantified (B). Data represent the mean ± SD of three independent 











As the world’s population is rapidly ageing, the number of patients suffering 
from PD is increasing significantly. Although the cause of PD has not been 
definitively verified, recent research findings have suggested that oxidative 
stress and the impairment of the proteasome are major events in its 
pathogenesis (Ciechanover and Kwon, 2015). Oxidative stress has been 
implicated in ageing and neurodegenerative diseases such as PD. Oxidative 
stress induces the oxidation and aggregation of proteins in the brain 
(Butterfield and Kanski, 2001). In addition, excessive oxidative stress 
advances cellular apoptosis through the accumulation of oxidized proteins 
(Klovekorn and Munch, 1998). Many studies have reported that protein 
homeostasis is essential for cellular physiology and that the proteasome is 
responsible for selectively degrading targets including short-lived, damaged 
or misfolded protein, which comprise approximately 80% of all intracellular 
proteins. Hence, considerable interest has been paid to the importance of the 
role of the proteasome. The ubiquitination process is activated by ubiquitin-
activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin-
transferring enzymes (E3). Through a sequential enzymatic reaction, proteins 
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are polyubiquitinated by E3 ligase. The polyubiquitin chain is recognized by 
the regulatory domain of the proteasome, in which the target protein is 
degraded by the catalytic core domain (Amm et al., 2014). Under normal 
conditions, polyubiquitinated proteins are rapidly degraded and do not 
accumulate. The accumulation of polyubiquitinated proteins is observed when 
excessive intracellular ROS, cellular stress, and diverse stress impair 
proteasome function (Elkon et al., 2004), and the accumulation of 
polyubiquitinated proteins induces neurotoxicity and neurodegeneration. 
Thus, the restoration of proteasome activity through the down-regulation of 
intracellular ROS is one of the primary mechanisms regulating ubiquitin-
conjugated proteins, Lewy body-associated α-synuclein, and synphilin-1 
proteins and the protection against neuronal cell death.  
 In the present study, 6-OHDA-induced ROS generation decreased in a 
concentration-dependent manner when cells were treated with different 
concentrations of CTE50 or the three orobol derivatives, and these compounds 
significantly elicited their neuroprotective effects against 6-OHDA-induced 
cell death and inhibited 6-OHDA-induced changes in cell morphology 
including shrinkage and rounding. In addition, we evaluated the inhibitory 
effects of CTE50 and the three orobol derivatives on the levels of cleaved 
caspase-9, caspase-3 and PARP, which are apoptosis signal factors; 6-OHDA 
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treatment increased the levels of cleaved caspase-9, caspase-3 and PARP 
protein; however, these increases were inhibited by co-treatment with CTE50 
and the three orobol derivatives. A previous study demonstrated that the 
inhibitory effect of (-)-epigallocatechin-3-gallate (EGCG) on ROS generation 
led to a suppression of apoptosis (Ning et al., 2016). In our results, the 
inhibitory effects of CTE50 and three orobol derivatives on ROS generation 
are also concomitant with the protection against neuronal cell death and the 
activation of apoptosis signalling markers. Based on the neuroprotective 
effects of three orobol derivatives, we evaluated structure-bioactivity 
relationship (SAR). The compounds with two hydroxy groups at C-3′ and C-
4′ in B-ring of flavonoid (1 – 5) exhibited neuroprotective effects, whereas the 
others with one hydroxy group at C-4’ (6 – 9) did not. This suggested that the 
hydroxy group in the B-ring of flavonoid influences neuroprotective effects. 
The neuroprotective effect of prenyl-groups is not clear from 9 isolates to 
evaluate SAR. Therefore, further study will be necessary to evaluate SAR with 
prenylated flavonoids on neuroprotective activity. 
 A recent study emphasized the role of the proteasome in neurodegenerative 
disease and showed that proteasome inhibition induced neurotoxicity via the 
accumulation of polyubiquitinated proteins and protein aggregation (Canu et 
al., 2000). As neuronal cells are vulnerable to the accumulation of 
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polyubiquitinated proteins, several neurodegenerative diseases are related to 
the neurotoxicity resulting from protein accumulation. It has been shown that 
proteasome activity can gradually decrease with ageing and environmental 
stress, among other reasons, which results in a reduced ability to degrade 
misfolded proteins, contributing to the development of pathological protein 
aggregates (Ciechanover and Kwon, 2015). In cellular models, proteasome 
inhibition induced apoptosis and neuronal cell degeneration (Park et al., 2011; 
Sun et al., 2006), whereas proteasome activation enhanced neuronal cell 
survival (Seo et al., 2007). Thus, the protection against proteasome 
dysfunction could be a possible therapeutic strategy for neuroprotection. To 
investigate the mechanism underlying the protective effects of CTE50 and the 
three orobol derivatives against 6-OHDA-induced neuronal cell death, 
chymotrypsin-, trypsin-, and caspase-like proteasome activities were 
measured in SH-SY5Y cells. Our results showed that 6-OHDA significantly 
inhibited all three types of proteasome activities due to excessive ROS 
generation, and these results correlate with previously reported studies (Elkon 
et al., 2004). CTE50 and the three orobol derivatives at concentration of 20 
µg/mL and 25 µM, respectively, attenuated 6-OHDA-induced dysfunction of 
the proteasome and nearly restored proteasome activities to normal levels. 
Additionally, we measured the levels of ubiquitin-conjugated proteins and 
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found an increase following 6-OHDA treatment. However, CTE50 (20 µg/mL) 
and the three orobol derivatives (25 µM) attenuated the 6-OHDA-induced 
increase in ubiquitin-conjugated protein levels to almost normal. These results 
suggested that 6-OHDA-induced proteasome dysfunction triggers the 
accumulation of ubiquitin-conjugated proteins, leading to neuronal cell death; 
however, CTE50 and the three orobol derivatives prevented the dysfunction 
of ubiquitin proteasome system (UPS) and protected against neuronal cell 
death. The impairment of UPS is involved in the formation of Lewy bodies, 
which is a characteristic hallmark of PD. Lewy bodies are composed of 
abnormal filamentous aggregates containing α-synuclein, and synphilin-1 has 
been found to colocalize with α-synuclein in Lewy bodies. It has been 
demonstrated that the overexpression of α-synuclein in Drosophila and C. 
elegans induced neuronal cell loss (Kontopoulos et al., 2006; Pesah et al., 
2005). It has also been reported that α-synuclein filaments and oligomers 
themselves inhibited proteasome activities (Lindersson et al., 2004). 
Synphilin-1 has been reported to enhance the aggregation and neurotoxicity 
of α-synuclein (Buttner et al., 2010) and to promote inclusion formation under 
conditions of proteasome inhibition. Additionally, it has been reported that 
synphilin-1 inhibits the degradation of α-synuclein by the proteasome and thus 
increases the half-life of α-synuclein (Alvarez-Castelao and Castano, 2011). 
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Therefore, it has been suggested that the regulation of α-synuclein and 
synphilin-1 through UPS is important for neuroprotection (Sidhu et al., 2004). 
It was also previously reported that a relationship exists between proteasome 
dysfunction and neuronal cell death. Proteasome inhibition triggers a dramatic 
activation of the pro-apoptotic caspase-3,-9, PARP and DNA fragment (Sun 
et al., 2006; Yuan et al., 2008). The proteasome inhibitor MG132 induces 
dopaminergic neuronal cell degeneration and apoptosis (Park et al., 2011), and 
bortezomib, a proteasome inhibitor, induces caspase-dependent apoptosis. In 
contrast, a proteasome activator enhances the survival of neuronal cells (Seo 
et al., 2007), and betulinic acid and demethylsuberosin, reported to be 
proteasome activators, showed neuroprotective effects (Eksioglu-Demiralp et 
al., 2010; Kim, B-H et al., 2015). In our results, 6-OHDA-induced proteasome 
dysfunction resulted in the polyubiquitination of α-synuclein and synphilin-1 
protein. However, CTE50 and the three orobol derivatives reduced the levels 
of 6-OHDA-induced polyubiquitination of α-synuclein and synphilin-1 
protein in addition to ameliorating the dysfunction of proteasome activities. 
Furthermore, treatment with MG132, a proteasome inhibitor, significantly 
reduced the protective effects of CTE50 and the three orobol derivatives 
against 6-OHDA-induced neuronal cell death and proteasome dysfunction, 
suggesting that their neuronal cell protective effects are partly due to the 
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protection against proteasome dysfunction. In spite of the evidence for 
neuroprotection by orobol derivatives, there has been little research reported 
on the blood-brain barrier (BBB) permeability of orobol derivatives. However, 
some studies have demonstrated that isoflavones and several metabolites have 
been proven to transverse the BBB (Chandrasekharan and Aglin, 2013; 
Youdim et al., 2003). Therefore, BBB permeability of orobol and its 
derivatives should be studied to elucidate its potential for permeation across 
















In conclusion, this study demonstrated that CTE50 and three orobol 
derivatives protected against neuronal cell death and ROS generation, and 
attenuated proteasome dysfunction, the accumulation of ubiquitin-conjugated 
proteins, and the levels of polyubiquitinated α-synuclein and synphilin-1, the 
constituents of Lewy bodies. However, the neuroprotective effects of CTE50 
and three orobol derivatives and the attenuation of proteasome dysfunction 
were significantly inhibited by MG132, suggesting their neuroprotective 
effects are partly due to the protection of the ubiquitin/proteasome-dependent 
degradation of α-synuclein and synphilin-1. Based on the results, it was 
suggested that CTE50 and the three orobol derivatives might be promising 









Figure 34. A scheme of protective effects of CTE50 and three orobol 
derivatives on 6-OHDA-induced neuronal cell death via enhancing 
proteasome activity and the ubiquitin/proteasome-dependent 
degradation of α-synuclein and synphilin-1. 
CTE50 and three orobol derivatives protected against neuronal cell death, 
ROS generation, and accumulation of ubiquitin-conjugated proteins, 













Protective effects of TH3-125-4 (TH20) from the root 
barks of Cudrania tricuspidata on CCCP-induced 
neuronal cell death via the inhibition of USP30 












Mitophagy, a specialized autophagy pathway that mediates the clearance of 
damaged mitochondria by lysosomes, is important for mitochondrial quality 
control. Defective mitochondria, if left uncleared, can be a source of oxidative 
stress and compromise the health of the entire mitochondrial network. 
Parkinson’s disease is characterized prominently, but not solely, by loss of 
dopaminergic neurons in the substantia nigra. Although the pathogenic 
mechanisms of Parkinson’s disease are unclear, several lines of evidence 
propose that mitochondrial dysfunction is central to the disease. Most 
compellingly, familial Parkinson’s disease can be caused by mutations in the 
ubiquitin ligase parkin and protein kinase PINK1 (Valente et al., 2004), both 
of which maintain healthy mitochondria via regulating mitochondrial 
dynamics and quality control (Narendra and Youle, 2011). Genetic studies 
established that PINK1 acts upstream of parkin (Park, J et al., 2006a). PINK1 
recruits parkin from the cytoplasm to the surface of damaged mitochondria, 
leading to parkin-mediated ubiquitination of mitochondrial outer membrane 
proteins and deletion of damaged mitochondria by mitophagy (Narendra et al., 
2010; Chan et al., 2011). Parkinson’s disease-associated mutations in PINK1 
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or parkin impair parkin recruitment, mitochondrial ubiquitination, and/or 
mitophagy (Matsuda et al., 2010; Vives-Bauza et al., 2010). In the context of 
the inherently high mitochondrial oxidative stress in substantia nigra 
dopamine neurons, loss of parkin-mediated mitophagy could explain the 
greater susceptibility of substantia nigra neurons to neurodegeneration. Thus, 
promoting mitophagy and enhancing mitochondrial quality control could 
benefit dopaminergic neurons. Recent studies reported that deubiquitinating 
enzyme antagonizes the role of parkin e3 ligase. In culture of dopaminergic 
cells overexpressing parkin, Ubiquitin-specific protease (USP) 15, 30 blocks 
ubiquitination of mitochondrial proteins by parkin and inhibits lysosomal 
delivery of mitochondria and mitophagy (Nakamura and Hirose, 2008) . USP 
30 can counteract parkin-mediated ubiquitination and degradation of 
mitochondrial Rho GTPase 1 (MIRO1) and translocase of outer mitochondrial 
membrane 20 (TOM20), two mitochondrial proteins, after mitochondrial 
damage. Also, USP30 can inhibit parkin-mediated ubiquitination of mitofusin 
1, 2 (Mfn1,2), mitochondria fusion proteins. In cells transfected with green-
fluorescent-protein-parkin (GFP-parkin) and expressing pathogenic parkin 
mutations, the mitophagy process is deficient. In this model, a knockdown of 
USP30 protein restores mitophagy, allowing cells to overcome parkin 
deficiency. Finally, using PINK1 or parkin mutant Drosophilia, the authors 
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demonstrated that USP30 suppression maintained mitochondrial health, 
improved climbing capability, and prevented dopamine depletion (Park, J et 
al., 2006b). Finally, in flies treated by paraquat, a mitochondrial toxin 
inducing parkinsonism, knockdown of USP30 rescued climbing ability, 
improved flies’ survival, and prevented dopamine depletion (Tanner et al., 
2011). All of these experiments show that USP30 plays a major role in 
dopaminergic cell dysfunction by altering mitophagy and that inhibiting this 
protein could represent a promising strategy for PD treatment. In this study, 
we evaluated the inhibitory effects of the isolated compounds from C. 
tricuspidata on USP15, 30. Also, the study investigated the potential effects 
on neuroprotection, parkin mediated mitophagy, mitochondrial membrane 
potential against CCCP-induced SH-SY5Y cells and parkin knock down SH-









2. Material and methods  
 
2.1. Chemicals and reagents  
Carbonyl cyanide 3-chlorophenylhydrazone (CCCP), JC-1, MG132, CCK-8, 
mitotracker, and PR-619 were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Dulbecco’s modified Eagle’s medium (DMEM) and fetal bovine serum 
(FBS) were purchased from Gibco BRL (Rockville, MD, USA). Hybond-
polyvinylidene difluoride (PVDF) membranes were purchased from 
Amersham Pharmacia Biotechnology Inc. (Piscataway, NJ, USA). PRO-
PREP protein extraction solution and WEST-Queen® ECL solution were 
purchased from iNtRON Biotech Inc. (Kyunggi, Korea). USP15, USP30, tetra 
ubiquitin peptides were purchased from Bio-Vision, Inc. (Milpitas, CA, USA) 
Parkin siRNA, scrambled siRNA, Mfn1, Mfn2, ubiquitin, USP15, USP30, 
OPA1, VDAC, alpha-tubulin, parkin, LC3-II first antibody, secondary 
antibody and FITC-conjugated secondary antibody were purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA)  
 
2.2. Preparation of TH3-125-4 (TH20) 
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Cudrania tricuspidata was stored at the Korea Forest Research Institute at 
Southern Forest Research Center (Jinju, Korea) in September 2008. A voucher 
specimen (accession number KH1-4-090814) was kept at the Department of 
Biosystems and Biotechnology at Korea University (Seoul, Korea). TH3-125-
4 (TH20) was isolated from the roots of Cudrania tricuspidata and the 
structure of TH3-125-4 (TH20) was determined by spectroscopic methods, 
and the purity was more than 98% (Wei and Yu, 2008). TH3-125-4 (TH20) 
was dissolved in DMSO and diluted with PBS to obtain the proper 
concentration. Final concentration of DMSO was less than 0.1% and it didn’t 
influence the performed assays. 
 
2.3. Cell cultures  
The human neuroblastoma cell line SH-SY5Y (ATCC No. CRL-2266) was 
purchased from the American Type Culture Collection (Manassas, VA, USA) 
and cultured in DMEM supplemented with 10 % heat-inactivated FBS and 1 % 
penicillin/streptomycin at 37 ºC in a humidified 5 % CO2 atmosphere.  
 
2.4. Measurement of cell viability  
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SH-SY5Y cells were seeded at a density of 1×105 cells/200 µL/well in 96-well 
plates for 24 h, and the cells were pre-treated with isolated compounds from 
C. tricuspidata for 24 h followed by subsequent treatment with CCCP (10 µM) 
for an additional 24 h. To evaluate the effect of parkin, cells were transfected 
with scrambled siRNA or parkin siRNA for 48 h and its final concentration 
was 100 nM. After transfected cells were treated with isolated compounds and 
CCCP (10 µM), cell viability was determined using a CCK-8 and measured 
by ELISA (Koo et al., 2011). 
 
2.5. Measurement of mitochondrial membrane potential by JC-1 staining 
SH-SY5Y cells were seeded at a density of 2×105 cells/2 mL/well in 6-well 
plates for 24 h, and the cells were pre-treated with isolated compounds for 24 
h followed by subsequent treatment with CCCP (10 µM) for an additional 8 h. 
Mitochondrial membrane potential was determined using a JC-1 dyes. Briefly, 
the cells were washed with PBS, and then incubated with 10 µg/mL of JC-1 
for 30 min at 37 ºC in the dark. The cells were then washed with PBS. The 




2.6. Measurement of intracellular ROS by Flow cytometry  
ROS levels in cells were measured with the 2',7'-dichlorofluorescein diacetate 
(DCFH-DA) method (Munch et al., 1998a). Briefly, the cells were washed 
with PBS, and then incubated with 4 µM of DCFH-DA for 30 min at 37 ºC in 
the dark. The cells were then washed with PBS. The fluorescence intensities 
were measured by flow cytometry (BD FACSCalibur TM). 
 
2.7. Mitochondrial and cytosolic fraction preparations  
The mitochondrial and cytosolic proteins were extracted with a commercial 
kit (Mitochondria/Cytosol Fractionation Kit) according to the manufacturer’s 
procedure (Bio-Vision, Milpitas, CA,). Briefly, the cells were incubated in 
cytosolic fraction buffer on ice for 15 min and homogenize cells in an ice-cold 
dounce tissue grinder. After homogenize, centrifuged for 10 min at 700 x g in 
a microcentrifuge at 4 ºC. Transfer the supernatant to a fresh 1.5-ml tube, and 
centrifuge at 10,000 x g in a microcentrifuge for 30 min at 4 ºC. Collect 
supernatant as a cytosolic fraction and mitochondrial pellet were washed with 
cold PBS, extracted completely with mitochondrial fraction buffer.  
 
2.8. Parkin knock down via the transfection of small interfering RNA 
(siRNA)  
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The transfection with scrambled siRNA or parkin siRNA were progressed at 
final concentrations of 100 nM for 48 h by Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) prior to treatment with isolated compounds and CCCP (10 µM) 
as recommended by the manufacturer’s guidelines.  
 
2.9. Measurement of protein expression  
The cells were collected, washed with PBS and lysed with a PRO-PREP 
protein extraction solution at -20 ºC for 20 min. After centrifugation at 13,000 
x g for 30 min, the supernatant was used as the total protein extracts. Western 
blot analysis was accomplished as previously described method (Ham et al., 
2013).  
 
2.10. Immunoprecipitation assay 
Immunoprecipitation was performed as previously described with slight 
modifications (Chen et al., 2014). After treatment, cells were washed three 
times with PBS and homogenized and lysed in cold-lysis buffer (50 mM Tris, 
1 mM PMSF, 150 mM NaCl, 50 mM NaF, 1% Nonidet P-40, 0.25% sodium 
deoxycholate, 10 mM sodium pyrophosphate) and centrifuged at 14,000 × g 
(10 min, 4 °C), and the supernatant was transferred to a new ep-tube and 
incubated with 2 µg of Mfn1 or Mfn2 antibody overnight at 4 °C. The next 
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day, A/G plus agarose beads were added and incubated overnight at 4 °C 
followed by 3 washes in cold-lysis buffer. The loading samples were adjusted 
to total volume of 30 µL with lysis buffer, and the immune-complexes were 
eluted at 95 °C on a heating block for 5 min, vortexed, and spun down by 
centrifugation at 15,000 × g for 10 min.  
 
2.11. Measurement of mitophagy by fluorescence microscope  
The culture dish was coated with 0.2 % gelatin at 37 °C for 30 min and dried 
at RT on a clean bench. The SH-SY5Y cells were plated at a density of 5×104 
cells/200 µL/well in coated dishes for 24 h and CCCP for 8 h. After treatment, 
the cells were washed with 1x PBS/Tween-20 buffer (pH 7.4) (PBST) once. 
The cells were fixed with 4 % paraformaldehyde for 30 min at room 
temperature (RT). After washing with PBST, the blocking steps were 
performed with 1 % BSA in PBST. Next, the cells were incubated with the 
primary antibody at 4 °C overnight. The next day, the cells were washed with 
PBST 3 times and incubated with FITC-conjugated secondary antibody for 1 
h at RT. After 1 h, the cells were washed with PBST 3 times, and DAPI 
staining was performed for 5 min at RT. Lastly, the PBST washing and 
mounting steps were conducted. 
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2.12. Measurement of deubiquitinating enzyme activity 
DUB assay buffer is composed of 20 mM HEPES at pH7.2, 100 mM NaCl, 
0.05 % Tween 20, 0.1 mg/mL BSA, 1 mM DTT. Purified DUBs at optimal 
concentrations (USP 15, 50 nmol/L; USP30, 50 nmol/L) were incubated in 
DUB buffer containing isolated compounds (indicated concentration), vehicle 
alone (DMSO), or PR-619, (positive control for DUB inhibition) in a 100 µL 
reaction volume for 30 to 60 minutes at 37 °C. The reaction was initiated by 
the addition of 500 nmol/L Ub-AMC, and the release of AMC fluorescence 
was recorded at excitation/emission of 380/480 using a fluorometer. 
  
2.13. Measurement of ubiquitin chain disassembly 
In vitro disassembly of purified polyubiquitin chains (K48/K63 linked) was 
performed as described earlier (Dayal et al., 2009). USP30 (50 ng) prepared 
in DUB buffer was incubated with K48- or K63-linked chains (1 µg) and 
isolated compound for 15 min at 37 °C. The extent of chain disassembly was 
assessed by Western blotting. 
 
2.14. Statistical analysis  
All experimental data are expressed as mean value ± standard deviation. 
Statistical significance between multiple groups was determined by one-way 
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ANOVA (PRISM Graph Pad, San Diego, CA, USA). When ANOVA had a 
significant difference, post hoc Bonferroni’s multiple comparison tests was 





















3.1. Inhibitory effect of TH3-125-4 (TH20) on deubiquitinating enzymes, 
USP15, USP30.  
 
The isolated compounds from C. tricuspidata were evaluated to determine its 
inhibitory effects on deubiquitinating enzyme (DUB) activity. As shown in 
Table. 4, twelve isolated compounds inhibited USP15, USP30 activity. 
Among twelve isolated compounds, TH3-125-4 (TH20) showed potent 
inhibitory effects on USP30 with an IC50 values of 38.1 µM. TH20 inhibited 
USP30 enzyme activity concentration-dependently manner (Fig. 36). 
However, TH20 did not show inhibitory effect on USP15, total DUB enzyme 
activity. PR-619, a non-selective DUB inhibitor, significantly inhibited 
USP15, USP30, and total DUB enzyme activities, respectively (Fig. 37). The 




















Table 4. Inhibitory effect of isolated compounds from C.tricuspidata on 












































































155.2 >160 >160 
… … … … … 
129 JY1-134-5 >160 >160 >160 
130 PR619 4 6.7 8.5 
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Figure 36. Inhibitory effects of TH3-125-4 (TH20) on USP15 and USP30 
enzyme activities. 
TH20 was incubated with 1 x DUB assay buffer for 30 min. DUB enzyme 
activities were measured by multiplate reader with fluorophore-linked Ub-
AMC peptide substrates. The relative fluorescence intensity was indicated. 








Figure 37. Inhibitory effects of PR-619 on USP15 and USP30 enzyme 
activities. 
PR-619 was incubated with 1 x DUB assay buffer for 30 min. DUB enzyme 
activities were measured by multiplate reader with fluorophore-linked Ub-
AMC peptide substrates. The relative fluorescence intensity was indicated. 






3.2. Effect of TH3-125-4 (TH20) on ubiquitin chain disassembly 
 
The polyubiquitin chains (K48/K63 linked) are formed by e3 ligase like a 
parkin. The polyubiquitin chains are resolved by DUB. The incubation 
polyubiquitin chain with USP30 significantly induced disassembly of tetra 
ubiquitin. However, incubation with TH3-125-4 (TH20) inhibited 
disassembly of tetra ubiquitin at a concentration-dependent manner. The 80 
µM of TH20 completely blocked the degradation of tetra ubiquitin. The results 














Figure 38. Inhibitory effects of TH3-125-4 (TH20) on USP30 enzyme 
mediated tetra ubiquitin disassembly. 
TH20 was incubated with 1 x DUB assay buffer for 30 min. USP30 enzyme 
activities were measured by western blot assay with tetra ubiquitin peptide 







3.3. The protective effects of TH3-125-4 (TH20) against CCCP-induced 
neuronal cell death in parkin knock down SH-SY5Y cells.  
 
The previous study revealed that parkin knock down cells were increased the 
vulnerability against CCCP neurotoxin. In the results, parkin siRNA 
transfected SH-SY5Y cells were more vulnerable to CCCP induce than 
scramble siRNA transfected SH-SY5Y cells. Also, USP15 or USP30 siRNA-
transfected SH-SY5Y cells significantly protected the CCCP-induced cell 
death (Fig.39 and 40). Pre-treatment of TH20 protected CCCP-induced parkin 
knock down cell death at a concentration dependent manner. However, TH20 












Figure 39. The protective effects of USP15 siRNA against CCCP-induced 
neuronal cell death in parkin knock down SH-SY5Y cells.  
The cells were double-transfected with different concentrations of USP15 
siRNA (10 - 50 nM) and Parkin siRNA or scramble siRNA (100 nM) for 48 
h. After 24h, cells were subsequently treated with CCCP (10 µM) for another 





Figure 40. The protective effects of TH3-125-4 (TH20) against CCCP-
induced neuronal cell death in parkin knock down SH-SY5Y cells.  
The cells were double-transfected with different concentrations of USP30 
siRNA (10 - 50 nM) and Parkin siRNA or scramble siRNA (100 nM) for 48 
h. After 24h, cells were subsequently treated with CCCP (10 µM) for another 





Figure 41. The protective effects of TH3-125-4 (TH20) against CCCP-
induced neuronal cell death in parkin knock down SH-SY5Y cells.  
The cells were pre-treated with different concentrations of TH20 (1 - 10 µM) 
for 24 h and subsequently treated with CCCP (10 µM) for another 24 h. The 
cells were transfected with Parkin siRNA or scramble siRNA (100 nM) for 
48 h before the treatment with TH20. The cell viability was determined by 






3.4. Inhibitory effect of TH3-125-4 (TH20) on USP30 protein expression 
in SH-SY5Y cells. 
 
We evaluated USP15, USP30 protein expression in SH-SY5Y cells. Among 
twelve isolated compounds, TH20 inhibited USP30 protein expression (Fig. 
42). However, TH20 did not affect the protein expression of USP15. The 
protein expression of USP30 were gradually decreased by TH20 treatment at 
a concentration dependent manner. PR-619, a non-selective DUB inhibitor, 
did not affect the protein expression of USP15, USP30 (Fig. 43). The 













Figure 42. Inhibitory effect of TH3-125-4 (TH20) on USP30 protein 
expression in SH-SY5Y cells. 
The cells were treated with TH20 (10 µM) for different durations (0 - 24 h). 
After treatment, the total protein was extracted and determined protein 
expression level by western blot assay. Representative data from three 









Figure 43. The protective effects of TH3-125-4 (TH20) against CCCP-
induced neuronal cell death in parkin knock down SH-SY5Y cells.  
The cells were treated with PR-619 (2.5 µM) for different durations (0 - 24 h). 
After treatment, the total protein was extracted and determined protein 
expression level by western blot assay. Representative data from three 









3.5. Effect of TH3-125-4 (TH20) on CCCP-induced disruption of 
mitochondrial membrane potential. 
 
CCCP induces the rapid collapse of mitochondrial membrane potential 
(MMP) in SH-SY5Y cells. In our results, CCCP-induced collapse of MMP 
was peaked at 8 h. To evaluate the effect of TH20 on MMP, SH-SY5Y cell 
were pre-treated by TH20 for 24h. After then, MMP was disrupted by CCCP 
for 8h. TH20 did not protected CCCP-induced disruption of MMP (Fig. 44). 
The 10 µM of TH20 treatment slightly protected CCCP-induced collapse of 













Figure 44. Effect of TH3-125-4 (TH20) on CCCP-induced disruption of 
mitochondrial membrane potential. 
The cells were pre-treated with different concentrations of TH20 (1 - 10 µM) 
for 24 h and subsequently treated with CCCP (10 µM) for another 8 h. The 
cells were stained with JC-1 dyes for 30 min and determined by FACS 
analysis using FL-1 and FL-2 channel. The values of fluorescence intensity 







Parkinson’s disease is the most common neurodegenerative movement 
disorder. Although most cases are sporadic, several genes have been recently 
linked to familial PD, and loss-of-function mutations in Park2, the gene 
coding for the ubiquitin ligase Parkin, represent the most common recessive 
cause (Kitada et al., 1998). Parkin-null Drosophila melanogaster exhibit a 
severe phenotype, with the loss of dopaminergic neurons, disrupted 
spermatogenesis, and swollen and disordered mitochondria appearing before 
degeneration of their indirect flight muscles (Greene et al., 2003). The role of 
parkin in mitochondria phenotype was demonstrated. Parkin is selectively 
recruited to dysfunctional mitochondria in mammalian cells, and that after 
recruitment, Parkin mediates the engulfment of mitochondria by 
autophagosomes and their subsequent degradation. The results suggest that 
loss of Parkin activity may allow the accumulation of dysfunctional 
mitochondria, leading to neuron loss in PD, and that Parkin normally functions 
to survey mitochondrial activity and maintain mitochondrial fidelity by 
activating the autophagy of damaged organelles (Narendra et al., 2008). A 
recent proteomic study in human cells showed that Parkin ubiquitinates over 
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100 sites in more than 30 different MOM proteins, including Mfn1,2, in 
response to mitochondrial depolarization (Sarraf et al., 2013). In a recent 
research, deubiquitinating enzymes were reported that it can be an antagonist 
of parkin e3 ligase and inhibit parkin-mediated mitophagy. Among diverse 
DUBs, USP15 and USP30 were emerged as a major factor in opposing parkin 
e3 ligase activity. USP15, -30 deubiquitinates parkin-mediated mitochondrial 
fusion, fission proteins (Bingol et al., 2014; Cornelissen et al., 2014). Hence, 
the inhibition of USP15,-30 could be a therapeutic implication for familial PD. 
 In the current study, we identified a small natural compound, TH3-125-4 
(TH20) derived from C. tricuspidata, which potently inhibits USP30 enzyme 
activity. However, TH20 did not significantly affect USP15 and total DUB 
enzyme activity. The inhibition of USP30 enzyme activity has a major role in 
PINK1-Parkin mediated mitophagy. It was reported that UPS30 physically 
interacts with Mfn1, 2 and decreases ubiquitination of Mfn1and Mfn2, 
whereas mutation of the active cysteine (C77) in the catalytic domain to serine 
abolishes its deubiquitinase activity, and thus the USP30-C77S mutant is 
unable to affect the ubiquitination of Mfns. Furthermore, it was demonstrated 
that inhibition of USP30 could lead to enhanced ubiquitination of Mfn1 or 
Mfn2, which promotes mitochondrial fusion (Yue et al., 2014). Hence, 
inhibitory effect of TH20 on USP30 enzyme activity could enhance PINK1-
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Parkin mediated mitophagy. When the cells were transfected with Parkin 
siRNA, CCCP-induced neuronal cell death was increased comparing scramble 
siRNA treated SH-SY5Y. While TH20 treatment protected CCCP-induced 
neuronal cell death in Parkin K.D. SH-SY5Y cells, TH20 did not show 
protective effect against CCCP-induced neuronal cell death in scramble K.D. 
SH-SY5Y cells. Also, TH20 did not protect CCCP-induced disruption of 
MMP. The neuroprotective effect of TH20 in Parkin K.D. SH-SY5Y cells was 
predicted to be due to the DUB inhibitory effect, and the experiment for the 
DUB inhibitory effect was carried out. TH20 inhibited the enzymatic activity 
of USP30, while the inhibitory effect on USP15 and total DUB activity was 
weak. In addition, TH20 decreased the protein expression of USP30 in SH-
SY5Y cells. Based on our results, we suggest that the protective effect of 
TH20 on CCCP-induced neuronal cell death in Parkin K.D. SH-SY5Y cells is 
mainly inhibition of USP30 enzyme activity. Further studies are needed to 
validate the hypothesis of the study, such as the effects of TH20 on Mfn1,2, 
OPA1, VDAC, LC3-beta, and p62 which are one of Parkin-mediated 
mitophagy factors. We are under investigating the effect of TH20 on Parkin-






In conclusion, this study demonstrated that TH20 protected against CCCP-
induced neuronal cell death in Parkin K.D. SH-SY5Y cells. Also, TH20 
significantly inhibited USP30 enzyme activity and disassembly of 
polyubiquitin chain in in vitro assay. Our results showed that the protein 
expression of USP30 was decreased by treatment with TH20. Based on our 
results, we suggest that TH20 might be promising candidates for the therapy 
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꾸지뽕나무로부터 분리한 유효성분물질의 파킨슨병 
세포모델에서의 신경보호효과: Ubiquitin-proteasome system 및  
Nrf2-ARE 관련 기전에 관한 효과연구 
 
김 동 우 
약학과 천연물과학 전공 
서울대학교 약학대학 대학원 
 
파킨슨 병은  운동 장애, 기억 상실, 운동 부조 및 도파민 신경의 
손실등의 특징을 보이는 퇴행성 뇌질환이다. 파킨슨 병의 원인은 
명확하게 특정되지 않았지만 산화적 스트레스, 유비퀴틴 – 
프로테아좀 기능저하, mitophagy 기능이상은 세포 기능 장애 및 
과도한 독성단백질의 축적 및 미토콘드리아 장애를 초래하며 주요 
병인으로 간주되고있다. 신경독성으로 알려진 6-OHDA, CCCP 는 
라디칼과 같은 과도한 활성산소종을 유도하거나 미토콘드리아의 
기능이상을 유도함으로써 도파민 뉴런을 파괴하고 단백질 산화 및 
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신경 세포 사멸을 일으킨다. 산화적스트레스는 다양한 
분자병리학적 기전을 통해 세포사멸을 유발하며, 유비퀴틴 – 
프로테아좀 기능저하는 독성 단백질의 과다축적을 유도하고 
이로인해 신경 세포사를 초래한다. Mitophagy 의 기능이상은  
제거해야할 미토콘드리아의 과축적을 유발하여 신경 세포사를 
초래한다. 현재 개발중인 새로운 치료법은 도파민 뉴런을 보호하는 
것을 목적으로 하고 있다. 본 연구에서 파킨슨 병의 치료제제로써 
가능성 있는 선도 화합물을 발견하기 위해 SH-SY5Y 신경아종 
세포에서 6-OHDA, CCCP 로 유도한 뇌세포 사멸 보호효과 및 관련 
기전에 대하여 연구하였다. 
 첫번째로, 꾸지뽕나무 뿌리로부터 분리한 5,7-Dihydroxychromone 
(DHC)의 Nrf2/ARE 기전 활성화를 통한 6-OHDA 로 유도한 
뇌세포사멸 보호효과를 연구하고자 하였다. 6-OHDA 로 유도한 SH-
SY5Y 뇌세포 사멸은 DHC 처리에 의해 농도의존적으로 감소하는 
결과를 보였으며, 세포내 활성산소종 역시 DHC 처리에 의해 
감소하는 결과를 확인하였다. 이에 DHC 의 뇌세포사멸 보호효과의 
기전을 확인하고자, DHC 의 Nrf2 nuclear translocation 에 대해 
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연구하였고, DHC 처리에 의해 Nrf2 의 핵안으로 이동이 증가함을 
확인하였다. 이어진 연구에 의해 핵안으로 이동한 Nrf2 가 ARE 와 
binding 하는 것을 확인할 수 있었으며, 이로인해 phase 2 antioxidant 
enzyme 의 발현량이 증가하는 결과를 확인하였다. 이어진 실험에서 
Nrf2  knock down 시킨 세포주에서 DHC 의 뇌세포사멸 보호효과는 
현저히 감소되는 결과를 확인하였다. 즉, DHC 의  6-OHDA 로 
유도한 뇌세포사멸의 보호효과가 Nrf2/ARE 기전을 통한 phase 2 
antioxidant enzyme 의 활성화를 통한것임을 증명할 수 있었다. 
최종적으로 Nrf2/ARE 기전의 활성화를 통한 퇴행성뇌질환 예방 및 
치료제 선도물질로써 가능성을 제시할 수 있다.  
 두번째로, 꾸지뽕나무 열매로부터 분리한 Orobol 유도체 및 
에탄올 추출물을 이용하여 6-OHDA 로 유도한 뇌세포 사멸 및 
ubiquitin-proteasome system 에 대한 효과를 연구 하였다. 꾸지뽕나무 
열매 50% 에탄올 추출물 및 orobol, 6-prenylorobol, 6,8-
diprenylorobol 이 6-OHDA 로 유도한 SH-SY5Y 뇌세포사멸 
보호효과가 가장 우수하였다. 또한, 50% 에탄올 추출물 및 orobol 
유도체는 6-OHDA 로 유도한 proteasome dysfunction 을 효과적으로 
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보호하는 결과를 보였다. Proteasome  보호효과를 통해 파킨슨 
질환의 주요 독성 단백질 중 하나인 a-synuclein, synphilin-1 의 
제거를 효과적으로 유도하였다. 하지만 proteasome inhibitor 인 
MG132 를 처리함에 따라 50% 에탄올 추출물 및 orobol 유도체의 
세포사멸 보호효과 및 proteasome 보호효과가 현저히 저하되는 
결과를 보였다. 즉, 꾸지뽕나무 열매 50% 에탄올 추출물 및 orobol 
유도체는 ubiquituin-proteasome system 의 정상화를 통해 a-synuclein, 
synphilin-1 의 제거를 유도하고, apoptosis, 활성산소종 생성을 
억제하며 뇌세포를 효과적으로 보호함을 증명할 수 있었다. 
최종적으로 proteasome 보호효과를 통한 퇴행성 뇌질환 예방 및 
치료제의 선도물질로써의 가능성을 제시할 수 있다. 
 마지막으로, 꾸지뽕나무로부터 분리한 유효물질이 deubiquitinating 
효소에 미치는 영향을 연구 하였다. 꾸지뽕나무 뿌리로부터 분리 
된 TH3-125-4 (TH20)는 Parkin K.D. SH-SY5Y 세포주에서 CCCP 로 
유도한 신경 세포 사멸을 보호하였다. TH20 은 deubiquitinating 
효소로 알려진 USP30 의 활성을 효과적으로 억제하였으며, USP30 의 
polyubiquitin 분해활성 역시 억제하는 효과를 보였다. 또한, TH20 은 
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USP30 의 단백질 발현을 감소시켰다. 연구 결과에 따르면 TH20 은 
Parkin 매개 mitophagy 를 정상적으로 회복하여 유전형 파킨슨 병의 
치료제 선도물질로써의 가능성을 보였다.  
 
 
주요어: 꾸지뽕나무, 산화적 스트레스, 6-OHDA, 뇌세포사멸 보호, 
5,7-Dihydroxychromone, Nrf2/ARE pathway, orobol 유도체, 프로테아좀 
활성, ubiquitination, deubiquitinating 효소, PINK1, Parkin, mitophagy  
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